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SUMMARY  
 
Summary 
 
During this work, a Pseudomonas aeruginosa optimized, strand-specific RNA-sequencing method was 
developed to allow for multiplexed transcriptome data acquisition on Illumina next generation 
sequencing systems. This technique was used to obtain global sequence and expression information 
from 149 clinical isolates of different sample origins and with diverse antibiotic resistance profiles 
(most of them multidrug resistant). The received fraction of up to 75 % mapped mRNA reads per 
sample, resulting in up to 90 % total genome coverage, was sufficient for in depth data analysis at the 
single nucleotide level. This data was successfully used to determine high resolution taxonomic 
relatedness of the isolates and screen for genetic determinants correlating with β-lactam resistance 
phenotypes of phylogenetically unrelated strains. A combination of de novo assembly and coverage 
determination was used to search for acquired resistance genes and led to the identification of nine 
different β-lactamases in overall 19 isolates. Furthermore, unbiased statistical comparisons were 
developed and integrated in a publically available database for the analysis of core genetic alteration 
enrichments (SNPs, stops, gene expression) in phenotypically related groups of isolates. Thereby, six 
genes of significance in ceftazidime and two in meropenem non-susceptible isolates were identified. 
Detailed single gene investigation revealed that more than 95 % of the isolates harbored known, 
dominant genetic resistance determinants which, apart from acquired enzymes, were displayed by 
constitutive intrinsic ampC overexpression or lack of OprD porin due to expression repression or 
nonsense mutation. Penicillin binding proteins did not seem to be involved in ceftazidime or 
meropenem resistance of clinical isolates. 
Furthermore, the effects of low-level sub-inhibitory concentrations of bactericidal antibiotics from 
different compound classes on the transcriptome of PA14 wild type cells were investigated, revealing 
a variety of specific responses (DNA repair, cell envelope modification, ribosome regulation), but also 
common ones as SOS response and the induction of denitrification pathways. These results could be 
connected to global metabolic reactions as a consequence of intracellular reactive oxygen stress. 
Using isotope labelling studies, we detected an enhanced biosynthesis of amino acids which are 
directly derived from tricarboxylic acid cycle dependent or closely related NAD+ and NADP+ 
dependent pathways. This suggests common impacts of low-level bactericidal antimicrobials on 
bacterial cellular systems, regardless of their chemical structure, with a likely connection to 
respiration hyperactivation. 
ZUSAMMENFASSUNG  
 
Zusammenfassung 
 
Im Verlauf dieser Arbeit wurde eine für Pseudomonas aeruginosa optimierte, Strang-spezifische 
Sequenziermethode entwickelt, die das Multiplexen verschiedener cDNA-Proben in einem einzigen 
gemeinsamen Illumina Sequenzieransatz ermöglicht sowie die nachträgliche probenspezifische 
Zuordnung der einzelnen Transkriptomdatensätze. Diese Technik wurde genutzt um globale 
Sequenz- und Expressionsinformationen von 149 klinischen Isolaten unterschiedlicher geografischer 
Herkunft und variierender Antibiotikaresistenzprofile (in der Mehrzahl multiresistent) aufzunehmen. 
Mit einem Anteil von bis zu 75 % mRNA pro Probe konnte eine Gesamtgenomabdeckung von bis zu 
90 % erzielt werden, welche ausreichend für detaillierte, sequenzspezifische Analysen auf 
Einzelnukleotidebene war. Diese Daten wurden dazu genutzt, die Verwandtschaftsbeziehungen der 
verschiedenen Isolate hoch-auflösend darzustellen und nach genetischen Markern zu suchen, welche 
in nicht verwandten Stämmen in Zusammenhang mit β-Lactam-Resistenz standen. Durch eine 
Kombination aus de novo assembly und Analyse der relativen Genabdeckung konnten insgesamt 
neun verschiedene erworbene β-Lactamasen in zusammen 19 Isolaten detektiert werden. Des 
Weiteren wurden datenbankintegrierte Hilfsmittel für statistische Vergleiche entwickelt um die 
Anreicherungen intrinsischer genetischer Marker (SNPs, Stopps, Expressionsdifferenzen) in 
phänotypisch ähnlichen Gruppen von Isolaten zu ermöglichen. Hiermit konnten sechs signifikante 
Gene in Ceftazidim und zwei in Meropenem resistenten Isolaten identifiziert werden, die insgesamt 
zusätzlich Hinweise auf erworbene Kreuzresistenzen und kompensatorische Anpassungen lieferten. 
Eine detaillierte Untersuchung ausgewählter Gene zeigte zudem, dass in über 95 % die jeweilige 
erworbene β-Lactam-Resistenz auf bekannte Hauptmarker wie erworbenen Resistenzenzyme, eine 
Überexpression der intrinsischen β-Lactamase ampC oder ein Fehlen des OprD porins zurückzuführen 
war (Penicillin bindende Proteine schienen hingegen nicht nennenswert beteiligt). 
Weiterhin wurde der Effekt von geringen, sub-inhibitorischen Konzentrationen bakterizider 
Antibiotika auf Wildtyp Zellen untersucht. Hierbei konnten neben spezifischen transkriptionellen 
Anpassungen eine Reihe von globalen Stressadaptionen wie die Induktion der SOS Antwort und des 
Denitrifikationsstoffwechsels beobachtet werden, die vermutlich aufgrund erhöhter intrazellulärer 
Sauerstoffradikalkonzentrationen auftraten. Mit Hilfe von Isotopenmarkierungen konnte eine 
Verbindung zu globalen metabolischen Veränderungen aufgezeigt werden. Diese führten  
unabhängig vom eingesetzten Antibiotikum zu einer erhöhten Biosynthese von Aminosäuren, die in 
direkter Abhängigkeit zum Zitratzyklus oder nahe verwandten NAD+ und NADP+ bedingten Prozessen 
standen. Somit lässt sich eine Überstimulation der Atmungskette als unabhängige Stressantwort auf 
geringe Antibiotikakonzentrationen vermuten. 
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1 Introduction 
1.1 Pseudomonas aeruginosa as a model organism 
Pseudomonas aeruginosa is probably the best characterized member of the genus Pseudomonas, 
which belongs to the class of γ-Proteobacteria. This diverse genus was first described in 1894 by the 
German botanist Walter Migula and served as a collecting pond for rod-shaped, polar-flagellated 
Gram-negative bacteria, which gained energy through oxygen dependent respiration [1]. Modern 
molecular taxonomy based on DNA-DNA-, rRNA-DNA-hybridization and, most importantly, 16S rRNA 
similarity has greatly improved phenotype independent classification [2,3]. At present, the genus 
comprises 230 species and subspecies [4]. 
Due to their metabolic flexibility, P. aeruginosa is able to thrive in diverse ecological niches and can 
thus be found ubiquitously in soil and water habitats [5]. The bacterium favors oxygen as a terminal 
electron acceptor within the respiratory chain, but can as well generate ATP under anaerobic 
conditions using nitrate or nitrite as alternative electron acceptors [6,7]. In the absence of a terminal 
electron acceptor, P. aeruginosa is able to ferment the amino acids arginine and pyruvate [8-10]. 
However, this metabolic pathway does not support cell growth and proliferation, but merely long-
term survival under anaerobic conditions. Furthermore, P. aeruginosa is capable of degrading various 
carbon sources as sugars, fatty acids, alcohols, glycols, aromatic compounds, amines and amino acids 
[11], although it prefers the degradation of organic acids, e.g. acetic acid. Of note, when 
P. aeruginosa metabolizes glucose, this is, as opposed to most other bacteria, usually not done by 
glycolysis (Embden-Meyerhoff-Parnas pathway), or the pentose-phosphate pathway, but by the 
Entner-Doudoroff pathway (ED) [12]. This pathway uses 6-phosphogluconate dehydratase and 2-
keto-3-deoxyphosphogluconate aldolase to create pyruvates from glucose [13]. 
Besides its free-living, environmental lifestyle, the catabolic adaptability and metabolic versatility 
allows P. aeruginosa likewise to colonize various plants and animal surface tissues, as well as human 
skin, where it may behave as an opportunistic pathogen. Interestingly, the bacterium uses the same 
repertoire of virulence factors in all hosts [14-16]. 
1.2 Pseudomonas aeruginosa as an opportunistic nosocomial pathogen 
Despite its ubiquitous appearance, P. aeruginosa is rarely found in the normal human microbial flora 
and usually does not colonize and infect healthy individuals [17].  However, it can cause severe 
infections in immunocompromised people, were colonization rates can increase from nearly zero to 
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over 50 % during hospitalization [18]. As a consequence, this bacterium is responsible for 9 % of all 
hospital acquired infections in the USA, designating it one of the leading nosocomial pathogens [19]. 
Especially catheterized patients and burn wound victims are prone to life threatening infections, and 
P. aeruginosa is the leading cause of nosocomial pneumonia in the United States (51,000 cases in 
2013) [20,21]. Most frequently, lung infections of P. aeruginosa occur in patients suffering from 
cystic fibrosis (CF). CF is an autosomal, recessively passed genetic disorder in which mutations of the 
cystic fibrosis transmembrane regulator (CFTR) lead to a reduction of the sodium and chloride ion 
transport across the epithelium. This results in increased mucus viscosity and promotes bacterial 
colonization of the lung. As a consequence, chronic P. aeruginosa infections establish, which 
represent the leading cause of lung function decline and ultimate mortality in CF patients [22-24]. 
Effective treatment and bacterial eradication proves to be difficult as P. aeruginosa is able to form 
biofilms and possesses complex virulence and protection systems, including pili for adhesion, 
siderophores for the acquisition of extracellular iron and mechanism for the secretion of exotoxins, 
phenazines and rhamnolipids [25-29]. 
However, the most evident threat poses the frequent occurrence of single and multiple antimicrobial 
resistant variants. While the overall P. aeruginosa infection rates in intensive care units (ICU) 
remained more or less stable during the past 30 years, there has been an alarming increase in drug 
resistant isolates [20]. About 13 % of severe healthcare-associated Pseudomonas aeruginosa 
infections (6,700 cases, resulting in 440 deaths in the USA in 2013) were caused by multidrug 
resistant (MDR) bacteria [21]. MDR defines acquired non-susceptibility to at least one agent in three 
or more antimicrobial categories, in this case the important anti-pseudomonal antibiotics 
aminoglycosides, fluoroquinolones and β-lactams [30]. Recently, a further nomenclature for 
multidrug resistant Gram-negative rods including Pseudomonas aeruginosa was introduced by the 
Robert Koch-Institut for improved risk management in hospitals. It suggested additional classification 
of the bacteria as 3MRGN or 4MRGN (for multi-resistant Gram-negative), when they display 
resistance to three or four of the following classes of antibiotic, respectively: penicillins, 
cephalosporins, carbapenems, and fluoroquinolones [31]. Drug-resistance in P. aeruginosa is 
associated with significant increases in morbidity, mortality, need for surgical intervention, length of 
hospital stay, and thus overall health care costs [32-35]. 
1.3 Antibiotics: past and present 
Although the antimicrobial properties of certain extracts from molds and plants had been recognized 
as treatments of infections already over 2000 years ago, it was not until the early 20
th
 century that 
antibiotics truly revolutionized modern medical therapy [36]. This new era was launched in 1928 by 
CHAPTER 1: INTRODUCTION 3 
 
the Scottish scientist and Nobel laureate Alexander Fleming who made an unexpected discovery 
during his work at St. Mary’s Hospital in London: Staphylococcus colonies on a culture plate were 
destroyed in the neighborhood of a fungus contamination by a substance with an obvious 
antimicrobial activity. Fleming named this substance Penicillin, which only a decade later went into 
successful large-scale production [37]. Selman Waksman finally introduced the term “antibiotic” in a 
journal article in 1947, describing any substance produced by a microorganism that is antagonistic to 
the growth of other microorganisms in high dilution [38]. 
Subsequently, the use of antibiotics constituted a dramatic improvement in the treatment of life-
threatening bacterial diseases as compared to the pre-antibiotic era characterized by the absence of 
adequate therapy [39]. As one example, the mortality rate of acute meningococcal meningitis was 
lowered from 70-90 % to 10 % [40]. Between 1940 and 1962 more than 20 new classes of antibiotics 
were marketed worldwide [41]. 
However, in the succeeding decades the more cost-efficient production of semisynthetic drug 
analogues gained increasing importance with only two novel classes discovered since [41]. Today, the 
overall yearly number of new antibiotic approvals by the Food and Drug Administration (FDA) is in a 
constant decline (Figure 1.1)[21]. 
 
 
Figure 1.1 Number of new drug applications (NDA) approvals per year interval. 
Intervals from 1980-2009 are 5-year intervals; 2010-2012 is a 3-year interval. Drugs are limited to systemic 
agents. Data of FDA’s Center for Drug Evaluation and Research (CDER). Figure taken from [21]. 
 
Today’s antibiotics can be divided into two groups based on their biological activity: bactericidal 
agents which induce cell death and bacteriostatic agents which merely stall bacterial growth and 
proliferation [42]. Further classification is done based on their cellular targets. Most current 
bactericidal antibiotics inhibit DNA, RNA or cell wall synthesis, while bacteriostatic ones usually halt 
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protein production (with the exception of the bactericidal aminoglycosides) [43]. Three bactericidal 
classes of antibiotics are of particular clinical relevance in the treatment of P. aeruginosa infections: 
aminoglycosides, fluoroquinolones and β-lactams [44]. 
Aminoglycosides bind to the 30S subunit of the bacterial ribosome and impair the incorporation of 
amino acids into elongating peptides, which leads to the production of misfolded proteins [45]. 
Fluoroquinolones interfere with changes in DNA supercoiling by binding to complexes of DNA and 
either one of the two target enzymes DNA gyrase and topoisomerase IV, and thus inhibit DNA 
replication [46]. The third group, β-lactams, induces lytic cell death by intervening with the synthesis 
of the bacterial cell wall [47]. 
1.3.1 β-lactams – inhibitors of cell wall biosynthesis 
β-lactam antibiotics belong to one of the three largest classes of antibiotics and represent over 65 % 
of the world’s antibiotic market [48]. They gain their antibiotic activity by interfering with the 
biosynthesis of the bacterial cell wall and can be used for the treatment of a variety of Gram-positive 
and Gram-negative infections [49]. 
The bacterial cell wall is composed of stabilizing layers of peptidoglycan, which plays a key role in 
maintaining cell shape and counteracting internal osmotic pressure [50]. Peptidoglycan is a 
covalently cross-linked polymer matrix consisting of two alternating amino sugars, namely N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc), which are connected by β-(1,4)-
glycosidic bonds. Adjacent MurNAc chains are further interlinked with each other by peptide cross-
connections [51]. These cross-connections are accomplished by the activity of the penicillin-binding-
proteins (PBPs) which recognize a natural D-Ala-D-Ala motive in the MurNAc adherent peptide chain 
[52]. β-lactams are analogues of the D-Ala-D-Ala dipeptide. They bind irreversibly to the active site of 
the PBPs instead, and thus prevent the cross-linking of the peptidoglycan units by inhibiting the 
peptide bond formation [53]. Most bacterial species have various types of PBPs. They differ in their 
molecular weight, enzymatic activity and affinity for binding penicillin or other β-lactam antibiotics 
[52]. 
Besides affecting the peptidoglycan stability per se, the inhibition of PBPs causes a build-up of 
peptidoglycan precursors. This rearrangement within the cell wall triggers a stress response which 
results in the autolytic hydrolysis of the existing peptidoglycan and promotes production of new 
peptidoglycan, and consequently further enhances the bactericidal activity of the antibiotic [42]. 
All β-lactam antibiotics commonly share the molecular β-lactam ring structure, but are classified into 
different subgroups according to additionally varying core structures. Members of four of these 
subgroups are administered to treat P. aeruginosa infections, the penicillins (penams), 
monobactams, cephalosporins (cephems) and carbapenems (Figure 1.2) [48]. 
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Two β-lactams with particularly high anti-pseudomonal activity which are commonly used in the 
clinics, are the third generation cephalosporin ceftazidime (CAZ) and the carbapenem meropenem 
(MEM) [44]. 
 
 
Figure 1.2 Core structure of the different classes of β-lactams. 
The characteristic β-lactam ring structure is marked in red. β-lactams fused to thiazolidine rings are named 
penicillins, if they contain a 3,6-dihydro-2H-1,3-thiazine ring, cephalosporins.  Carbapenems incorporate a 2,3-
dihydro-1H-pyrrole, while monobactams do not contain any additional ring structure. Figure adapted from [48]. 
1.4 Antibiotic resistance in Pseudomonas aeruginosa 
In 2013 Pseudomonas aeruginosa was classified as “a serious concern to public health, requiring 
prompt and sustained action“ by the U.S. Center for Disease Control (CDC), due to its MDR antibiotic 
resistance profile [21]. Selection of adequate antibiotics becomes increasingly complicated, since 
P. aeruginosa does not only harbor a variety of intrinsic resistance mechanisms, but also a great 
capacity to acquire new ones by additional gene uptake or mutation. The latter is a particular threat 
during ongoing antibiotic medication, which can easily promote resistance development and MDR 
phenotypes, and thus increase the risk of treatment failure [54,55]. Resistance rates for β-lactams, 
fluoroquinolones and aminoglycosides from patients’ isolates ranged up to 32 %, 35 % and 22 %, 
respectively in 2002, while MDR strains were isolated in 26 % of the cases [18]. 
Often a combination of chromosomally encoded mechanisms, including over time evolved 
chromosomal changes, and the acquisition of mechanisms imported on mobile genetic elements is 
responsible for the respective resistance phenotype [56]. 
1.4.1 Chromosomally encoded β-lactam resistance mechanisms affecting antibiotic 
influx and efflux 
P. aeruginosa intrinsically exhibits low susceptibility towards a broad range of different antimicrobial 
classes. Two reasons for this are the low outer membrane permeability and the expression of several 
pump systems, which passively decreases the influx and actively increases the efflux of antimicrobial 
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substances to reduce drug accumulation inside the cell [57,58]. The low permeability is achieved by 
the asymmetric bilayer of the outer membrane with its variable lipopolysaccharide (LPS) which acts 
as an effective barrier against the rapid penetration of lipophilic antibiotics, and the lack of high-
permeability porins for hydrophilic agents which are present in most other Gram-negatives [59]. 
1.4.1.1 Multidrug efflux systems 
Additionally to its low membrane permeability, P. aeruginosa possesses nine multidrug efflux (Mex) 
pump systems of the resistance-nodulation-division (RND) family which are responsible for the 
extrusion of antibiotics (Table 1.1) [18].  
 
Table 1.1 Overview of RND efflux pumps in Pseudomonas aeruginosa. 
Modified from Lister and colleagues [18]. 
        
Efflux system 
Regulators 
Antibiotic substrates 
Direct Indirect 
MexAB-OprM MexR, NalD NalC β-lactams, fluoroquinolones, tetracyclines, 
chloramphenicol, macrolides, novobiocin, trimethoprim, 
sulfonamides 
MexCD-OprJ NfxB β-lactams, fluoroquinolones, tetracyclines, 
chloramphenicol, macrolides, novobiocin 
MexEF-OprN MexT MexS, MvaT fluoroquinolones, chloramphenicol, trimethoprim 
MexXY-OprM/Opm-x MexZ β-lactams, fluoroquinolones, aminoglycosides, 
tetracyclines, chloramphenicol, macrolides 
MexJK-OprM/OpmH MexL tetracycline, erythromycin 
MexGHI-OpmD SoxR fluoroquinolones 
MexVW-OprM fluoroquinolones, tetracyclines, chloramphenicol, 
erythromycin 
MexPQ-OpmE fluoroquinolones, tetracyclines, chloramphenicol, 
macrolides 
MexMN-OprM     cloramphenicol, triamphenicol 
x, the efflux system MexXY may use OpmB, OpmG, OpmH and/or OmpI 
 
RND efflux pumps typically consist of three individual components: a periplasmic membrane fusion 
protein (MFP), a cytoplasmic membrane transporter (RND), and an outer membrane factor (OMF). 
MFP and RND are obligatorily co-transcribed in one operon, while the OMF can optionally be a part 
of the same operon or be an individually transcribed component (Figure 1.3). Regulation of the 
operons occurs by adjacent, direct regulators (usually transcriptional repressors) and partly in 
combination with secondary, indirect regulators [18]. Members of the RND family are secondary 
active transporters and gain their energy required for substrate extrusion from proton motive force 
[60]. 
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Figure 1.3 Structure and function of RND efflux pumps in Pseudomonas aeruginosa. 
A: RND pumps typically exist in a tripartite system consisting of an RND cytoplasmic membrane transporter 
(RND), a membrane fusion protein (MFP), and an outer membrane factor (OMF). Genes encoding for MFP and 
RND are always transcribed from the same operon, while the OMF gene may be part of the same operon. 
Primary regulation is usually mediated by an adjacently transcribed regulator (reg). B: The RND complex forms 
a channel spanning the entire cell envelope (including outer membrane, peptidoglycan, periplasm and inner 
cell membrane), which allows for the proton-driven transport of lipophilic and amphiphilic substances from the 
cytoplasm to the outside of the cell. The RND efflux pumps can also extrude drugs from the periplasmic space 
before they cross the cytoplasmic membrane. Figure modified from [18]. 
 
Although antimicrobial agents do not appear to be their natural substrates, RND efflux pumps show 
broad substrate specificity toward various classes of antibiotics [61-63]. However, only MexAB-OprM 
is expressed at sufficient levels to influence intrinsic multidrug susceptibility in wild-type cells [64]. In 
the case of the remaining Mex pumps, up-regulation has to be triggered by mutational disruption of 
the corresponding repressors. This can occur via non-synonymous single nucleotide polymorphisms 
(SNPs) or, more frequently, via unspecific short insertions or deletions within the repressing 
regulator gene that lead to the expression of a non-functional protein [65-67]. As during antibiotic 
treatment adaptive mutations which induce drug tolerance are strongly selected, alterations within 
efflux regulatory genes are an important step towards initial bacterial survival [68]. However, RND 
systems are only able to confer low level antibiotic resistance. Thus, more specific antibiotic target 
mutations have to follow promptly to conquer high level antibiotic exposure [69]. 
Three Mex pump systems, namely MexAB-OprM, MexCD-OprJ, and MexXY have been described 
previously to export β-lactam antibiotics [18]. However, the latter two have only a very narrow 
substrate profile. MexCD-OprJ prefers fourth generation cephalosporins as cefepime, cefpirome and 
cefozopran and shows no significant activity towards meropenem, and the extent of activity of 
MexXY for meropenem and ceftazidime is not completely clear, but MIC changes range among low 
susceptibility values and are generally lower for carbapenems than cephalosporins [70-72]. MexAB-
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OprM on the other hand exhibits broad substrate specificity among β-lactams, including the clinically 
relevant third generation cephalosporins and meropenem, and has a more pronounced effect on the 
respective susceptibility phenotype [18,73,74]. 
1.4.1.2 Porins and β-lactam resistance: OprD 
The outer membrane of Gram-negative bacteria is a semipermeable construct and functions as a 
barrier to direct the uptake of environmental substances. Permeability varies among different 
bacterial species and is decreased by 92 % in P. aeruginosa compared with E. coli [75]. Nevertheless, 
bacteria have to ensure sufficient nutrient uptake into the cell, which is achieved by a collection of 
water-filled protein channels, the porins. These porins play an important role in the transport of 
sugars, amino acids, phosphates, divalent cations, and siderophores [75]. However, since porins are 
non-specific or only contain stereospecific binding sites, they also allow the passage of hydrophilic 
antibiotics, as β-lactam, across the membrane [76-78]. Genome sequencing revealed 64 known or 
predicted porins in P. aeruginosa of which 19 belong to the family of OprD porins with 46 % to 57 % 
amino acid sequence similarity to the OprD protein [75,79]. 
OprD is a 443 amino acid long porin, specific for the uptake of basic amino acids, for example 
arginine, small peptides containing these amino acids, and respective analogues as carbapenem 
antibiotics for which it is the preferential entry portal [80,81]. Consequently, a decreased expression 
of functional OprD can increase carbapenem resistance [82,83]. Interestingly, due to the competition 
of carbapenems and amino acids passing through the channel, environmental conditions providing 
high concentrations of different amino acids, such as in serum or culture medium, can alter 
carbapenem MIC values by up to 2-fold [84,85]. However, mutants lacking OprD are not necessarily 
compromised in growth, since other porins can counteract the loss and take over specific amino acid 
transporting activities, as OpdP in the case of arginine [86,87]. 
The pathway of OprD mediated resistance can involve transcriptional repression or mutational 
disruption of the gene inducing conformational changes or premature translational stops, both 
frequently occurring during carbapenem treatment [88-90]. 
As other typical porin proteins, OprD contains a transmembrane β-barrel structure comprising 16 
strands interconnected with seven short periplasmic turns, acting as hinges, and eight external loops 
[91,92]. X-ray crystal structures even suggest an 18-stranded β-barrel with nine external loops [93]. 
This particular structure is essential for the semi-selective substance transport, as it was shown by 
deletion experiments that the different external loops specifically interact with putative substrates, 
and missing amino acids can increase or decrease the susceptibility towards individual antibiotics or 
whole substance classes as carbapenems or other β-lactams  [88,91,92,94-96]. 
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Despite the importance of the external loops in substrate up-take, OprD shows a high natural 
variability, especially within these regions, also among carbapenem susceptible strains and 
particularly clinical isolates [92,96,97]. One reason could be selective pressure upon specific 
environmental conditions, as the immune system for example recognizes bacteria first by distinct 
surface markers, in particular outer membrane proteins. Thus, high porin surface variability 
influences host pathogen interactions and aids in immune evasion [98]. 
Besides mutational disruption, transcriptional repression of oprD is a key principle in carbapenem 
resistance. However, regulation of oprD comprises a complex network and is not yet completely 
understood. Transcription of oprD can be initiated from two start sites, 23 and 71 bases upstream of 
the gene, which are both used with equal frequencies [18]. Ochs and colleagues even described a 
third start site at position -89 and additionally identified the arginine responsive regulator ArgR as 
one of the direct transcription inducers [99]. They also proposed a second amino acid dependent 
induction mechanism, as glutamate as carbon source triggers oprD expression independently of 
ArgR. 
On the other hand, multiple ways of transcriptional repression are known as well, which include 
trace metal (particularly zinc and copper) dependent repression via CrcS, CrzR, and the two 
component regulatory system CopR-CopS [100-102]. Recently another two-component regulatory 
system, ParR-ParS which is also involved in MexXY regulation was described to possibly influence 
imipenem susceptibility by repressing oprD expression [103]. Synergistic regulation of OprD and 
efflux pumps seems to be of general importance, as this has also been described for the MexEF-OprN 
efflux pump. The mexEF-oprN operon is, amongst other factors, controlled by the adjacently 
transcribed transcriptional activator MexT, which was shown to not only positively regulate mexEF-
oprN but also negatively regulate oprD expression [104,105]. However, it is not known so far, 
whether MexT directly interacts with the oprD promoter or rather stimulates indirect transcriptional 
regulation, and there is further evidence for MexT-mediated posttranscriptional effects [106]. 
1.4.2 β-lactamases – hydrolyzing enzymes 
Besides controlling antibiotic influx and efflux, a third important β-lactam resistance mechanism in 
Gram-negative bacteria is the antibiotic degradation by corresponding enzymes, the β-lactamases 
[47]. β-lactamases are able to inactivate antibiotics by hydrolyzing the amide bond of their 
characteristic four-membered β-lactam core ring-structure [107,108]. Thus, they lose their PBP 
binding capacity and thereby their membrane destructive functions. In fact, hydrolysis of β-lactam 
antibiotics by β-lactamases is the most common mechanism of resistance for this class of 
antibacterial agents in clinically important Gram-negative bacteria [109]. By late 2009, 890 unique 
variants of these enzymes had been reported, but this number is constantly growing [109-113]. 
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Depending on their different molecular structure, β-lactamases can be divided into two families, 
serine-β-lactamases and metallo-β-lactamases (MBL). While MBLs need zinc to be functionally active 
and are inhibited by metal chelators as EDTA, serine-β-lactamases remain unaffected [114]. Further 
classification is done based on the amino acid sequence similarities of these enzymes. To date, four 
classes are recognized (A-D): classes A, C, and D act by a serine-based mechanism, whereas class B 
contains the MBLs. Classes A, C and D show high substrate diversities including narrow and wide 
spectrum activity, including a few carbapenemases and extended spectrum β-lactamases (ESBLs). 
MBLs likewise display varying substrate specificities; however, they share the common features of 
potent carbapenemase activity, resistance to clinical β-lactamase inhibitors and lack of activity 
against monobactams [115-117]. For an overview on β-lactamase classification and properties, see 
Table 1.2. 
 
Table 1.2 Classification and properties of β-lactamases. 
Table modified from [47] with further modifications from [109,113,114,118]. 
Class Type of enzyme Preferred substrates 
Inhibited by 
Representative enzymes or 
enzyme families CA or 
TZB* 
EDTA 
A Penicillinase Penicillins yes no Penicillinases from Gram-
positives 
 RSBL Penicillins, cephalosporins yes no TEM-1, TEM-2, SHV-1 
 ESBL Penicillins, cephalosporins
a
, 
monobactams 
yes no SHV, TEM, CTX-M, PER-1, VEB, 
GES,  
 IR β-lactamase Penicillins, cephalosporins no no TEM-30 to -41, -44, -45, -51, -54 
 
IR ESBL Penicillins, cephalosporins
a
 no no TEM-50, -68, -80 
 Carbapenemase Penicillins, cephalosporins, 
carbapenems, monobactams; 
sometimes es-β-lactams
b
 
some no SME, IMI, KPC, GES-2, SHV-38 
B Carbapenemase Most β-lactams no yes 
IMP, VIM, SPM, IND, NDM, GIM, 
AIM, FIM, SIM, DIM 
C Expanded-spectrum 
cephalosporinase 
Penicillins, carbapenems, es-β-
lactams
b
 and 4th generation 
cephalosporins 
no no CMY, LAT, MOX, FOX, ACT, MIR, 
DHA, CFE-1 
 
D 
 
Narrow-spectrum 
penicillinase 
Penicillins, cloxacillin some no OXA 
  
ESBL 
 
Penicillins, cloxacillin, es-β-
lactams
b
, sometimes 
monobactams or cephalosporins
c
 
 
some 
 
no 
several OXA-2 and -10 
derivatives, OXA-18, -29, -30, -
31, -32, -45 
  
Carbapenemase penicillins, oxacillin, carbapenems yes no 
several OXA-23 to -24, -48, -51, 
-55, -58, -60, -62 derivatives 
a
 including narrow and extended spectrum cephalosporins; 
b
 extended spectrum beta-lactams; 
c
 4th generation 
cephalosporins; * cluvanic acid and tazobactam; ESBL, extended spectrum beta-lactamase; RSBL, restricted 
spectrum beta-lactamase; IR, inhibitor resistant 
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1.4.2.1 Acquired β-lactamases 
Horizontally acquired β-lactamases largely contribute to a rapid intra- and inter-species spread of β-
lactam resistances among clinical isolates [119-122]. They are either plasmid encoded or associated 
with transposable genetic elements to facilitate mobility, including transfer across different bacterial 
genera [123]. The respective genes may be parts of single small mobile elements known as gene 
cassettes, which comprise the open reading frame (ORF) and a downstream recombination site, or 
be organized in large integrons, which are the major vectors of antibiotic multi-resistance in Gram-
negative bacteria [124,125]. Integrons are genetic elements that harbor a number of different gene 
cassettes, usually commonly transcribed from one integron specific promoter [126]. Furthermore, an 
integron comprises an individually expressed, recombinase (e.g. IntI) that promotes the specific 
excision of genes cassettes and their integration at an adjacent attI site [127,128]. 
Among the acquired β-lactamases, ESBLs and carbapenemases pose a particular threat as they 
constitute broad resistance towards almost all β-lactam antibiotics. Although these enzymes show 
world-wide dissemination, epidemiological patterns differ country specific [114]. To date, seven 
types of MBL carbapenemases, IMP, VIM, NDM, SPM, GIM, AIM and FIM, and tree types of serine 
carbapenemases, GES, KPC and OXA have been described in P. aeruginosa [113,114,129]. However, 
MBLs are the most prevalent group of carbapenemases in this organism [129]. Among the ESBLs, 
CTX-M, VEB, and PER variants have the most widespread dissemination and, along with OXA ESBLs, 
have been found in clinical P. aeruginosa isolates [130-136].  
1.4.2.2 P. aeruginosa endogenous β-lactamases: OXA-50 and AmpC 
Besides the potential to acquire new β-lactamases from other bacteria, the P. aeruginosa genome 
also encodes for two endogenous β-lactamases, a constitutively expressed oxacillinase, OXA-50 
(PoxB) and an inducible, expanded spectrum cephalosporinase, AmpC [137]. While OXA-50 has only 
very narrow substrate specificity and low hydrolysis potential, AmpC is capable of efficiently 
degrading all β-lactam antibiotics except carbapenems, whose hydrolysis only occurs upon specific 
mutational changes within AmpC [137-139]. However, AmpC is only produced at very low, basal 
levels in wild-type cells and resistance is dependent on induction or constitutive overexpression of 
the gene. This explains the effectiveness of anti-pseudomonal β-lactam antibiotics as ceftazidime and 
piperacillin, which lack sufficient AmpC induction activity (opposed to narrow spectrum 
cephalosporins and benzyl-penicillins) [138,140]. Interestingly, carbapenems are able to induce ampC 
expression, although they are not (or only marginally, as for imipenem) hydrolyzed by the native 
AmpC enzyme [141,142]. 
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Mutational induction of ampC overexpression is a common mechanism and of great clinical 
significance, as it has previously been described that bacteremia patients with AmpC overproducing 
P. aeruginosa were 67 times more likely to receive inappropriate empiric antibiotics and were thus 
likewise more prone to acquire persistent bacteremia (45 % vs. 6 %) [143-145]. However, the 
mutational sites where such mutations can occur are diverse due to the complex ampC-regulatory 
network. 
 
 
Figure 1.4 Mechanisms involved in ampC expression regulation. 
A: Wild-type basal expression of ampC. During normal cell wall recycling, 1,6-anhydromuropeptides (AHMPs) 
are removed from the cell wall and transported into the cytoplasm via the AmpG permease. The AHMPs are 
cleaved by AmpD, and later converted into UDP-MurNAc-pentapeptides (UDP-PPs). These UDP-PPs interact 
with AmpR bound to the ampR-ampC intergenic region, creating a conformation that represses transcription of 
ampC, resulting in only low, basal levels of AmpC. B: β-lactam induction of ampC expression. Inducing β-
lactams enter the periplasmic space and interact with target PBPs. This leads to an increase in cell wall 
fragment (AHMPs), which AmpD is unable to process efficiently. The AHMPs (inducing peptides) replace UDP-
PPs (suppressing peptides) bound to AmpR, causing a conformational change that converts AmpR into a 
transcriptional activator. Thus, ampC is expressed at higher levels. Figure modified from [18]. 
 
Direct regulation of ampC expression is controlled by the transcriptional regulator AmpR, which binds 
to the ampR-ampC intergenic region. Whether AmpR activates or represses ampC expression is 
dependent on the type of additional cofactor and is tightly interlinked with the process of 
peptidoglycan precursor recycling, as depicted in Figure 1.4 [18,107]. During normal cell wall 
synthesis, muropeptides are produced, which enter the cytoplasm through the permease AmpG 
[146]. In the cytoplasm, they are modified by AmpD and UDP is added [50,147,148]. These UPD-
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peptides have a repressing function when binding AmpR, resulting in only low level basal expression 
of ampC [149]. When inducing β-lactams enter the cell, they lead to an increased production of 
muropeptides, which AmpD is not able to handle anymore [150]. Thus, these muropeptides bind 
AmpR instead of the UPD-peptides. This leads to a conformational change in AmpR, which now 
activates high expression of ampC [149]. Once the level of β-lactams has decreased again due to 
degradation by AmpC, wild-type ampC expression is automatically restored [18]. 
Constitutive overexpression (de-repression) of ampC can result from a modification of any of the 
involved regulatory components. However, some AmpC-overproducing P. aeruginosa strains do not 
exhibit mutations in either ampR, ampD, or the ampR-ampC intergenic region and do not exhibit 
changes in the level of ampD expression [151,152]. Therefore it is suggested that further factors for 
AmpC regulation exist, possibly including AmpD homologues – P. aeruginosa exhibits two additional 
AmpD homologues, AmpDh2 and AmpDh2 – , AmpE or PBP4 [153-155]. 
1.5 How antibiotics affect bacteria – from specific targets to global networks 
Most investigations on how bactericidal antibiotics affect bacteria and induce cell death are centered 
on the antibiotic’s primary targets. Aminoglycosides stall translation by binding the ribosomes, 
quinolones prevent DNA replication by interfering with gyrase and topoisomerase, and β-lactams 
inhibit cell wall biosynthesis. However, in recent studies secondary mechanisms beyond primary 
targets have been described as important contributors to antibiotic tolerance. In these publications, 
large collections of P. aeruginosa transposon mutants were screened for susceptibility to different 
antibiotics (ciprofloxacin, tobramycin, amikacin, meropenem, imipenem, ceftazidime, tetracycline 
and polymixins), identifying genes of diverse functions, which are not related to efflux systems or cell 
envelope composition, but often involved in the bacterial metabolism [156-160]. While the identified 
genes are often unique for a particular substrate, there are also overlaps across structurally different 
classes of antibiotics, as ftsK, encoding for a protein involved in cell division, was shown to be 
involved in low level resistance to quinolones and β-lactams [157,159]. 
Even more overlaps could be detected in the case of the catabolite repression control regulator Crc. 
Crc is a post-transcriptional repressor that regulates the use of carbon sources in nutrient complex 
environments [161]. Inhibition of Crc makes P. aeruginosa less virulent and more susceptible to 
antibiotics in planktonic culture and biofilms, emphasizing the influence of global regulatory 
networks on antibiotic resistance [162,163]. 
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Figure 1.5 Common mechanism of cell death induced by bactericidal antibiotics. 
The primary drug-target interaction (aminoglycosides with ribosomes, quinolones with gyrase/topoisomerase, 
and β-lactams with PBPs) stimulates the oxidation of NADH through the electron transport chain, which is 
dependent on the tricarboxylic acid (TCA) cycle. Hyperactivation of the electron chain stimulates superoxide 
(O2
-
) formation, which damage iron-sulfur clusters. This leads to the formation of hydroxyl radicals (.OH) by the 
Fenton reaction which damage DNA, proteins and lipids and thus contributes to antibiotic-induced cell death. 
Another mechanism to trigger hydroxyl radical formation is through two component systems, as the redox 
responsive Arc system or the envelope responsive Cpx system, and it is suggested that redox sensitive proteins 
containing disulphides might also contribute to this mechanism. Figure from [42]. 
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Kohanski and colleagues even went a step further when they introduced their model of cell death by 
bactericidal antibiotics in 2007 [164]. Hence it is proposed that not only interconnected antibiotic 
tolerance mechanisms exist, but that there is also a common mechanism of killing by these 
antibiotics, regardless of their structural class and primary target. 
In this proposed model a common downstream cascade upon primary drug-target interaction is 
described which leads to the production of lethal doses of reactive oxygen species (ROS) (Figure 1.5). 
When the antibiotics bind their targets, they stimulate a metabolic feedback that conducts the 
oxidation of NADH by the electron transport chain within the tricarboxylic acid (TCA) cycle. A 
hyperactivation of this electron chain stimulates the formation of superoxides which damage iron-
sulfur clusters and thus make free iron available for oxidation through hydrogen peroxide by in the 
Fenton reaction. As a result, hydroxyl radicals are formed that damage DNA, proteins and lipids and 
thus promote antibiotic-induced cell death [164]. However, this model is still widely discussed with 
several recent approving and rejecting studies [165-169].  
1.6 Recent progress in next generation sequencing 
The “genomic era” started with the first complete bacterial genome which was sequenced using 
Sanger sequencing technology in 1995 [170]. Although sequencing greatly progressed during the 
following years, mostly due to the human Genome Project, the complete sequencing of one single 
genome still required years of time and very large budgets. Ten years later, in 2005, the introduction 
of “next generation sequencing” finally led to significant advances towards more cost efficient, high-
throughput technologies [171,172]. In recent years, the sequencing capability has even been 
doubling every 6 to 9 months – much faster than Moore’s law [173,174]. As one example, while there 
were only 11 publically available unique and complete Pseudomonas aeruginosa sequences released 
between 2000 and 2012, this number had increased to 21 by January 2014 [175]. 
Next generation sequencing technologies include a number of different methods [176-178] that vary 
in costs, sequencing time, read lengths, and accuracy, but all of them comprise the three steps of 
template library preparation, sequencing, and data analysis [179]. Sequencing techniques can 
contain the detection of bioluminescent or up to four colors fluorescent signals, and usually include 
the immobilization of spatially separated template sites either on beads in emulsion (Roche/Life 
Technologies) or on solid phase (Illumina/Pacific Biosciences) [179]. 
Besides whole genome sequencing, next generation technologies also revolutionized transcriptome 
analysis, as they show clear advantages compared with the before widely used microarrays. 
Transcriptome sequencing (RNA-seq) provides sequence and expression information at the same 
time and thus allows for de novo sequence assembly instead of hybridization to a predefined tiling 
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array matrix [180]. This facilitates the detection of previously unannotated genes and sequences. 
Furthermore, RNA-sequencing offers a higher dynamic range and increased sensitivity for low 
abundant transcripts, as well as single nucleotide resolution of transcript boundaries [181,182]. 
These benefits over microarrays have recently made RNA-sequencing a valuable tool for determining 
the transcriptomes of a variety of prokaryotes [183-185]. 
Furthermore, it is suggested that rapid and cheap sequencing could, besides basic research, also 
transform clinical microbiology. On the one hand by providing innovative molecular diagnostic tools 
to apply customized, targeted treatment approaches and thus avoid treatment failure, on the other 
hand by seeking for a comprehensive understanding of the genomic background and evolutionary 
biology of pathogens [186,187]. Here, RNA-sequencing provides a considerable advantage over DNA-
sequencing as the additional gene expression data facilitate the detection of adaptive mutations 
within the diverse genetic background of clinical isolates [188].  
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1.7 Aims of the thesis 
The frequency of antibiotic resistance in bacterial pathogens is steadily increasing around the world, 
resulting in a growing threat to public health. While the widespread and empirical use of antibiotics 
further promotes the expansion of resistance phenotypes and the occurrence of multi-drug 
resistance, at the same time adequate treatment options are diminishing due to the constantly 
declining approval rate of novel antibiotic compounds. Besides the promotion of drug discovery and 
approval, the continuing rapid evolution and spread of antibiotic resistances thus call for alternative 
strategies to combat bacterial infections. 
One major concern in this context is the treatment of multi-drug resistant Pseudomonas aeruginosa 
infections. This nosocomial pathogen is of particular importance since is does not only feature a large 
repertoire of intrinsic resistances, but also a great capacity to incorporate acquired ones. Thereby, 
not only the import of resistance mechanisms on mobile genetic elements is a growing concern, but 
also the bacteria’s impressive ability to develop resistance during the course of an infection through 
adaptive chromosomal mutational changes. While many direct antibiotic targets have already been 
described, their complex regulatory networks, cross-resistance interplay, and predisposing factors 
are still largely unknown and call for further, detailed investigation. 
 
The overall aim of this thesis was to shed more light on the P. aeruginosa resistome and evaluate 
potential targets for molecular diagnostic approaches and optimized treatment strategies. To achieve 
this goal, we aimed at using a cost efficient RNA-sequencing method to investigate the 
transcriptomes of large amounts of clinical P. aeruginosa isolates from diverse geographical and 
infection site origins in respect to their β-lactam antibiotic resistance determinants. Thereby global 
phenotype-genotype correlations should be applied to uncover all known as well as potentially knew 
core genetic resistance markers and identify their nature, dimension, and interaction. Furthermore, 
the accessory transcriptome of these isolates was to be analyzed for mobile, acquired genetic 
elements. 
To gain more insight into the evolution of resistance and cooperating regulatory networks, we also 
aimed to explore the impact of low, sub-lethal antibiotic exposure and its effects on transcriptional 
and metabolic profiles. In this regard it was particularly of interest, if different antibiotics from 
diverse substance classes and with variable direct cellular targets induce similar or divergent cellular 
responses.
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2 Materials and Methods 
2.1 Bacterial strains and growth conditions 
The bacterial strains used in this study are listed in Tables 2.1-2.2. All strains were maintained at 
-70 °C as 15 % (v/v) glycerol stocks. Escherichia coli strain DH5α was used for all cloning steps, and 
strain S17-1 for conjugative DNA transfer. As Pseudomonas aeruginosa reference strain, the well-
established and completely sequenced PA14 strain was used. 
All P. aeruginosa and E. coli strains were cultured at 37 °C in Luria-Bertani broth (LB; 1 l = 5 g yeast-
extract, 7.5 g NaCl, 10 g tryptone), shaking (180 rpm), unless indicated differently. LB medium was 
solidified by addition of 1.6 % (w/v) agar. 
When required for selection, the following antibiotics were used for Pseudomonas and E. coli, 
respectively: 100 µg/ml and 10 µg/ml tetracycline, 30 μg/ml and 15 μg/ml gentamycin, 400 μg/ml 
carbenicillin and 100 μg/ml ampicillin. Oligomers used for cloning and RNA-sequencing (Table 2.3) 
were ordered from Eurofins MWG Operon. Primers for cloning were designed based on the PA14 
genome sequence [189], and PCR amplifications were performed using PA14 genomic DNA as 
template. All obtained constructs were sequenced at Eurofins MWG Operon to rule out PCR errors. 
 
Table 2.1 Bacterial strains used in this study (not including clinical isolates). 
      
Strain Relevant genotype  Reference 
E. coli     
DH5α F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZ M15 
[190] 
(lacZYA-argF)U169, hsdR17(rK-mK+), λ- 
S17-1 C600::RP-4 2-(Tc::Mu) (Kn::Tn7) thi pro hsdR hsdM+recA [191] 
P. aeruginosa 
PA14 wt [192] 
PA14ΔmexS mexS knock-out mutant constructed in the PA14 wt strain This study 
PA14ΔoprD oprD knock-out mutant constructed in the PA14 wt strain This study 
PA14ΔmexR mexR knock-out mutant constructed in the PA14 wt strain [69] 
PA14ΔmexZ mexZ knock-out mutant constructed in the PA14 wt strain [69] 
PA14ΔnfxB nfxB knock-out mutant constructed in the PA14 wt strain [69] 
PA14ΔoprDΔmexR oprD / mexR double knock-out mutant constructed in PA14ΔmexR This study 
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2.1.1 Clinical strain collection 
The 149 in this study investigated clinical P. aeruginosa isolates were provided by different clinics and 
research institutions. In total, 87 isolates were collected at the Hannover Medical School (MHH), 40 
isolates were from a strain collection provided by the University of Freiburg (sampled in numerous 
countries across Europe), 14 isolates were received from the Robert-Koch-Institute in Wernigerode, 
and 8 isolates were provided by the National Reference Centre for multidrug-resistant Gram-
negative Bacteria in Bochum. The resulting strain-collection contained a cross-sectional distribution 
with diverse sample origins (Table 2.2). Most of the isolates were categorized as multidrug-resistant 
(resistant to three or more antimicrobial classes, according to Magiorakos et al., [30]). The antibiotic 
susceptibility data were either hospital- or institution-derived or determined in house using the 
Vitek2 system (bioMérieux) or E-tests (bioMérieux).  
 
Table 2.2 Clinical isolates used in this study. 
                  
Origin Strain CF Material City, country 
RNA-seq pool and 
barcode 
CAZ 
MIC 
MEM 
MIC 
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B197 nd nd nd clinical_pool_11_bc3 8 S 16 R 
B214 nd nd nd clinical_pool_11_bc4 8 S 8 I 
B266 nd nd nd clinical_pool_11_bc6 16 I 16 R 
B271 nd nd nd clinical_pool_11_bc5 1 S 0.5 S 
B337 nd nd nd clinical_pool_11_bc8 1 S 8 I 
B34 nd nd nd clinical_pool_11_bc1 265 R 0.25 S 
B428 nd nd nd clinical_pool_11_bc9 8 S 32 R 
B445 nd nd nd clinical_pool_11_bc10 1 S 32 R 
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MHH10047 no tonsil swab Hannover, Germany clinical_pool_6_bc18 8 S 1 S 
MHH10049 yes nasal swab Hannover, Germany clinical_pool_6_bc19 8 S 2 S 
MHH10660 yes lung transplant donor Hannover, Germany MHH-pool-04_bc20 256 R 16 R 
MHH10978 yes tonsil swab Hannover, Germany clinical_pool_7_bc7 32 R 4 S 
MHH11148 no tonsil swab Hannover, Germany clinical_pool_7_bc10 16 I 1 S 
MHH11444 yes tonsil swab Hannover, Germany MHH-pool-05_bc6 8 S 16 R 
MHH11445 yes tonsil swab Hannover, Germany MHH-pool-05_bc7 8 S 4 S 
MHH11540 no midstream urine Hannover, Germany clinical_pool_9_bc6 32 R 8 I 
MHH11572 no midstream urine Hannover, Germany clinical_pool_8_bc23 256 R 16 R 
MHH11785 yes lung transplant donor Hannover, Germany MHH-pool-04_bc11 256 R 8 I 
MHH11935 no bronchoalveolar lavage Hannover, Germany clinical_pool_8_bc1 8 S 8 I 
MHH11989 yes tonsil swab Hannover, Germany clinical_pool_7_bc8 8 S 8 I 
MHH12178 no catheter swab abdomen Hannover, Germany clinical_pool_6_bc9 16 I 16 R 
MHH12207 yes bronchoalveolar lavage Hannover, Germany MHH-pool-05_bc3 32 R 8 I 
MHH12269 yes sputum Hannover, Germany MHH-pool-05_bc4 32 R 16 R 
MHH12274 no bronchoalveolar lavage Hannover, Germany clinical_pool_7_bc9 16 I 0.5 S 
MHH13062 no permanent catheter urine Hannover, Germany clinical_pool_9_bc7 8 S 4 S 
MHH13224 no bronchial rinsing Hannover, Germany clinical_pool_9_bc2 8 S 8 I 
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MHH13305 yes bronchial secrete Hannover, Germany clinical_pool_7_bc11 32 R 16 R 
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MHH13395 no bronchoalveolar lavage Hannover, Germany MHH-pool-05_bc5 8 S 8 I 
MHH13428 no swab intraop abdomen Hannover, Germany clinical_pool_9_bc4 32 R 2 S 
MHH13633 no tracheal secrete Hannover, Germany MHH-pool-04_bc12 2 S 1 S 
MHH13682 yes lung transplant donor Hannover, Germany clinical_pool_6_bc8 256 R 8 I 
MHH13684 yes lung transplant recipient Hannover, Germany clinical_pool_9_bc5 256 R 4 S 
MHH13714 no permanent catheter urine Hannover, Germany clinical_pool_7_bc1 8 S 0.25 S 
MHH14088 no perfusate Hannover, Germany clinical_pool_7_bc2 8 S 2 S 
MHH14103 no swab heel Hannover, Germany clinical_pool_7_bc5 32 R 8 I 
MHH14322 no bronchial rinsing Hannover, Germany clinical_pool_7_bc3 8 S 0.5 S 
MHH14387 yes lung transplant recipient Hannover, Germany clinical_pool_7_bc6 4 S 4 S 
MHH14449 no bronchial secrete Hannover, Germany clinical_pool_7_bc4 16 I 16 R 
MHH6827 no midstream urine Hannover, Germany MHH-pool-02_bc12 32 R 8 I 
MHH6829 no midstream urine Hannover, Germany MHH-pool-02_bc1 16 I 16 R 
MHH6870 no midstream urine Hannover, Germany MHH-pool-02_bc2 32 R 8 I 
MHH6887 no tracheal secrete Hannover, Germany clinical_pool_6_bc10 32 R 0.125 S 
MHH6938 no bronchoalveolar lavage Hannover, Germany MHH-pool-05_bc1 16 I 4 S 
MHH6964 no wound swab abdomen Hannover, Germany MHH-pool-02_bc3 8 S 8 I 
MHH7032 no venous catheter Hannover, Germany MHH-pool-04_bc13 16 I 8 I 
MHH7055 no bronchoalveolar lavage Hannover, Germany MHH-pool-03_bc1 4 S 8 I 
MHH7084 no permanent catheter urine Hannover, Germany MHH-pool-03_bc2 32 R 8 I 
MHH7091 yes lung transplant recipient Hannover, Germany MHH-pool-04_bc5 4 S 0.5 S 
MHH7125 no tonsil swab Hannover, Germany MHH-pool-04_bc14 8 S 4 S 
MHH7135 no bronchial secrete Hannover, Germany MHH-pool-04_bc9 4 S 4 S 
MHH7176 no midstream urine Hannover, Germany MHH-pool-04_bc15 32 R 8 I 
MHH7200 yes tonsil swab Hannover, Germany MHH-pool-03_bc4 32 R 4 S 
MHH7252 no tracheal secrete Hannover, Germany MHH-pool-03_bc7 2 S 4 S 
MHH7261 no permanent catheter urine Hannover, Germany MHH-pool-02_bc10 32 R 8 I 
MHH7313 no tracheal secrete Hannover, Germany MHH-pool-01_bc6 4 S 8 I 
MHH7368 no nasal swab Hannover, Germany MHH-pool-02_bc11 16 I 8 I 
MHH7444 yes bronchoalveolar lavage Hannover, Germany MHH-pool-03_bc3 32 R 8 I 
MHH7508 yes bronchial secrete Hannover, Germany MHH-pool-02_bc4 32 R 8 I 
MHH7818 yes tracheal secrete Hannover, Germany MHH-pool-02_bc7 8 S 4 S 
MHH7823 no tonsil swab Hannover, Germany MHH-pool-03_bc5 32 R 8 I 
MHH7863 no bronchial secrete Hannover, Germany MHH-pool-03_bc6 32 R 8 I 
MHH8044 yes tracheal secrete Hannover, Germany MHH-pool-02_bc8 32 R 8 I 
MHH8349 no midstream urine Hannover, Germany MHH-pool-01_bc1 32 R 8 I 
MHH8478 no midstream urine Hannover, Germany MHH-pool-01_bc2 32 R 1 S 
MHH8481 yes bronchial secrete Hannover, Germany MHH-pool-04_bc16 256 R 32 R 
MHH8482 yes bronchial secrete Hannover, Germany MHH-pool-01_bc9 32 R 8 I 
MHH8607 no sputum Hannover, Germany clinical_pool_6_bc13 32 R 16 R 
MHH8613 no ear swab Hannover, Germany MHH-pool-03_bc8 32 R 2 S 
MHH8614 no midstream urine Hannover, Germany MHH-pool-01_bc3 32 R 1 S 
MHH8627 no drainage bile duct Hannover, Germany MHH-pool-01_bc4 16 I 32 R 
MHH8697 no rectal swab Hannover, Germany MHH-pool-02_bc9 1 S 16 R 
MHH8931 yes lung transplant donor Hannover, Germany MHH-pool-05_bc17 256 R 16 R 
MHH9157 no wound swab abdomen Hannover, Germany MHH-pool-01_bc5 32 R 1 S 
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MHH9229 no tonsil swab Hannover, Germany MHH-pool-01_bc10 16 I 4 S 
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MHH9460 nd tracheal secrete Hannover, Germany MHH-pool-01_bc7 32 R 8 I 
MHH9481 no bronchial rinsing Hannover, Germany clinical_pool_8_bc13 32 R 4 S 
MHH9484 no tonsil swab Hannover, Germany MHH-pool-01_bc8 8 S 8 I 
MHH9509 nd tracheal secrete Hannover, Germany MHH-pool-01_bc11 32 R 8 I 
MHH9534 no bronchial secrete Hannover, Germany MHH-pool-05_bc18 32 R 8 I 
MHH9536 nd tracheal secrete Hannover, Germany MHH-pool-01_bc12 32 R 16 R 
MHH9561 nd tonsil swab Hannover, Germany MHH-pool-03_bc13 32 R 16 R 
MHH9604 nd bronchial secrete Hannover, Germany MHH-pool-03_bc14 32 R 8 I 
MHH9619 nd tonsil swab Hannover, Germany MHH-pool-03_bc15 32 R 8 I 
MHH9639 nd tonsil swab Hannover, Germany MHH-pool-03_bc16 32 R 8 I 
MHH9652 no drainage liquid Hannover, Germany clinical_pool_6_bc14 32 R 8 I 
MHH9674 no bronchoalveolar lavage Hannover, Germany clinical_pool_6_bc15 2 S 0.125 S 
MHH9678 nd tonsil swab Hannover, Germany clinical_pool_7_bc12 32 R 8 I 
MHH9709 nd tonsil swab Hannover, Germany MHH-pool-05_bc8 32 R 8 I 
MHH9717 no tracheal secrete Hannover, Germany MHH-pool-04_bc10 8 S 16 R 
MHH9748 no tonsil swab Hannover, Germany MHH-pool-05_bc16 4 S 4 S 
MHH9830 no tracheal secrete Hannover, Germany MHH-pool-05_bc9 32 R 8 I 
MHH9847 nd tracheal secrete Hannover, Germany MHH-pool-05_bc10 32 R 8 I 
MHH9854 yes nasal swab Hannover, Germany clinical_pool_6_bc17 256 R 8 I 
MHH9923 nd tracheal secrete Hannover, Germany clinical_pool_6_bc11 32 R 8 I 
MHH9924 nd swab intraoperative Hannover, Germany clinical_pool_6_bc12 32 R 8 I 
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Psae0613 nd nd nd PSAE_1_PE_bc1 8 S 0.25 S 
Psae1152 nd drainage catheter Stuttgart, Germany PSAE_1_PE_bc10 128 R 64 R 
Psae1471 nd respiratory tract Berlin, Germany PSAE_1_PE_bc3 2 S 0.5 S 
Psae1640 nd urine Munich, Germany clinical_pool_9_bc12 8 S 2 S 
Psae1646 nd urine Munich, Germany clinical_pool_10_bc5 4 S 16 R 
Psae1655 nd respiratory tract Munich, Germany clinical_pool_10_bc2 4 S 8 I 
Psae1657 nd respiratory tract Munich, Germany clinical_pool_10_bc7 8 S 16 R 
Psae1659 nd respiratory tract Munich, Germany clinical_pool_10_bc8 16 I 8 I 
Psae1660 nd respiratory tract Munich, Germany clinical_pool_10_bc6 8 S 16 R 
Psae1661 nd respiratory tract Freiburg, Germany clinical_pool_8_bc17 64 R 128 R 
Psae1688 nd urine Limburg, Germany clinical_pool_10_bc9 4 S 8 I 
Psae1695 nd respiratory tract Bremen, Germany clinical_pool_10_bc15 4 S 1 S 
Psae1711 nd nd Regensburg, Germany PSAE_1_PE_bc7 1 S 0.5 S 
Psae1715 nd respiratory tract Freiburg, Germany clinical_pool_10_bc10 4 S 8 I 
Psae1716 nd blood Freiburg, Germany clinical_pool_8_bc16 32 R 8 I 
Psae1747 nd respiratory tract Freiburg, Germany PSAE_1_PE_bc2 64 R 16 R 
Psae1758 nd respiratory tract Limburg, Germany PSAE_1_PE_bc6 2 S 0.25 S 
Psae1766 nd respiratory tract Bremen, Germany PSAE_1_PE_bc8 8 S 16 R 
Psae1775 nd respiratory tract Ruedesheim, Germany clinical_pool_10_bc11 4 S 8 I 
Psae1793 nd respiratory tract nd clinical_pool_10_bc4 8 S 32 R 
Psae1807 nd respiratory tract Berlin, Germany clinical_pool_10_bc12 64 R 8 I 
Psae1829 nd respiratory tract Regensburg, Germany clinical_pool_10_bc13 4 S 8 I 
Psae1875 nd respiratory tract Berlin, Germany PSAE_1_PE_bc9 4 S 16 R 
Psae1892 nd respiratory tract Gera, Germany clinical_pool_9_bc11 4 S 2 S 
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Psae1910 nd respiratory tract Regensburg, Germany clinical_pool_9_bc13 1 S 0.25 S 
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Psae1928 nd respiratory tract Bremen, Germany clinical_pool_9_bc14 32 R 2 S 
Psae1950 nd respiratory tract Bremen, Germany clinical_pool_9_bc8 0.5 S 1 S 
Psae2134 nd respiratory tract Timisoara, Rumania clinical_pool_9_bc9 16 I 32 R 
Psae2136 nd respiratory tract Timisoara, Rumania PSAE_1_PE_bc12 64 R 16 R 
Psae2162 nd nd Catania, Italy PSAE_1_PE_bc11 128 R 32 R 
Psae2180 nd urine nd clinical_pool_8_bc18 128 R 64 R 
Psae2302 nd respiratory tract Rozzano, Italy clinical_pool_8_bc15 64 R 8 I 
Psae2305 nd respiratory tract Sassari, Italy clinical_pool_9_bc10 4 S 0.25 S 
Psae2307 nd respiratory tract Sassari, Italy clinical_pool_8_bc19 128 R 32 R 
Psae2319 nd nd Palermo, Italy clinical_pool_8_bc22 128 R 64 R 
Psae2324 nd respiratory tract Neubrandenburg, Germany PSAE_1_PE_bc4 2 S 4 S 
Psae2326 nd urine Neubrandenburg, Germany clinical_pool_8_bc14 32 R 16 R 
Psae2328 nd urine Neubrandenburg, Germany PSAE_1_PE_bc5 2 S 16 R 
Psae2335 nd urine Trencin, Hungary clinical_pool_8_bc20 256 R 128 R 
Psae2338 nd respiratory tract Bari, Italy clinical_pool_8_bc21 128 R 64 R 
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RKI_100_12 nd nd nd clinical_pool_12_bc9 32 R 32 R 
RKI_12_11 nd nd nd clinical_pool_11_bc12 8 S 32 R 
RKI_24_11 nd nd nd clinical_pool_12_bc13 32 R 32 R 
RKI_339_12 nd nd nd clinical_pool_12_bc20 256 R 32 R 
RKI_359_11 nd nd nd clinical_pool_12_bc24 32 R 32 R 
RKI_360_11 nd nd nd clinical_pool_12_bc7 16 I 32 R 
RKI_37_11 nd nd nd clinical_pool_12_bc16 16 I 32 R 
RKI_392_11 nd nd nd clinical_pool_12_bc10 8 S 0.25 S 
RKI_395_11 nd nd nd clinical_pool_12_bc15 32 R 8 I 
RKI_53_11 nd nd nd clinical_pool_12_bc18 32 R 4 S 
RKI_82_10 nd nd nd clinical_pool_12_bc22 32 R 32 R 
RKI_96_12 nd nd nd clinical_pool_11_bc14 32 R 8 I 
RKI_98_12 nd nd nd clinical_pool_12_bc11 4 S 16 R 
RKI_99_12 nd nd nd clinical_pool_12_bc17 32 R 16 R 
  
CF, patients diagnosed with cystic fibrosis; nd, not determined 
2.2 Plasmids and Oligomers 
Plasmids used for cloning can be found in the respective materials and methods section 
(Constructions of mexS and oprD knock-out mutants), a list of all oligomers used in this study is 
presented below, in Table 2.3. 
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Table 2.3 Oligomers used for PCR and RNA-sequencing. 
        
Oligoname Sequence* Classification Used for 
R 5' AAAAAAAAAAAAAAAAAAGAGCCGACATCGAGGTGCCAAAC 3' Capture oligomer rRNA removal 
4Pse 5' AAAAAAAAAAAAAAAAAAGGGTTGCGCTCGTTACGGGACTT 3' Capture oligomer rRNA removal 
4R 5' AAAAAAAAAAAAAAAAAAACTTACCCGACAAGGAATTTCGC 3' Capture oligomer rRNA removal 
1R 5' AAAAAAAAAAAAAAAAAATGGACTACCAGGGTATCTAATCC 3' Capture oligomer rRNA removal 
807-R 5' Biotin-GAGCCGACATCGAGGTGCCAAAC 3' Capture oligomer rRNA removal 
111-4Pse 5' Biotin-GGGTTGCGCTCGTTACGGGACTT 3' Capture oligomer rRNA removal 
195-4R 5' Biotin-ACTTACCCGACAAGGAATTTCGC 3' Capture oligomer rRNA removal 
251-1R 5' Biotin-TGGACTACCAGGGTATCTAATCC 3' Capture oligomer rRNA removal 
2-PolyA 5' AAAAAAAAAAAAAAAAAAGCTCCCTTCATCCGCTCGACTT 3' Capture oligomer rRNA removal 
9-PolyA 5' AAAAAAAAAAAAAAAAAAGTGCTTTACAATCCGAAGACCT 3' Capture oligomer rRNA removal 
27-PolyA 5' AAAAAAAAAAAAAAAAAATACTAGCGATTCCGACTTCACG 3' Capture oligomer rRNA removal 
3-PolyA 5' AAAAAAAAAAAAAAAAAAACTACTAAGGGAATCTCGGTTGA 3' Capture oligomer rRNA removal 
10-PolyA 5' AAAAAAAAAAAAAAAAAATTCCGCGCAGGCCGACTCGACTA 3' Capture oligomer rRNA removal 
RT 
 
5' GCTGAACCGCTCTTCCGATCT 3' 
 
Reverse transcription 
 
RNA-sequencing 
Primer A 5' AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCT 3' 
 
PCR primer RNA-sequencing 
Primer B 5 'CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTG
AACCGCTCTTCCGATCT 3' 
PCR primer RNA-sequencing 
B2 5' P-AGAUCGGAAGAGCGGUUCAGC-ddC 3' RNA-Adapter (3' Adapter) RNA-sequencing 
BC6-1 5' UACACGACGCUCUUCCGAUCUACGAGA 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-2 5' UACACGACGCUCUUCCGAUCUACUUGC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-3 5' UACACGACGCUCUUCCGAUCUAUCUGG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-4 5' UACACGACGCUCUUCCGAUCUCAUACG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-5 5' UACACGACGCUCUUCCGAUCUCGUCAU 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-6 5' UACACGACGCUCUUCCGAUCUGGUUAC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-7 5' UACACGACGCUCUUCCGAUCUGUACCU 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-8 5' UACACGACGCUCUUCCGAUCUGUCAAG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-9 5' UACACGACGCUCUUCCGAUCUUCUCUG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-10 5' UACACGACGCUCUUCCGAUCUUGGUUC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-11 5' UACACGACGCUCUUCCGAUCUUUCCGA 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-12 5' UACACGACGCUCUUCCGAUCUUUGCAG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-13 5' UACACGACGCUCUUCCGAUCUAAUCGG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-14 5' UACACGACGCUCUUCCGAUCUAGAGAC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-15 5' UACACGACGCUCUUCCGAUCUAGUCUC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-16 5' UACACGACGCUCUUCCGAUCUAUUGCC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-17 5' UACACGACGCUCUUCCGAUCUCCAUCG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-18 5' UACACGACGCUCUUCCGAUCUCGACCA 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-19 5' UACACGACGCUCUUCCGAUCUGACCUG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-20 5' UACACGACGCUCUUCCGAUCUGCUAGG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-21 5' UACACGACGCUCUUCCGAUCUGUCGGU 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-22 5' UACACGACGCUCUUCCGAUCUUAAGCG 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-23 5' UACACGACGCUCUUCCGAUCUUCCAAC 3' RNA-Adapter (5' Adapter) RNA-sequencing 
BC6-24 5' UACACGACGCUCUUCCGAUCUUUGGCU 3' RNA-Adapter (5' Adapter) RNA-sequencing 
mexS_FP1_XbaI 5' ACATCATCTAGAAGCACAACCCAAGCGATCAA 3' PCR primer mexS knock-out 
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mexS_RP1+20bp 5' ATGCACTGCAGAGGTTTGCGCGGGTATTCGAGTTCGACCAG 3' PCR primer mexS knock-out 
mexS_FP2+20bp 5' TGGTCGAACTCGAATACCCGCGCAAACCTCTGCAGTGCATC 3' PCR primer mexS knock-out 
mexS_RP2_HindIII 5' ACATCAAAGCTTAGGTGGGCGAAGATTTCCTG 3' PCR primer mexS knock-out 
oprD_FP1_XbaI 5' ACATCATCTAGAGCAGGTACAGGCGTTGATCC 3' PCR primer oprD knock-out 
oprD_RP1+20bp 5' AAACCAAAGGAGCAATCACACGACTATCCGCTGTCGATCC 3' PCR primer oprD knock-out 
oprD_FP2+20bp 5' GGATCGACAGCGGATAGTCGTGTGATTGCTCCTTTGGTTTTGA 3' PCR primer oprD knock-out 
oprD_RP2_HindIII 5' ACATCAAAGCTTGCAACCAACCCTTGAAGCAG 3' PCR primer oprD knock-out 
SeqPr_Oxa224_R 5' TTATAAATTTAGTGTGTTTAGAATGGTG 3' PCR primer β-lactamase amplification 
SeqPr_Oxa224_F 5' ATGAAAAACACAATACATATCAACTTC 3' PCR primer β-lactamase amplification 
SeqPr_Vim2_R 5' ATGTTCAAACTTTTGAGTAAGTTATTGG 3' PCR primer β-lactamase amplification 
SeqPr_Vim2_F 5' CTACTCAACGACTGAGCGATTTG 3' PCR primer β-lactamase amplification 
SeqPr_Vim1_R 5' ATGTTAAAAGTTATTAGTAGTTTATTGG 3' PCR primer β-lactamase amplification 
SeqPr_Vim1_F 5' CTACTCGGCGACTGAGCGATT 3' PCR primer β-lactamase amplification 
SeqPr_Imp7 _F 5' ATGAAAAAGTTATCAGTATTCTTTATGTTTTT 3' PCR primer β-lactamase amplification 
SeqPr_Imp7 _R 5' TTAGTTACTTGGTTTTGATAGCTTTTTAC 3' PCR primer β-lactamase amplification 
SeqPr_ctx123 _F 5' ATGGTTAAAAAATCACTGCGC 3' PCR primer β-lactamase amplification 
SeqPr_ctx123 _R 5' TTTCCGCTATTACAAACCGT 3' PCR primer β-lactamase amplification 
 
* Restriction sites are underlined, barcode sequences are marked in orange. 
 
2.3 DNA transfer techniques 
2.3.1 Transformation of chemically competent E. coli 
For the preparation of chemically competent E. coli, 50 ml LB were inoculated 1:1000 from an 
overnight culture of the respective strain and cultivated to an OD600 of 0.3-0.5. To prevent further 
growth, the culture was chilled on ice for 15 min before harvesting the cells by centrifugation at 4 °C 
at 3,200xg for 15 min. Subsequent steps were carried out on ice. The pellet was resuspended in 18 ml 
RF1 buffer (100 mM RbCl; 50 mM MnCl2; 30 mM potassium acetate; 10 mM CaCl2; pH 5.8). After a 
second centrifugation step, cells were resuspended in 2 ml ice-cold RF2 buffer (10 mM RbCl; 10 mM 
MOPS; 75 mM CaCl2; 15 % (v/v) glycerol; pH 5.8) and incubated on ice for 15 min. The competent 
cells were aliquoted 125 µl each, frozen in liquid nitrogen and stored at -70 °C. For transformation, 
competent cells were gently thawed on ice for 15 min, mixed with the respective DNA and further 
incubated on ice for 20 min. After a heat shock for 90 s at 42 °C, 800 µl LB was added and the cells 
were incubated shaking at 37 °C for 1 h. Thereafter, 100 µl of the transformation reaction was plated 
on LB agar containing antibiotics for selection of transformants. The plates were incubated overnight 
at 37 °C. 
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2.3.2 Electroporation of P. aeruginosa 
To prepare electrocompetent P. aeruginosa cells, a thick lawn of cells from an overnight grown LB 
agar plate was used. Half of the plate was harvested with an inoculation loop and resuspended in 
1 ml 0.3 M sucrose solution. The bacteria were collected by centrifugation (16,000xg for 2 min) and 
washed 3 additional times with sucrose solution to remove extracellular matrix compounds. Finally, 
the pellet was resuspended in 100 µl deionized water, mixed with 100 ng plasmid DNA, and 
transferred to an electroporation cuvette (2 mm electrode gap). The electroporation was carried out 
in a Gene Pulser II (Bio-Rad) with settings 2.45 kV voltage, 25 µF capacitance and 200 Ω resistance. 
1 ml pre-warmed LB was added directly after the discharge, the cells were transferred to a microfuge 
tube and incubated for 1.5 h at 37 °C. To select for transformants, 100 µl of cells were plated on LB 
agar containing antibiotics and incubated overnight at 37 °C. Electrocompetent P. aeruginosa cells 
were freshly prepared each time before use.  
2.3.3 Plasmid transfer by diparental mating (conjugation) 
When pex18AP constructs were used to create knock-out mutants, plasmids were introduced by 
conjugation with E. coli S17-1 as the donor strain. For conjugation experiments, the P. aeruginosa 
recipient was grown in 5 ml LB broth for 20 h at 42 °C, while the E. coli donor carrying the respective 
pex18AP construct was grown in 10 ml LB broth, supplemented with ampicillin for 6 h at 37 °C. 
Bacterial cultures were mixed in a 1:10 ratio, using 100 µl P. aeruginosa and 1 ml E. coli suspension. 
The cell-mix was harvested by centrifugation (6,000xg, 5 min), washed twice with LB and finally 
resuspended in 100 µl LB, before it was applied as a single drop on an LB agar plate. After 16 h of 
incubation at 37 °C, the drop was thoroughly washed off the agar plate with 2 ml PBS, and 100 µl of 
the suspension was plated on LB agar plates containing carbenicillin (400 µg/ml) and nalidixic acid 
(10 µg/ml) to counter select the E. coli donor cells and any P. aeruginosa which did not take in the 
pex18AP. To promote plasmid loss, single colonies were picked, cultivated overnight in 5 ml NaCl free 
LB broth containing 10 % sucrose, and passaged in this medium 3 times with 50 µl inoculum and an 
incubation time of 8-16 h for each passage. After the final passage, cells were diluted to obtain single 
colonies when plated on LB agar supplemented with 10 % sucrose. Successful mutation integration 
was screened for by checking the growth of single colonies on selective LB agar plates containing 
antibiotics. 
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2.4 Antibiotic susceptibility testing 
2.4.1 E-test 
Antibiotic susceptibility for selected clinical isolates was determined by E-test (bioMérieux) according 
to the manufacturer’s guidelines. From an overnight culture of the respective strain incubated at 
37 °C, 180 rpm in LB broth, 2 ml suspension of an OD600 of 0.132 (≙ McFarland standard 0.5) were 
prepared in PBS. Approximately 100 µl of this suspension were thoroughly applied to a Mueller-
Hinton agar plate by streaking it three times with a cotton swab. Once the remaining liquid was 
absorbed by the agar, the E-test stripe was applied to the plate. MIC values were determined after 
18 h of incubation at 37 °C. 
2.4.2 Broth dilution 
Antibiotic susceptibility and MIC values are specific for the applied culturing conditions, bacterial 
inoculation amount and media. Thus, to define suitable sub-inhibitory antibiotic concentrations in LB 
broth, MIC values for the PA14 wt were determined in liquid culture. Therefore, bacterial overnight 
pre-cultures were diluted to an OD600 of 3 (≙ 3*10
8
 CFU/ml) and 0.01 (≙ 1*10
6
 CFU/ml), respectively 
in LB broth, and 100 µl culture was mixed with 100 µl antibiotic in 96 well plate format. Antibiotic 
stock concentrations as listed in Table 2.4 were used to prepare five 1:1 serial dilutions in LB broth. 
Bacterial growth was monitored in triplicates after 12 h incubation at 37 °C, shaking. 
 
Table 2.4 Stock concentrations of antibiotics for MIC determination in liquid culture. 
Antibiotic Stock concentration 
Meropenem (MEM) 4 µg/ml 
Ciprofloxacin (CIP) 0.5 µg/ml 
Piperacillin (PIP) 64 µg/ml 
Ceftazidim (CAZ) 32 µg/ml 
Tobramycin (TOB) 4 µg/ml 
 
2.5 RNA-sequencing – sample preparation 
2.5.1 Culturing conditions and harvesting 
Whole, single nucleotide transcriptome-sequencing was performed using a custom-made protocol 
with 5’-barcoded RNA-libraries to enable a pooled sequencing of numerous samples at once [193].  
For each strain, three main cultures were inoculated in 10 ml LB from individual overnight pre-
cultures to an OD600 of 0.02. Of note, the cells used for inoculation were beforehand collected by 
centrifugation, and resuspended in LB. If not indicated differently, the main cultures were cultivated 
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until OD600 of 2 ± 0.1 at 37 °C, 180 rpm. The three individual bacterial cultures were pooled and 4 ml 
culture was collected to the same amount RNAprotect (Qiagen). After 10 min incubation at room 
temperature, the suspension was centrifuged 5 min at 6,000xg and the supernatant was carefully 
removed. Pellets were stored at -70 °C for no longer than 4 weeks before processing them further. 
2.5.2 RNA-extraction and DNA removal 
After thawing, the pellet was centrifuged again for 5 min at 6,000xg to remove any residual 
supernatant. The pellet was thoroughly resuspended in 100 µl TE buffer (10 mM Tris-HCl; 1 mM 
EDTA, pH 8) supplemented with 800 µg Lysozyme per 1 ml by pipetting, vortexing and 10 min 
incubation at room temperature. Following, 350 µl of RLT buffer (Qiagen) supplemented with 10 µl 
per 1 ml β-mercaptoethanol was added and the suspension was frozen for 30 min at -70 °C and 
thawed again for additional cell destruction. Total RNA was extracted with Qiashredder columns 
(Qiagen) and the RNeasy plus kit (Qiagen) according to the manufacturer’s instructions and the total 
RNA was collected in a final 50 µl. Residual DNA was removed by DNAse (Ambion) treatment (1 µl 
DNase per 50 µl total RNA, incubated for 30 min at 37 °C). 
2.5.3 rRNA removal by hybridization using oligo(dT)25 beads 
To evaluate the rRNA reduction rate by indirect hybridization, four polyadenylated capture oligos (R, 
1R, 4R and 4PSE; see Table 2.3, Pseudomonas specific sequences were obtained from Ambion) were 
used in combination with oligo(dT)25 magnetic beads (Dynabeads, Invitrogen). 200 µl of well 
resuspended bead-suspension was applied to a new tube and beads were collected by a magnetic 
rack to remove the supernatant, before they were resuspended in 100 µl binding buffer (20 mM Tris-
HCl, pH 7.5 supplemented with 1 M LiCl and 2 mM EDTA). Separately, 5 µg total PA14 RNA were 
incubated with a mix of 1 µl of each capture oligo in 100 µl binding buffer. After short vortexing, the 
sample was incubated at 65 °C for 2 min to dissolve RNA secondary structure, before it was directly 
added to the 100 µl of prepared beads. For oligo binding and subsequent capture by the poly-T 
beads, the mix was incubated rotating at room temperature for 10 min. Following, the beads were 
removed with the help of a magnetic rack and the supernatant containing the enriched mRNA was 
stored on ice. Residual, unintentionally captured mRNA was removed from the beads in an additional 
washing step using 100 µl washing buffer (10 mM Tris-HCl, pH 7.5 supplemented with 0.15 M LiCl 
and 1 mM EDTA). Beads were mixed in the washing buffer by slowly tapping the tube and thoroughly 
collected in a magnetic rack, before the supernatant was carefully removed and pooled with the 
initial mRNA fraction. 
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2.5.4 rRNA removal by hybridization using streptavidin tagged magnetic beads 
For the removal of rRNA by biotin-streptavidin binding, the same rRNA complementary oligos were 
used as in 2.5.3, but in a biotinylated instead of the polyadenylated version, now named 807-R, 111-
4Pse, 195-4R and 251-1R (Table 2.3). Correspondingly, removal was performed using streptavidin 
tagged magnetic beads (M-280 Dynabeads, Invitrogen). Before use, 50-100 µl beads were pre-
washed several times with 100 µl of the following solutions: 3 x buffer B&W, 2 x solution A, 1 x 
solution B. Following, the beads were resuspended in the same amount of B&W buffer. Meanwhile, 
5 µg of total bacterial RNA (PA14 wt) were prepared in 100 µl B&W buffer and mixed with 4 µl of 
capture oligos (25 µM each). The RNA-oligo suspension was incubated for 10 min at 70 °C to dissolve 
secondary structures, followed by 15 min at 37 °C to allow oligo-rRNA binding. Thereafter, the pre-
washed beads were added and incubated for another 15 min either at 37 °C, shaking, or room 
temperature, rotating, to capture the oligos’ biotin tag. To collect the beads and separate them from 
the supernatant containing mRNA, a magnetic rack was used. Solution compositions were as follows: 
B&W buffer (5mM Tris-HCl, pH 7.5; 0.5 mM EDTA; 1 M NaCl), solution A (0.1 M NaOH, 0.05 M NaCl), 
solution B (0.1 M NaCl). 
2.5.5 rRNA removal by hybridization using MICROBExpress 
If not indicated differently, rRNA was depleted from total RNA by the use of magnetic beads with the 
MICROBExpress Kit (Ambion). According to the manufacturer’s instructions, 7 µg total RNA were 
prepared in 15 µl TE, mixed with 200 µl binding buffer, 4 µl capture oligo-mix and 50 µl magnetic 
beads, and mixed by tapping.  The suspension was incubated for 10 min at 70 °C to denature RNA 
secondary structures and incubated for 1 h at 37 °C for hybridization. The oligo-mix consisted of 4 
polyadenylated capture oligomers (25 µM each), R, 1R, 4R and 4PSE (Table 2.3), which were mixed to 
equal amounts.  Beads were pre-washed before use, once with nuclease free water and once with 
binding buffer, before resuspension in binding buffer (50 µl each) and pre-adjustment to 37 °C. To 
gather the mRNA containing supernatant, the beads were collected for separation in a magnetic rack. 
Any unintentionally bound mRNA was eluted from the beads during an additional washing step with 
100 µl pre-warmed wash solution. After gentle vortexing, the supernatant was again aspirated in a 
magnetic rack and pooled with the previously collected fraction. 
2.5.6 Enzymatic rRNA removal by terminator-5’-phosphate-dependent exonuclease 
In order to access the applicability of enzymatic rRNA removal in P. aeruginosa, terminator-5’-
phosphate-dependent exonuclease (TEX, Epicentre) was used according to the manufacturer’s 
instructions. Initial amount of RNA, enzyme, incubation time and buffer are specifically indicated 
separately for every corresponding experiment. 
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2.5.7 rRNA removal by duplex-specific nuclease (DSN) 
In order to maximize mRNA content of the samples, a second rRNA removal step was applied before 
sequencing, additional to the preceding hybridization-based rRNA depletion of the P. aeruginosa 
clinical isolates and PA14 wt under varying environmental conditions. This second removal step was 
based on DSN (duplex-specific nuclease, Evrogen) treatment and conducted according to Illumina’s 
”DSN Normalization Sample Preparation Guide” after pooling the final cDNA libraries for sequencing. 
The DSN enzyme is supposed to degrade duplex DNA in preference to single stranded DNA and can 
thus be used to normalize the relative transcript abundance in favor of mRNA derived cDNA 
fragments. DSN treatment of cDNA libraries had been shown previously to efficiently decrease rRNA 
transcripts while at the same time preserving the original relative abundance of mRNA species in 
bacterial cells [194]. 
2.5.8 RNA clean up and concentration by precipitation and chloroform-phenol 
purification 
Whenever RNA needed to be concentrated to smaller volumes or it was necessary to remove 
residual chemicals, this was done by sodium acetate/ethanol precipitation adding 1/10 volume 3 M 
sodium acetate, 1/50 volume glycogen and 3 volumes of ethanol. The sample was thoroughly 
vortexed and incubated for 1 h at -70 °C for precipitation. Following, the precipitant was collected by 
centrifugation at 4 °C (10,000xg, 30 min) and residual sodium acetate was removed by washing the 
RNA pellet twice with 750 µl 70 % (v/v) ethanol. 
If protein remains had to be removed as well, chloroform-phenol purification was applied prior to 
precipitation. In order to extract the proteins, the sample volume was adjusted to 200 µl with RNase 
free water and vigorously mixed by shaking with the same amount of phenol-chloroform-isoamyl 
alcohol (25:24:1, Roth) in MaXtract High Density tubes (Qiagen). After centrifugation (5 min, 
10,000xg) the upper, aqueous phase was removed and its RNA precipitated. 
2.5.9 cDNA library construction 
cDNA library construction from mRNA was a multistep procedure. The principle of the custom 
created method (original idea developed by Andreas Dötsch, Helmholtz Centre for Infection 
Research) is shown in Figure 2.1, while detailed protocol description can be found in this text. 
First, the mRNA obtained after MICROBExpress rRNA removal (if not indicated differently) was 
mechanically fragmented to a median size of ~200 nt by sonication (S2 single tube system, Covaris) 
with settings 150 s processing time, intensity 5, duty cycle 10 %. As fragmentation required specific 
buffer conditions, the mRNA was afore precipitated and the pellet resuspended in 130 µl TE (10 mM 
Tris-HCl, pH 8; 1 mM EDTA). For concentrating the RNA fragments after shearing, a second 
precipitation was performed, after which the pellet was resuspended in 15 µl RNase free water. 
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Figure 2.1 Principle of cDNA library construction by a custom made protocol. 
Bacterial mRNA was fragmented by sonication and treated with T4 kinase to ensure 5’-phosphorylation (P) and 
3’-dephosphorylation of every fragment. To ligate adapters specifically to 3’- and 5’-ends of the fragments, a 3’-
RNA-adapter with 5’-phosphorylation and 3’-protection by dideoxycytidine (ddC) was used. In contrast, the 
afterwards ligated 5’-RNA-adapter was not modified, but because of the ddC only able to attach to the 
phosphorylated 5’-end of the RNA fragments. Furthermore, the 5’-adapter included a 6 nt specific sequence 
(barcode) to enable strand-specificity of the protocol and allow multiplexing of several samples for sequencing. 
After RNA-adapter ligation, cDNA was transcribed using 3’-RNA-adapter complementary primers for reverse 
transcription. First strand cDNA was amplified to create a double-stranded cDNA library in a maximum of 15 
cycles (to minimize PCR bias) by DNA primers matching the RNA adapter sequences and containing additional 
Illumina flowcell compatible parts.  
 
To prepare the RNA fragments for adapter ligation, 5’-phosphorylation and 3’-dephosphorylation 
was carried out by incubation with T4 polynucleotide kinase (T4 Pnk, Fermentas) for 25 min at 37 °C 
(using 1x buffer A, 10 U T4 Pnk and 5 mM ATP). Before, 3’- and 5’-RNA-adapter oligonucleotides 
(Table 2.3) were ligated, the RNA was purified by phenol-chloroform purification and additional 
ethanol precipitation. Adapter ligation was conducted over night at 16 °C with 10 U T4 RNA ligase 
(Thermo Scientific) in a total volume of 20 µl containing 5 mM ATP and an access of 50 pmol adapter. 
After 3’- and 5’-RNA-adapter ligation, RNA was purified using the RNeasy MinElute cleanup kit 
(Qiagen) to remove unbound adapter oligomers. Strand-specific cDNA libraries were generated by 
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reverse transcription using SuperScript II or III (Invitrogen) together with a DNA primer 
complementary to the 3’-adapter sequence to generate first-strand cDNA (RT primer), followed by 15 
cycles PCR amplification with Herculase II polymerase (Agilent Technologies) in combination with PCR 
primers matching Illumina specific regions for compatibility with Genome Analyzer flowcells. 
Herculase polymerase was shown previously to produce barely amplification bias due to length or 
GC % variations, in contrast to other polymerases as Phusion, Pfu or Taq [195]. 
Samples were pooled to equal amounts and a maximum of 12 samples per pool. Before sequencing 
on an Illumina Genome Analyzer IIx, DSN treatment was applied to each pool (see “rRNA removal by 
duplex-specific nuclease (DSN)”). Quality and size distributions of the samples were checked 
throughout the library preparation process on an Agilent 2100 Bioanalyzer Pico Chip (Agilent).  
Sequencing was performed either in paired-end mode, generating reads with a length of 76 or 110 nt 
(clinical isolates) or single-end mode, generating 36 nt reads (PA14 wt at varying environmental 
conditions).  
2.6 RNA-sequencing – raw data processing 
The dataset obtained from Illumina sequencing was analyzed using a custom bioinformatical pipeline 
(developed by Andreas Dötsch, HZI, Braunschweig), starting with the sorting of the raw sequence 
reads obtained in Illumina FASTQ-format by their expected barcode sequence. For successfully 
sorted reads, the barcode and adapter sequences were removed, while reads containing a barcode 
sequence with more than one error were discarded. The reads were mapped to the PA14 reference 
genome, which is available for download from the Pseudomonas Genome database 
(http://v2.pseudomonas.com, [189]). Mapping was performed using stampy, a short-read aligner 
that allows for gapped alignments [196], for quantification of gene expression, and SAMtools [197] 
was utilized for sequence variation calling. The reads per gene (rpg) values of all genes were 
calculated from the SAM output files. Testing for differential expression against PA14 wt was 
performed with DESeq [198], an R software package that uses a statistical model based on the 
negative binomial distribution. All short sequence read data have been deposited at the National 
Center for Biotechnology Information sequence read archive (http://www.ncbi.nlm.nih.gov/sra) 
under the accession number SRP034661. Library preparation, sequencing and raw data analysis of 
the 149 clinical isolates was performed in equal amounts together with Monika Schniederjans 
(Helmholtz Centre for Infection Research). 
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2.7 Detection of acquired resistance enzymes 
For the analysis of the accessory genome and the detection of acquired resistance genes, a de novo 
transcriptome assembly was applied using Oases [199] (version 0.2.06) with settings kmin = 25, kmax 
= 29, minimal transcript length = 100. As Oases input, the clipped FASTQ files of each paired-end 
sample were merged into one and shuffled. The following generated contigs were aligned with 
BlastN against a custom file containing a collection of 658 transposable resistance genes, including 
514 β-lactamases (genelist downloadable from Bactome (see chapter 2.9) in FASTA format). The 
results were filtered for redundancy, displaying only the top hit for every detected gene (regarding 
fragment length and sequence match). 
Additionally, a second approach was performed using the custom resistance gene collection as an 
“artificial genome” against which the sequencing reads were mapped. This method allows calculating 
the relative sequence coverage of each resistance gene. Both approaches were compared and their 
results combined to improve prediction correctness for the presence of acquired enzymes. 
To verify the bioinformatical prediction, primers were designed for the multiplexed amplification of 
previously detected resistance genes and the amplified DNA was subsequently Sanger sequenced. 
PCR settings, tested clinical isolates and amplifiable genes for each pair of primers are listed in Table 
2.5. Alignments for primer design were created using MultAlign [200]. 
 
Table 2.5 Resistance gene amplification. 
 
      
Primer Ta* Template DNA Fragment sizes/amplifiable genes 
SeqPr_Oxa224_R 
62 °C PSAE2136, PSAE1747 831 bp/oxa224, oxa4 
SeqPr_Oxa224_F 
SeqPr_Vim2_R 
65 °C PSAE1716, PSAE1747, PSAE2307 801bp/vim2-3,6,8-11,15-18,23-24; 741 bp/vim30 
SeqPr_Vim2_F 
SeqPr_Vim1_R 
59 °C 
PSAE1152, PSAE1661, PSAE2162, 
PSAE2180, PSAE2319, PSAE2338 
801bp/vim1,4,14,19,26-27,32 
SeqPr_Vim1_F 
SeqPr_Imp7 _F 
64 °C PSAE2335 741 bp/imp7 
SeqPr_Imp7 _R 
SeqPr_ctx123 _F 
64 °C PSAE2326 
~885 bp/ctx-m-1,3,10-12,15,22-23,28-30,32-34,36-
37,42,52-58,60-62,66,68-69,71-72,79-
80,82,88,96,101,114,116 SeqPr_ctx123 _R 
* Ta, annealing temperature 
2.8 Phylogeny 
The phylogenetic tree was created using a total of 214 genes that were ≥ 90 % covered with 
sequencing reads from all clinical isolates and also had orthologs in all five Pseudomonas aeruginosa 
reference strains used here (PA14, PAO1, LESB58, PACS2, PA7). The ortholog information was 
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obtained from a pre-computed Pseudomonas genome alignment with Mauve 
(http://www.pseudomonas.com/mauve.jsp, [189]). To extract the gene sequences of the clinical 
isolates, consensus sequences were created using the SAMtools package. From the consensus 
sequences and the reference genomes, the 214 gene sequences were extracted using the annotation 
information, resulting in one concatenated sequence per strain. Phylogenetic distances between the 
strains were calculated using a k-mer approach developed by Ole Lund and Rolf Kaas (Technical 
University of Denmark, personal communication). The sequences were split into 17-mers, which 
were then compared between the strains. The resulting distance matrix (created by Sarah Pohl, 
Helmholtz Centre for Infection Research) was used to build a neighbor-joining tree in R using the 
package ape [201]. The tree was then visualized in Dendroscope [202] and supplemental information, 
as antibiotic resistance phenotype or acquired resistance genes, was added and visualized using iTOL 
(http://itol.embl.de, [203]). 
2.9 Data display: the Bactome database 
The Bactome ("Bacterial Genome") database was developed as a comprehensive project data 
resource and result storage system and programmed by Klaus Hornischer (Helmholtz Centre for 
Infection Research). By the end of 2013, Bactome consisted of 135 cDNA-sequenced P. aeruginosa 
clinical isolates, including information on their transcriptomes and phenotypes, and information on 
the P. aeruginosa PA14 reference genome for comparative analysis. The basic information for 
Bactome is extracted from RefSeq [204] files and additional annotation is imported from public data 
sources as Entrez [205] and UniProt [206]. Configurable program tools as protein domain annotation 
with Pfam/HMMER [207] create additional annotation. The content of the database is constantly 
updated through an automatic system of programs. Access to the data stored in Bactome is achieved 
through a system of web services, which offer tools for the display of the data, e.g. in form of a 
"Gene Feature Card", or for the processing of data sets with statistical analysis in R. The Bactome 
database is implemented on a Linux-based Apache web server and consists of data stored in a MySQL 
database system. Programs are written in Python, web pages in HTML with JavaScript functionality. 
Bactome stores the basic sequence information in flat files, whereas all of the annotation is 
contained in the MySQL database. 
2.9.1  SNP matrix calculation 
SNP matrices for statistical comparisons were created based on SAMtools .flt.vcf files and read 
coverage information for every position. For the “SNP-wise” approach, the annotated SNPs of all 
isolates defined for a particular group comparison in Bactome and with a SNP quality score above the 
CHAPTER 2: MATERIALS AND METHODS 34 
 
defined threshold were individually extracted via the Bactome database. Next, the read coverage for 
every SNP was examined and any SNP above the in Bactome defined read coverage threshold was 
regarded to be definitive positive. SNPs which did not fulfill the custom set coverage criteria were 
marked as uncertain. From this information a matrix was created, consisting of “0” for no SNP, “1” 
for definitive SNP and “NA” for uncertain SNP, which was then used for subsequent statistical 
analysis. 
The same method was applied for the "Gene-wise” SNP calculations with the exception that “1” 
indicates that at least one definitive SNP was found within the whole sequence of a gene and "NA" 
that exclusively uncertain SNPs were found. 
2.9.2  Stop matrix generation 
For the determination of those clinical isolates, in which a mutation caused the generation of a stop 
codon (and thus resulted in a truncated protein sequence), the PA14 reference coding sequence was 
extracted and used to generate two individual sequences. In the first sequence, only nucleotide 
exchanges of SNPs above defined quality and coverage thresholds were introduced, thus resulting in 
a mutated gene sequence with a minimal likelihood of false positive results. The second nucleotide 
sequence was created based on all detected SNPs, not considering quality or coverage thresholds. 
Next, both mutated sequences and the reference gene sequence were individually translated into 
the corresponding peptides, automatically cutting off residues beyond a predicted stop site. To 
generate a stop matrix to be used for the statistical analysis, the length of each mutated peptide 
sequence was compared to the reference peptide’s length. Same length peptides in both mutated 
cases are defined as “0”, while shortened first sequences are defined “1” and second sequences are 
defined “NA”. 
2.9.3  Gene expression matrix generation 
The calculation of significant differential gene expression between two groups in Bactome was based 
on the reads per gene (rpg) generated from SAM output files, size factor normalized in DESeq. 
Further normalization based on individual gene length was performed to obtain normalized reads per 
kilobase (nrpk) for every gene.  
2.9.4  Phenotype-genotype group comparisons 
Group comparisons of clinical isolates for significant differential gene expression were performed 
using Student’s T-test and group specific accumulations of mutations (SNPs and intragenic stop 
codons) were analyzed with Fisher's exact test. In both cases, the Benjamini-Hochberg (bh) 
correction was used to calculate adjusted p-values (padj) to control the false-discovery rate (FDR) in 
the list of regulated genes. However, due to the general low abundance of intragenic stop codons, 
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the uncorrected p-values were also considered in the stop comparisons and should thus be 
interpreted as “scores”, indicating a probably significant accumulation. 
2.10 Statistics for overall correlation 
Pearson’s correlation (r) was used to test for linear coherence as gene expression and MIC values, 
and Kendall’s rank-correlation (τ) was used to analyze the dependence of MIC values on a single, 
distinct feature (e.g. occurrence of specific enzymes or mutations). 
For the investigation of “optimal” (here maximizing true positives and minimizing false positive 
detection) expression thresholds to define binary resistance phenotype grouping (susceptible and 
non-susceptible), as in the case of ampC, a calculation of the receiver operating characteristic (ROC) 
curve was applied. In ROC analysis, the area under the curve (AUC) is the mean for correlation. To 
obtain information about the suitability of particular log2FC cutoffs, the rates of sensitivity (true 
positives) and specificity (false positives) were calculated for each expression value and compared to 
each other. 
2.11 Carbapenemase activity assay 
In order to verify the bioinformatical prediction of acquired carbapenemases, an enzymatic activity 
assay was performed as previously described by Lauretti and colleagues [208], with some 
modifications. Main cultures were inoculated in 5 ml LB broth with 300 µl bacterial suspension from 
overnight pre-cultures and cultivated for 4.5-5 h (early stationary growth phase) at 37 °C, 180 rpm. 
To harvest the cells, 1 ml culture was collected by centrifugation (2 min, 16,000xg) and resuspended 
in 500 µl 50 mM HEPES buffer (pH 7) supplemented with 10 µM ZnSO4 for metallo-β-lactamase 
activity. The cells were broken by sonication (3 cycles à 20 sec, duty cycle 40 %, output control 3.5, 
Branson Sonicator S250 Analogue). Unbroken cells were pelleted by centrifugation (10 min, 
10,000xg), while the remaining supernatant was collected in a fresh tube. Reactions were set up in 
duplicates for each measurement, mixing a total of 200 µl supernatant with 22 µl 150 mM MEM. The 
mix was incubated 20 min at 25 °C, before MEM hydrolysis was monitored at 297 nm and 300 nm 
using a NanoDrop spectrophotometer (Thermo Scientific). The values of both measurements from 
both duplicates were averaged to one and normalized to the respective total protein amount of the 
crude extracts as determined by Qubit Protein Assay (Invitrogen). 
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2.11.1 Carbapenemase assay with activity rescue 
For some strains, the carbapenemase activity assay described above showed ambiguous results, 
possibly due to interfering substances at the monitored wave length. In these cases, the respective 
strains were instead analyzed for carbapenemase activity rescue by adding ZnSO4 subsequent to 
incubation with EDTA. For this assay, the cells were grown and harvested as described above, with 
the exception of using 500 µl pure HEPES buffer for cell pellet resuspension. After lysis and the 
elimination of unbroken cells, 100 µl supernatant for each replicate was mixed in a new tube with 
100 µl HEPES supplemented with 4 mM EDTA (2 mM final concentration) and 300 µM MEM (150 µM 
final concentration). After 20 min incubation at 25 °C, the base extinction was measured at 297 nm 
and 300 nm. Afterwards, 4 µl 100 mM ZnSO4 was added (2 mM final concentration) to each sample, 
followed by a second 20 min incubation step at 25 °C and MEM hydrolysis monitoring at 297 nm and 
300 nm. From these values, the base extinctions during EDTA incubation (which inhibits metallo-β-
lactamase activity) were subtracted, before samples were again normalized to the total protein 
amount of the crude extracts. 
2.12 Constructions of mexS and oprD knock-out mutants 
To generate mexS and oprD knock-out mutants in the P. aeruginosa PA14 wt strain or a PA14ΔmexR 
mutant, respectively, mutagenesis was carried out by homologous recombination using the pEX18Ap 
plasmid [209]. Around 500 bp long, flanking regions upstream and downstream of the respective 
genes were amplified and an approximately 1000 bp fragment was created by overlap extension PCR 
as described previously [210], primers are listed in Table 2.3 and PCR parameters, using Phusion 
polymerase (Invitrogen) in Table 2.6. The fragment was introduced into pEX18Ap via HindIII/XbaI 
restriction sites and conjugated into PA14 with the help of E. coli S17-1. Mutant candidates were 
identified by plating on LB agar containing 0.25 µg/ml MEM (ΔoprD), and 1 µg/ml CIP (ΔmexS) and 
were further verified by PCR and Sanger sequencing. 
 
 
 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 37 
 
Table 2.6 PCR parameters for overlap extension PCR to create mexS and oprD knock-out mutants. 
   
PCR Primer 
PCR conditions
*
 
smexS, soprD, tex, Ta, ta 
1. PCR 
FP1_XbaI 
517 bp, 470 bp, 30 s, 68 °C, 20 s 
RP1+20bp 
2. PCR 
FP2+20bp 
455 bp, 485 bp, 30 s, 68 °C, 20 s 
RP2_HindIII 
3. PCR 
FP1_XbaI 
972 bp, 955 bp, 1 min 15 s, 68 °C, 30 s 
RP2_HindIII 
 
*
 smexS, fragment size mexS; soprD, fragment size oprD; tex, extension time; Ta, annealing temperature; ta, 
annealing time 
2.13 OprD antibody generation 
As OprD is an outer membrane protein, specific purification of sufficient soluble amounts of the 
protein as a whole provides a great challenge. Hence, we choose to use individual small peptides 
comprising parts of the P. aeruginosa PA14 OprD instead for antibody generation. Peptides suitable 
for synthetic production and subsequent antibody generation in rabbits had to fulfill the following 
criteria: 1) length of 10-13 amino acids, 2) a high number of hydrophilic amino acids for sufficient 
water solubility, 3) preferably at least one proline within the sequence to increase stability, 4) 
contain suitable epitope sites with high antibody binding specificity and sensitivity. The antibody 
binding parameters for linear B-cell epitopes of all parts of the OprD sequence were calculated with 
the BepiPred prediction tool, version 1.0b [211]. Two sequences which matched the above criteria 
and additionally were not mutated in any of the 135 phylogenetically unrelated clinical isolates were 
identified. These peptides were synthesized by Werner Tegge (Helmholtz Centre for Infection 
Research): peptide 1, amino acids 115-123 (NDGTPRDDYSR) and peptide 2, amino acids 329-340 
(YSDFNGPGEKS). The immunization of rabbits with the synthesized peptides to gain antisera was 
performed at BioGenes, Berlin. 
2.14 Antibody purification 
Before use, the polyclonal antisera obtained from immunization with OprD peptides (peptide 1 = 
serum 1, peptide 2 = serum 2) were purified using the respective peptide conjugated sepharose. A 
total of 1 g cyanogen bromide activated sepharose (CNBr-activated-sepharose 4B, GE Healthcare) 
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was equilibrated for 15 min in 20 ml dH2O and washed three times in a glass drip with 100 ml dH2O, 
200 ml 5mM HCl, and 200 ml borate buffer (0.1 M boric acid, 0.5 M NaCl, pH 8.4). Following, the 
sepharose was mixed with 10 mg of the respective peptide, dissolved in 2 ml borate buffer 
(additionally containing 500 µl DMSO for peptide 1 to prevent precipitation). The suspension was 
incubated rotating at 4 °C overnight to couple the peptide with the sepharose. The coupled 
sepharose was pelleted by centrifugation (5 min, 201xg), washed three times with 1.5 M Tris-HCl (pH 
8.8), incubated for 1 h rotating with the same solution and subsequently washed twice with PBS 
(phosphate buffered saline, 137 mM NaCl; 2.7 mM KCl; 10 mM Na2HPo4; 2 mM KH2PO4; pH 7.4). 
Following, the coupled sepharose was resuspended in 50 ml solution of a 1:1 mix of serum and PBS. 
The suspension was incubated overnight, gently rotating at 4 °C to allow the antibody to bind its 
antigen peptide. To eliminate unspecific binding, the sepharose was first thoroughly collected on a 
PBS pre-equilibrated plastic drip (PD-10 columns, GE Healthcare) by applying the suspension and the 
three following flow-throughs on the drip, and subsequently washed twice with 100 ml PBS and 
15 ml washing buffer (0.1 M acetate, 0.5 M NaCl, pH 4.8). The specifically bound antibodies were 
eluted with elution buffer (0.2 M acetate, 0.5M NaCl, pH 2.5) in ten 2 ml fractions. Protein 
concentrations were measured and fractions containing antibody were pooled, receiving 0.11 mg/ml 
antibody 1 and 1.26 mg/ml antibody 2. Both antibodies could be used diluted 1:500 in 
immunodetection assays. 
2.15 OprD protein detection by Western Blot 
For the detection of OprD protein with specific antibodies, cultures of P. aeruginosa clinical isolates 
and PA14 wt were inoculated from LB-agar plates and grown overnight at 37 °C in 5 ml LB broth.  An 
amount of bacterial cells equivalent to 1 ml adjusted to OD600 = 2 was collected by centrifugation for 
2 min at 16,000xg. The pellet was resuspended in 50 µl PBS, heat lysed, treated with Benzonase 
Nuclease (Novagen), and diluted 1:1 in SDS sample buffer. 10 µl were run on 10 % SDS-
polyacrylamide gels and subsequently blotted to a PVDF membrane (Immobilon-P, Millipore). OprD 
protein was detected with purified, polyclonal anti-OprD serum (1:500), followed by a peroxidase 
conjugated secondary antibody (anti-rabbit-POD, B4C, 1:2000) and Lumilight (chemiluminescent 
peroxidase substrate, Roche, Mannheim) incubation. 
2.16 Outer membrane protein visualization 
Selected clinical isolates, PA14 wt and PA14ΔoprD mutant were grown overnight in 100 ml LB broth 
at 37 °C, 180rpm. The cultures were harvested by centrifugation (10,000xg, 4 °C, 20 min), washed 
twice with Tris-Mg buffer (10 mM Tris, 5 mM MgCl2, pH 7.3), resuspended in 5 ml of the same buffer 
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and kept cooled on ice during further processing. To lyse the cells, sonication was used for 7 cycles, 2 
min each at level 5 and duty cycle 50 % (Branson Sonicator S250 Analogue) and unbroken cells were 
removed by centrifugation (10,000xg, 4 °C, 10 min). Membranes were pelleted from the supernatant 
by ultracentrifugation (100,000xg, 4 °C, 1 h) and the outer membrane was purified by washing the 
pellet twice with Tris-Mg buffer containing 2 % sodium lauryl sarcosinate (SLS). All steps involving SLS 
were carried out at room temperature to prevent precipitation of the detergent. For every washing 
step, pellets were resuspended, incubated 20 min and centrifuged 1 h. The final pellet was 
resuspended in 500 µl dH2O. Protein concentrations were measured and equally adjusted to 1.3 µg 
per µl. Each sample was diluted 1:1 in SDS sample buffer and heated to 95 °C for 5 min, before 
running 15 µl each on 10 % or 15 % SDS-polyacrylamide gels (SDS-PAGE). The bands were visualized 
with InstantBlue (Gentaur). 
2.17 LC-MS/MS sample preparation 
Sample preparation was conducted from InstantBlue strained SDS-polyacrylamide gels in the group 
of Cellular Proteomics at the Helmholtz Centre for Infection Research (Lothar Jänsch / Josef Wissing). 
For tandem liquid chromatography mass spectrometric analysis (LC-MS/MS), desired protein bands 
were cut from the gel and destained in a solution containing 30 % acetonitrile and 50 mM NH4HCO3. 
Following, the gel slices were reduced for 30 min at 56 °C with 20 mM DTT in 50 mM NH4HCO3, 
alkylated with 20 mM iodoacetamide in 50 mM NH4HCO3 and cut into small pieces. After two 
washings with 50 mM NH4HCO3, the gel pieces were dehydrated in acetonitrile and dried. For all 
procedures, the volume of the solutions was higher than 20 times the gel volume. Dried samples 
were rehydrated in 50 mM NH4HCO3 supplemented with 10 % acetonitrile and 1:20 sequencing grade 
modified trypsin (Promega). Digestion of the proteins was performed over night at 37 °C. Peptides 
were subsequently eluted several times (1 x H2O; 1 x 1 % triflouroacetic acid; 2 x 30 % acetonitrile 
containing 0.1% triflouroacetic acid) and dried in a vacuum centrifuge. For LC-MS/MS the dried pellet 
was desalted using ZipTip RP18 Tips (Millipore), evaporated, and re-solubilized in 3 % acetonitrile 
containing 0.5 % formic acid. 
2.18 LC-MS/MS data acquisition, data analysis and database searching 
Liquid chromatography coupled mass spectrometric analysis was performed by Josef Wissing 
(Helmholtz Centre for Infection Research). LC-MS/MS was carried out on a Dionex UltiMate 3000 n-
RSLC system connected to an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). Peptides 
were loaded onto a C18 pre-column (3 µm, Acclaim, 75 µm x 20 mm, Dionex) and washed for 3 min 
at a constant flow rate of 6 µl per min. Subsequently, peptides were separated on an analytical C18 
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column (3-μm, Acclaim PepMap RSLC, 75 µm x 25 cm, Dionex) at 350 µl per min via ultra 
performance liquid chromatography (UPLC) using a linear 120-min gradient from 100 % buffer A 
(0.1 % formic acid in H2O) to 25 % buffer B (0.1 % formic acid in acetonitrile), followed by a 50 min 
gradient from 25 % buffer to 80 % buffer B. The LC system was operated with Chromeleon Software 
(Version 6.8, Dionex), which was embedded in the Xcalibur software (Version 2.1, Thermo Scientific). 
The effluent from the analytical column was electro-sprayed (Pico Tip Emitter Needles, New 
Objectives) into the mass spectrometer (Orbitrap Velos Pro), which was controlled by Xcalibur 
software and operated in the data-dependent mode with the automatic selection of a maximum of 
10 doubly and triply charged peptides and their subsequent fragmentation. Peptide fragmentation 
was carried out using LTQ settings (Min signal 2000, Isolation width 4, Normalized collision energy 
35, Default Charge State 4 and Activation time 10 ms). The obtained raw data files were processed 
via the Proteome Discoverer program (Version 1.4, Thermo Scientific) on a Mascot server (V. 2.3.02, 
Matrix Science) using a Pseudomonas aeruginosa PA14 or PAO1 database extracted from SwissProt. 
The following search parameters were used: enzyme, trypsin; maximum missed cleavages, 1; fixed 
modification: carbamidomethyl (Cys); variable modifications: oxidation (Met), peptide tolerance, 
10 ppm; MS/MS tolerance, 0.4 Da.  
2.19 Fluorescence detection by flow cytometry 
Reactive oxygen species (ROS) were detected by flow cytometry using the cell-permeant fluorescent 
dye H2DCFDA (2',7'-dichlorodihydrofluorescein diacetate, Life Technologies). For sample preparation, 
the bacteria were cultivated in LB broth at an OD600 of 0.8, until the cultures were split into 10 ml 
each and treated with antibiotics or 50 µl DMSO (dimethyl sulfoxide) or 100 mM H2O2, respectively, 
as controls. Samples of 1 ml culture were harvested at time points one, two and three hours post 
treatment by centrifugation. The bacterial pellets were resuspended in 1 ml PBS, diluted 1:10 in PBS 
(final volume 1 ml) and incubated for 2 h at 37 °C, 180 rpm in the dark with 20 µl of 4 mM H2DCFDA, 
dissolved in DMSO. Measurement at the LSR II flow cytometer (BD Biosciences) and data analysis 
with FACSDiva software, version 6.1.3 were performed by Anne Lorenz (Helmholtz Centre for 
Infection Research). 
2.20 Metabolic isotope analysis 
Analysis of amino acid synthesis was carried out by Esther Surges and Wolf-Rainer Abraham 
(Helmholtz Centre for Infection Research). Samples were inoculated to an OD600 of 0.1 in 600 ml BM2 
(7mM (NH4)2SO4, 40 mM K2HPO4, 22 mM KH2PO4, 2mM MgSo4, 0.01 mM FeSo4, pH 7) supplemented 
with 50 mM glucose and grown until an OD600 of 0.8 before a final concentration of 2.5 mM 
CHAPTER 2: MATERIALS AND METHODS 41 
 
completely 
13
C labeled glucose or 1,2 
13
C labeled acetate was added. Following, the culture was split 
by 50 ml each and treated with the respective antibiotic. Samples of 2 ml were harvested by 
centrifugation at 1 h, 2 h, and 3 h time points post antibiotic exposure and bacterial cell numbers 
were calculated from CFU counts. Isotope measurements were conducted using a mass spectrometer 
(IRMS MAT 253) equipped with a Trace GC Plus gas chromatograph via GC Isolink IV (Thermo 
Scientific). Pee Dee Belemnite (PDB) was used as standard for the relative calculation of 
13
C 
incorporation into newly synthesized amino acids. 
2.20.1  Amino acid extraction 
Amino acids were extracted from a pellet of 2 ml bacterial culture by addition of 2 ml HCl and 24 h 
hydrolysis at 100 °C. The suspension was filtered (0.2 µm pore size, Whatman) to eliminate large 
unbroken particles, before the remaining acid was evaporated. The pellet was resuspended in 60 % 
(v/v) methanol if stored at -20 °C and evaporated again before further processing. For derivatization, 
in a first step 400 µl dichloromethane were added and subsequently evaporated to remove 
remaining water. The amino acids were esterified in 800 µl 5:1 isopropanol:acetyl chloride (v:v) for 
45 min at 100 °C and the derivatizing agents removed by evaporation, followed by a second 
dichloromethane evaporation step. A second step of derivatization was performed with 400 µl 1:1 
trifluoroacetate:dichloromethane (v:v) for 15 min at 100 °C. The derivatizing agents were carefully 
evaporated on ice and the amino acids were resuspended in ethyl acetate for GC measurement.
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3 Results 
3.1 An optimized protocol for cost efficient high-throughput transcriptome 
sequencing of P. aeruginosa 
In order to establish a way for cost efficient, high-throughput transcriptome-sequencing of large 
amounts of clinical P. aeruginosa isolates, a customized protocol was used to create barcoded cDNA 
libraries which are compatible with Illumina flow cells. For this purpose, total bacterial RNA was 
extracted and ligated during library construction to RNA adapters, which were specifically designed 
for 5’- and 3’-end ligation of the extracted RNA. Hereby the 5’-end adapters contained an individually 
assigned 6 nucleotide sequence which facilitated 5’-recognition of a transcript and thus strand-
specific sequencing, and multiplexing of several samples, as transcripts belonging to the same sample 
could be distinguished from each other by bioinformatical tools after sequencing. One limitation 
when multiplexing, however, is the necessity to obtain a sufficient sequencing depth with the desired 
transcripts, in this case, those from protein coding mRNA. 
3.1.1 mRNA enrichment strategies 
Bacterial total RNA comprises a variety of different types of RNA, including coding RNA (mRNA) and 
non-coding RNA (rRNA, tRNA, sRNA). The largest portion, which spans over 95 % of the total RNA, is 
made up by the non-coding RNAs, particularly rRNA. Conversely, valuable information on gene 
expression and gene transcript sequences is only present to less than 4 % in sequenced total 
bacterial RNA [212]. However, the efficient reduction of rRNA can shift the distribution in favor of the 
coding RNAs and increase the mRNA sequencing depth of individual samples, and thus also allow for 
multiplexing of several individual samples on one sequencing lane without immediate transcriptome 
coverage limitations. While rRNA depletion is rather unproblematic in eukaryotic material because of 
the natural polyadenylation of the mRNA, bacterial mRNA lacks this tag and therefore cannot be 
used for direct hybridization to immobilized poly-T sequences [213]. During this work, a variety of 
different indirect hybridization-based and enzymatic rRNA reduction methods were analyzed for 
their applicability and efficiency on P. aeruginosa rRNA depletion to maximize mRNA enrichment. 
Particularly a specific reduction of 16S and 32S rRNA was of importance, as the small 5S rRNA 
(120 nt) could be largely eliminated using size selecting columns during RNA extraction. 
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3.1.1.1 Hybridization-based rRNA depletion using magnetic beads 
One option to increase the amount of mRNA from a sample of total bacterial RNA is the extraction of 
rRNA using magnetic beads. For this approach, rRNA complementary oligomers were designed with a 
specific tail which allowed the capture by compatible magnetic beads. Once the oligos bound the 
rRNA, this complex could thus be extracted with the help of magnets. Figure 3.1 shows the 
electropherograms obtained from Bioanalyzer for all tested conditions after removal treatment using 
hybridization methods. Further information on initially applied amounts of total RNA, the total RNA 
reduction after each approach and the 16S and 23S specific ratios can be found in the corresponding 
Table 3.1. 
 
Table 3.1 rRNA reduction efficiencies using methods with rRNA complementary oligomers and magnetic 
beads. 
Total RNA reduction percentage was calculated from the amount of RNA left after treatment (measured by 
NanoDrop), while 16S and 23S rRNA ratios were calculated from Bioanalyzer electropherograms, respectively. 
            
Sample Total RNA [µg] 
RNA after treatment 
[ng total] 
Total RNA 
Reduction [%] 
16S [%] 23S [%] 
Control - - - 25.7 44.2 
Oligo (dT)25  5 500 90 20.7 39.4 
Streptavidin 50 µl 10 6600 34 21.8 33.3 
Streptavidin 2x 50 µl 10 3900 61 21.5 30.5 
Streptavidin 100 µl 10 5000 50 19 30.7 
Streptavidin 50 µl, rotating 5 2900 42 13.7 21.3 
Ambion oligos4 5 675 86.5 4.4 3.7 
Ambion oligos4 10 1450 85.5 7.5 20.5 
Ambion oligos5 10 1600 84 2.2 37.2 
Ambion oligos4+5 5 600 88 2 16.9 
Ambion 2x: oligos4, oligos5 10 950 90.5 0 3.4 
 
 
Figure 3.1 B depicts the result of an indirect hybridization approach using a mix of four different rRNA 
complementary capture oligos, each with a tail of 18 adenine residues (1R, 4R, R, and 4Pse; oligos4) 
in combination with matching oligo (dT)25 magnetic beads (Dynabeads, Invitrogen). Interestingly, 
despite a total RNA reduction of 90 % (Table 3.1), this approach led only to marginal reduction of 
rRNA with amounts of 16S rRNA decreased from 25 % to 20 % and 23S rRNA from 44 % to 37 %, 
respectively, determined from Bioanalyzer electropherograms, compared to the untreated total RNA 
(Figure 3.1 A).  
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Figure 3.1 rRNA depletion by magnetic beads. 
rRNA depletion of PA14 wt total RNA was performed using different methods based on the principles of rRNA 
complementary, tagged capture oligomers in combination with matching magnetic beads to capture the rRNA 
bound oligomers. A-K show the respective electropherograms obtained from Agilent 2100 Bioanalyzer. A: 
Untreated control (PA14 total RNA). B: Depletion using a mix of four specific, rRNA complementary oligomers 
with poly-A-tail (1R, 4R, R, and 4Pse) and matching oligo (dT)25 magnetic beads. C-F: rRNA depletion performed 
with streptavidin magnetic beads and a mix of four rRNA complementary, biotinylated oligomers (251-1R, 195-
4R, 807-R, and 111-4Pse). C: Sample was treated with 50 µl streptavidin magnetic beads. D: Two rounds of 
rRNA depletion as in (C) were applied after each other. E: Sample was treated with one round of rRNA 
depletion using the double amount of beads (100 µl) as in (C). F: Sample was rotated during treatment with 
magnetic beads, as opposed to C-E, were samples were kept shaking in a thermomixer. G-K: rRNA was depleted 
using the MICROBExpress kit (Ambion), which combines polyadenylated rRNA-complementary oligomers with 
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matching oligo (dT) magnetic beads. G: Four oligos (1R, 4R, R, and 4Pse) were used on 5 µg total RNA. H: The 
same oligos as in (G) were used on 10 µg total RNA. I: A mix of five oligos (2-PolyA, 9-PolyA, 27-PolyA, 3-PolyA, 
and 10-PolyA) was applied on 10 µg total RNA. J: A mix of nine oligos was used on 5 µg RNA, containing the 
oligos from (G) and (I) in equal amounts. K: 10 µg of total RNA were treated twice with the MICROBExpress kit 
using first four oligos as in (G), followed by a second round with five oligos as in (I). 
Samples A-B (Ladder 1), C-F (Ladder 2), and G-K (Ladder 3) were run together on individual Bioanalyzer pico 
chips. Probable 16S and 23S fractions were marked in pink and green, respectively. 
 
A similar output was obtained when using the same oligos in a biotinylated, instead of the 
polyadenylated version in combination with streptavidin-tagged magnetic beads (Dynabeads, 
Invitrogen), as shown in Figure 3.1 C. Here, the amount of 16S and 23S rRNA was reduced to 22 % 
and 33 %, respectively. Neither doubling the amount of oligos and beads, nor applying two individual 
rounds of rRNA removal after each other significantly affected the outcome (Figure 3.1 D-E). 
However, an improvement was made by rotating the sample instead of shaking, with a respective 
reduction to 14 % (16S) and 21 % (23S), which indicated that insufficient physical contact of rRNAs, 
oligos and beads under the selected conditions might have been one reason for the low removal 
efficiency. To optimize hybridization conditions, the commercially available MICROBExpress kit 
(Ambion) was used, which had previously been described to efficiently remove rRNA and provide 
samples with more than 40 % mRNA for selected organisms [214]. The MICROBExpress system is 
based on poly-T beads, thus the same oligo mix was used as for the Oligo (dT)25 Dynabeads. 
Application of the MICROBExpress buffer and beads led under comparative experimental conditions 
to a significant increase in rRNA reduction rate to only 4 % residual 16S and 23S rRNA when applied 
on 5 µg total RNA (Figure 3.1 G). Depletion was a little less efficient, particularly for 23S rRNA, when 
10 µg of total RNA were applied (Figure 3.1 H). To test whether the use of additional complementary 
oligos would further increase rRNA removal rates due to a greater number of rRNA target regions, 
five new oligos (2-PolyA, 9-PolyA, 27-PolyA, 3-PolyA, and 10-PolyA; oligos5) distinct from the first 
four were designed based on the P. aeruginosa rRNA sequence. rRNA depletion with these five oligos 
alone in combination with the MICROBExpress kit proved to be similarly efficient on 16S rRNA and 
only slightly less efficient on 23S rRNA compared to the previously tested oligo4 mix (Figure 3.1 I). 
However, a combination of all 9 (4+5) oligos in one mix could not provide more mRNA, but was on 
the contrary even slightly less efficient on 23S rRNA removal than application of only the oligos4 mix 
(Figure 3.1 J). Although the oligo sequences had afore been analyzed for inter- and intra-
complementarity, possible molecular interference cannot be completely excluded and might be an 
explanation for this unexpected result. Thus, two individual MICROBExpress reduction rounds were 
performed after each other with oligos4 in the first and oligos5 in the second, to avoid any secondary 
effects. As shown in Figure 3.1. K, these two individual reduction rounds with distinct sets of oligos 
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indeed strongly decreased rRNA amounts, even from 10 µg of initial total RNA. While 16S rRNA was 
completely eradicated, only 3.4 % of 23S rRNA was left from the initial 25 % (16S) and 44 % (23S), 
according to Bioanalyzer calculation (Table 3.1). However, as the costs for one MICROBExpress run 
made up 33 % of the costs for library preparation as a whole and more than 10 % of the total 
sequencing costs of one sample, the increased multiplexing capacity by applying two rounds of rRNA 
reduction proved to be not economical compared to the additional costs. Therefore, the applicability 
of enzymatic rRNA removal for P. aeruginosa was investigated as a possible alternative option. 
3.1.1.2 Enzymatic rRNA depletion by terminator-5´-phosphate-dependent 
exonuclease (TEX) 
Besides the capture of rRNA by magnetic beads, another option to remove prokaryotic rRNA which 
has previously been described for bacterial species is the specific enzymatic degradation [214]. While 
bacterial mRNA lacks polyadenylation, it contains a 5’-triphosphate instead. Mature rRNA and tRNA 
on the contrary exhibit a 5’-monophosphate. This difference can be used by the enzyme terminator-
5´-phosphate-dependent exonuclease (TEX) to specifically degrade non-mRNA transcripts. 
 
Table 3.2 rRNA reduction efficiencies using enzymatic degradation by terminator-5’-phosphate-dependent 
exonuclease (TEX). 
Samples were either treated with TEX enzyme alone or a combination of rRNA removal with Ambion magnetic 
beads (MICROBExpress) followed by TEX incubation (ATA, ATB). Samples TEX 150s b and T1A – ATB were 
Illumina sequenced and further analyzed (Figure 3.3). For sample TEX 180s no 16S and 23S ratios could be 
calculated due to overall fragmentation of the RNA (compare Figure 3.2). 
                    
Sample 
Total RNA 
[µg] 
RNA after 
treatment 
[ng total] 
RNA 
Reduction 
[%] 
TEX 
[U] 
TEX                   
[U/µg 
RNA] 
Inkubation 
[min] 
Buffer 
16S 
[%] 
23S 
[%] 
Control - - - - - - - 26.7 48.5 
TEX 150s a 15 2575 82 7 0.47 150 A 1.9 40.8 
TEX 150s b 7 975 86 6 0.85 150 A 1.3 33.8 
TEX 180s 7 825 88 7 1 180 A - - 
TEX 1U 2.5 1585 36 1 0.4 60 A 2.7 59.2 
TEX 5U 2.5 407 83 5 2 60 A 2.4 46.2 
T1A 2.5 780 68 1 0.4 60 A nd nd 
T1B 2.5 1170 53 1 0.4 60 B nd nd 
T5A 2.5 120 95 5 2 60 A nd nd 
T5B 2.5 390 84 5 2 60 B nd nd 
ATA 1.4 240 82 1 0.71 60 A nd nd 
ATB 1.4 420 70 1 0.71 60 B nd nd 
 
CHAPTER 3: RESULTS 47 
 
 
 
Figure 3.2 rRNA depletion by enzymatic degradation. 
PA14 wt total RNA was treated by specific enzymatic degradation using terminator-5´-phosphate-dependent 
exonuclease (TEX) to reduce the amount of rRNA content. A-F show the respective electropherograms 
obtained from Agilent 2100 Bioanalyzer. A: Untreated control sample (total RNA). B-F: Samples treated with 
TEX enzyme using different concentrations and incubation times. Details for each reaction setup can be 
obtained from Table 3.2. Samples A-C (Ladder 1), D-E (Ladder 2), and F (Ladder 3) were run together on 
individual Bioanalyzer pico chips. Probable 16S and 23S fractions were marked in pink and green, respectively. 
 
Figure 3.2 depicts the electropherograms obtained from Bioanalyzer for TEX treated samples with 
the influence of prolonged incubation and varied enzyme concentration. Further information on each 
sample set up, including initially applied amounts of total RNA and respective enzyme concentrations 
per µg RNA, as well as RNA reduction after each approach accompanied by the 16S and 23S specific 
ratios can be found in the corresponding Table 3.2. 
While hybridization-based approaches showed only a minor increased preference for 16S over 23S 
rRNA, TEX dependent enzymatic degradation clearly favored the depletion of 16S rRNA (Figure 3.2 B). 
As increased enzyme concentration did not alter rRNA removal ratios (Figure 3.2 C), one possible 
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explanation was thought to be the size difference of 16S (1500 nt) and 23S (2900 nt) rRNA, which 
resulted in supposedly longer degradation time for 23S. Thus, the incubation time was stepwise 
increased from 60 s to 150 s and 180 s. While only slight improvement was obtained at 150 s to 1 % 
16S and 34 % 23S rRNA compared to 27 % and 49 % for the control sample and 3 % and 46 % after 60 
min incubation, severe overall RNA degradation was observed at 180 s (Figure 3.2 D-F).  
To compare the effects of both, hybridization and enzymatic rRNA removal on the actually remaining 
proportion of mapped rRNA transcripts and examine method specific influences on the overall gene 
expression profile, one Ambion treated sample and one 150 s TEX treated sample were Illumina 
sequenced. Furthermore, four additional samples with varying TEX enzyme concentrations and 
reaction buffer conditions, and two samples treated with magnetic beads, followed by TEX 
incubation were investigated.  
As shown in Figure 3.3 A, the Ambion MICROBExpress treatment clearly led to the highest amount of 
rRNA reduction with an increase to 40 % mRNA transcripts. Additional TEX incubation in either buffer 
A or B did not influence this ratio (samples ATA and ATB). On the other hand, TEX incubation alone 
still remained with 85-95 % mapped rRNA reads, regardless of the selected conditions, although the 
previously by Bioanalyzer determined overall rRNA reduction differed only from 40 % (Ambion 
oligos4) to 46 % (TEX 150s b). This discrepancy likely results from incomplete rRNA degradation, 
producing augmented smaller fragments, instead of effectively removing the rRNA. Thus, the 
respective remaining fragments are still amplified and mapped, and continue to affect mRNA 
sequencing depth. 
Another interesting observation was the effect of enzymatic and hybridization dependent rRNA 
treatment on mRNA gene expression profiles, as depicted in Figure 3.3 B. As an example, the oprD 
gene was chosen, which is known to be initiated for transcription from at least two individual 
transcriptional start sites at -23 and -71 upstream of the gene [18]. Both start sites were clearly 
visible as significant, sharp peaks just before the oprD coding sequence, when rRNA was removed by 
hybridization. However, enzymatic TEX treatment, even as low as 0.4 U per µg total RNA (samples 
T1A and T1B), completely eradicated these significant start side peaks. Additionally, overall gene 
wide expression patterns differed greatly from the hybridization treated sample, particularly with 
increasing enzyme concentration, incubation duration and use of buffer B. It therefore appears that 
TEX dependent enzymatic rRNA degradation is not highly specific and as well affects mRNA 
transcripts. 
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Figure 3.3 Transcript distribution and gene expression profiles after rRNA removal. 
A: Abundance of mRNA, rRNA, sRNA and tRNA reads after mapping to the PA14 reference genome. B: Effects of 
different enzymatic and hybridization-based rRNA depletion protocols on mRNA transcripts (using the example 
of the oprD gene). Transcriptional start sites are indicated by red arrows. Expression profiles were visualized 
with Artemis genome browser [215], with gene expression of the plus strand shown in red and gene expression 
of the minus strand in green, respectively. 
 
Concluding, best results in terms of rRNA reduction, integrity of the mRNA in vivo profile of 
P. aeruginosa and overall cost efficiency for high-throughput application were obtained from 
treatment with one round of rRNA removal by Ambion MICROBExpress in combination with oligos4. 
To remain with sufficient amounts of mRNA for library preparation after reduction and still maximize 
the removal impact, 7 µg of total bacterial RNA were initially used per sample for preparation of the 
sequenced clinical isolates. 
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3.2 Transcriptome sequencing of clinical P. aeruginosa isolates 
Our study was designed to investigate the genetic modifications underlying antibiotic resistance 
phenotypes in P. aeruginosa clinical isolates. For this purpose, a cross-sectional study group was 
chosen with isolates sampled in different regions across Europe as well as diverse infection sites as 
wounds, catheters, urinary tract infections, and sections of the respiratory tract, including 30 
samples from cystic fibrosis patients. Altogether, our sample collection comprised 149 clinical 
P. aeruginosa isolates, provided by the Hannover Medical School (87), the University of Freiburg (40), 
the Robert-Koch-Institute in Wernigerode (14), and the National Reference Centre for multidrug-
resistant Gram-negative Bacteria in Bochum (8). To focus particularly on the subject of antibiotic 
resistances, the majority of the strains were selected because of their categorization as multidrug-
resistant. All strains were cultivated, RNA-sequenced, and analyzed based on the sequencing data for 
gene expression and mutations. 
3.2.1 Coverage and relative transcript abundance of clinical P. aeruginosa isolates 
Since this study aimed to analyze not only the gene expression profiles but also the transcript 
sequences of different P. aeruginosa isolates in order to search for resistance determining mutations, 
a sufficient read coverage had to be assured. This was of particular importance with the intention to 
maximize multiplexing on the same sequencing lane, thereby exhausting the entire scope of Illumina 
sequencing capacity. A second important challenge was to determine the analysis strategy in favor of 
either read mapping to a reference genome or whole transcriptome de novo assembly. 
Complete genome sequences of several P. aeruginosa isolates have already been made available to 
the community [79,216-218], and comparative analysis of the different strains discovered a mosaic 
genome. Approximately 90 % of the P. aeruginosa genome belongs to strongly conserved, ‘core’ 
genetic elements, interspread by only a small proportion of accessory genetic islands [219,220]. 
This allowed acquiring the vast majority of sequence and expression information by mapping the 
sequencing reads of the clinical isolates directly to the sequence of one known reference strain 
without the need for whole transcriptome de novo assembly. In this study, the clinical isolate UCBPP-
PA14 was used as genetic reference [189]. 
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Figure 3.4 Individual read counts and genome coverage of 149 clinical P. aeruginosa isolates. 
Clinical isolates are depicted from left to right in order of sample preparation and sequencing. A: Amounts of 
mapped reads (to the PA14 reference genome) obtained from RNA-sequencing per isolates. B: Whole genome 
coverage (nucleotide positions with ≥ 1 read) per sample. Different sequencing pools are separated by dashed 
lines. 
 
Figure 3.4 A depicts the individual numbers of mRNA reads mapped to the PA14 reference genome 
for each of the 149 clinical isolates. Hereby the read origins, as coding or non-coding RNA were not 
taken into account. Additionally, the corresponding total genome coverage was calculated as 
determined by the amount of nucleotide positions with at least one mapped read (Figure 3.4 B). 
Interestingly, the amounts of mapped reads fluctuated much more strongly than the correspondingly 
calculated coverage. Further analysis revealed that read quantity and genome coverage only showed 
a clear, nearly linear correlation (r = 0.83) within the range of up to 0.8 million mapped mRNA reads, 
resulting in approximately 75-80 % genome coverage. Above this threshold, saturation occurred and 
only a slight further increase in coverage ranging from 70 % to a maximum of 90 % could be seen 
(r = 0.50), despite more than doubling read quantities of up to 1.8 million mapped mRNA reads per 
sample (Figure 3.5). 
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Figure 3.5 Correlation between numbers of mapped reads and genome coverage. 
A clear linear correlation between the amount of mapped reads and the total genome coverage could be 
recognized until 0.8 million mRNA reads per sample (r = 0.83). Above this threshold, saturation was seen with 
only slight further increase in coverage despite doubling read numbers (r = 0.50). 
 
Overall, multiplexing of up to twelve individual samples in equal amounts on one Illumina Genome 
Analyzer IIx lane provided between two and 13 million mapped reads, with an average of five million 
reads per sample (Figure 3.6 A). Only sequencing the transcriptomes of the clinical isolates, thus a 
total genome coverage ranging from 40 % up to 90 % could be obtained with an average of 67 % 
genome coverage across the samples (Figure 3.6 B).  Furthermore, an averaged 49 % of the genomes 
were covered with at least three or more mapped reads. Of note, the total genome coverage of a 
paired end sequenced PA14 wt strain reached 70 %. 
This coverage was sufficient to enable us to use the transcriptome data for gaining information about 
sequence variations as single nucleotide polymorphisms (SNPs) or larger mutations as insertions and 
deletions. We employed this sequence information both for phylotyping to evaluate clonal 
relatedness within the sequenced strain collection and resistance phenotype prediction accompanied 
by unbiased, global phenotype-genotype correlations. 
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Figure 3.6 Overall RNA-seq data depth. 
A: Coverage distribution of the P. aeruginosa clinical isolates mapped to the PA14 reference genome. The total 
number of mapped reads varied between two and 13 million, with an average of five million per sample. B: 
Distribution of the whole genome coverage (nucleotide positions with ≥ 1 read) of the clinical isolates by 
transcriptome sequencing of P. aeruginosa clinical isolates ranged from 40 % - 90 %. On average, genome 
coverage of 67 % was reached. 
 
Besides the total amounts of mapped reads and the respective genome coverage, the relative 
transcript abundance of individual coding (mRNA) and non-coding (rRNA, sRNA, and tRNA) was 
determined to evaluate the impact of the library preparation method on small RNA species, and 
identify the rRNA removal and mRNA enrichment efficiency (Figure 3.7). 
For rRNA removal, the clinical isolates were treated with a combination of MICROBExpress (before 
library preparation) and duplex-specific nuclease treatment (DSN; after library preparation), which 
yielded in up to 75 % mRNA per sample. However, rRNA removal efficiency strongly varied (between 
less than 10 % and more than 70 % mRNA content) depending on the individual sample and partly on 
the sequencing pools as a whole.  Final mapped mRNA-rRNA ratios could not be predicted accurately 
CHAPTER 3: RESULTS 54 
 
from concentration decrease after hybridization or DSN, or Bioanalyzer ratio calculation (data not 
shown). 
Abundance of tRNA and sRNA was below 1 % and 8 %, respectively, throughout all samples. 
 
 
 
 
Figure 3.7 Distribution of mRNA, rRNA, sRNA and tRNA reads. 
Percentages for mRNA, rRNA, sRNA, and tRNA mapped reads to the PA14 reference genome were calculated 
from the amount of the reads per gene (rpgs) from each category divided by the total number of rpgs per 
strain. Clinical isolates are depicted from left to right and top to bottom in order of sample preparation and 
sequencing. Average values for the first 75 samples (top) were 20.1 % (mRNA), 77.1 % (rRNA), 2.6 % (sRNA), 
and 0.1 % (tRNA), while average values for the last 74 samples (bottom) were 41.7 % (mRNA), 54.9 % (rRNA), 
2.8 % (sRNA), and 0.2 % (tRNA), respectively. 
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3.2.2 Phylotyping by 214 genes identified a clonal outbreak 
With the data obtained from RNA-sequencing, our first aim was to have a look at the phylogenetic 
relatedness of the isolates. This was supposed to provide more insight into taxonomical distributions 
and furthermore, ensure an unbiased study group for subsequent genetic analysis. 
For obtaining information about phylogenetic distribution and clonal relatedness, strategies such as 
variable number tandem repeat (VNTR) and multilocus sequence typing (MLST) assays are widely 
used [221,222]. Although both methods are useful for strain typing, they are only based on a very 
limited level of sequence resolution, as for example just eight open reading frames (ORFs) are 
considered for conventional MLST analysis. A newer, higher-throughput, complementary approach 
was introduced in 2007 with the development of a typing microarray capable of discriminating 58 
binary single nucleotide polymorphisms (SNPs) in seven conserved ORFs, as well as identifying the 
presence of strain-specific horizontally acquired genomic islands and islets [223]. 
We wanted to provide even higher resolution and therefore performed phylogenetic analysis based 
on the sequence similarity of all commonly expressed core genes. Thus, the sequences of all genes 
with a coverage of at least 90 % in all clinical isolates and orthologs in five selected P. aeruginosa 
reference strains (PAO1, PA14, PACS2, LESB58 and PA7),  in total 214 genes, were compared with 
each other. The phylogenetic relationship was constructed from a k-mer-based matrix of this 
comparison, including the reference strains and the 149 sequenced clinical isolates.  
As shown in Figure 3.8, the generated phylogenetic tree separated into two main lineages, one 
including the PA14 reference strain and the other containing PACS2, LESB58 and PAO1. Additionally, 
there were some taxonomically more distant isolates (MHH6887, MHH13682, MHH13684, 
MHH9830, and B34) and the known outlier PA7. Although we also identified a few groups of more 
closely related isolates, overall, the samples exhibited a broad taxonomical heterogeneity. One 
particular cluster (highlighted in red), however, only consisted of samples isolated at the Hannover 
Medical School within a short time-period of only a few months. Further investigation of the 
expression profiles (Figure 3.9) confirmed that the specific isolates likewise exhibited a very similar 
gene expression pattern, with twelve of the fourteen clustering directly together. Combined with a 
retrospective analysis of the patients` data, the phylogenetic and expression-wise clustering 
indicated very close clonal relatedness. 
Since our study intended to identify resistance markers on a global scale by unbiased statistical 
analysis and provide information about the distribution and abundance of antibiotic resistance 
determinants within a cross-sectional group, all but one isolate (MHH8607) of this clonal cluster were 
excluded from further analyses (135 remaining isolates). 
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Figure 3.8 Phylogenetic clustering and antimicrobial resistance profile of all sequenced clinical isolates.
The phylogenetic tree of all sequenced clinical isolates and five reference strains (PA14, PAO1, LESB58, PACS2, 
PA7) was constructed with neighbor-joining algorithm 
for the analysis of phylogenetic distances was a 
coverage of at least 90 % in all clinical strains 
genes). Reference strains were framed
clonal cluster. The non-susceptibility (resistance or intermediate
important anti-pseudomonal drugs ciprofloxacin, tobramycin, ceftazidime and meropenem was indicated by 
respectively colored bars. The antibiotic resistance dataset was integrated 
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Figure 3.9 Gene expression clustering of clinical isolates. 
The heatmap shows the gene expression profiles of all sequenced isolates. Included were all differentially 
regulated genes with an interquartile range (iqr) = 2 calculated from nrpk values. Hierarchically clustering was 
performed with the Hclust algorithm in R. Isolates belonging to one likely clonal cluster are marked in red. 
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These 135 clinical isolates were then analyzed for their I) acquired genetic elements, II) gene 
expression profiles, and III) sequence mutations (including SNPs, stops, and insertions/deletions). 
While the information on gene expression and gene sequence can be obtained from mapping to the 
reference genome, the search for acquired genetic elements has to be based on alternative 
strategies.  
3.2.3 Nature and distribution of acquired β-lactamases 
P. aeruginosa is well known for its ability to acquire resistance via horizontal transfer of genetic 
elements like plasmids, transposons (especially associated with integrons), and acquired β-
lactamases which largely contribute to a rapid spread of β-lactam resistance among clinical isolates 
[140]. To search for the presence of such acquired resistance-conferring genes, particularly β-
lactamases, in our collection of clinical isolates, we applied two different approaches. The first was to 
generate a collection of contigs from de novo transcriptome assembly, which were then aligned to a 
comprehensive resistance gene library containing a collection of 658 prokaryotic, transposable 
resistance genes, including 514 β-lactamases. The second approach was to generate an artificial 
genome based on the alignment of the mentioned resistance gene library. RNA-sequencing reads 
were subsequently mapped to this artificial genome and the sequence coverage of every gene was 
determined. 
 
Figure 3.10 Direct comparison of bioinformatical β-lactamase detection approaches. 
A total of 19 β-lactamases in 17 strains was detected using de novo transcriptome assembly and blast 
comparison, while a mapping-based approach identified 25 β-lactamases with sequence coverage of more than 
90 %. Both approached showed a 46 % overlap with each other and an 83 % overlap with the supposed 
“actual” spectrum of acquired β-lactamases as validated by additional Sanger sequencing or phenotypic 
comparison. Venn diagram was created with VENNY [224]. 
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While both methods detected a largely overlapping set of acquired β-lactamases (83 %), the gene 
coverage-based approach exhibited higher sensitivity and a lower false discovery rate (Figure 3.10). 
The false discovery rate was assigned by comparing the computational results with additional 
experimental data. The presence of acquired genes was exemplary confirmed by PCR and Sanger-
sequencing, revealing a high accuracy of the transcriptomic approach. Additionally, we tested all 
MEM-CAZ resistant isolates for enzymatic carbapenemase activity, which matched the bioinformatic 
prediction (Figure 3.11). Eventually a combination of both approaches was used to unravel the 
complete acquired β-lactamase repertoire of all sequenced clinical isolates. 
 
 
Figure 3.11 Carbapenemase activity of meropenem resistant strains. 
Carbapenemase activity of all MEM-CAZ resistant clinical isolates in which bioinformatical approaches had not 
detected any presence of a corresponding enzyme was assayed by monitoring meropenem substrate hydrolysis 
spectrophotometrically at 297 and 300 nm. Depicted are the results from one representative experiment out of 
at least two biological replicates. PA14 wt was used as negative control, while the VIM-1 expressing PSAE1661 
served as positive control. Of note, values in (A) were obtained from basic carbapenemase activity test, values 
in (B) from carbapenemase activity rescue. See methods section for details.  
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Figure 3.12 Distribution of β-lactamases among clonally unrelated clinical isolates. 
The phylogenetic tree was constructed from all clonally unrelated clinical isolates (135 strains) using the same 
approach as previously described for generating the phylogenetic tree in Figure 3.9. A β-lactamase resistance 
enzyme dataset was integrated using iTOL. In total, nine different kinds of β-lactamases belonging to four 
enzymatic groups were detected in 19 isolates. β-lactamase distribution was widespread among isolates from 
diverse geographical origins and phylogenetic background. Six isolates contained two respective enzymes, 
however, in these cases one of the enzymes was an oxacillinase.  
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Various acquired β-lactamases (including broad- and extended-spectrum serine- (ESBL) and metallo-
beta-lactamases (MBL)) were detected singular or in combinations in the individual clinical isolates 
(Figure 3.12). In total, we identified nine different β-lactamases (OXA-2 and 4, VIM-1 and 2, GIM-2, 
IMP-1 and 7, PER-1, and CTX-M-3) in overall 19 isolates (14 %) of which six contained two respective 
enzymes (4.4 %). In any of these cases, one enzyme was a MBL or ESBL, while the second enzyme 
belonged to the class D oxacillinases. Interestingly, only one isolate from the Hannover Medical 
School contained acquired β-lactamases. 
Fourteen out of 45 meropenem (MIC ≥ 16 µg/ml) and 17 out of 61 ceftazidime (MIC ≥ 32 µg/ml) 
resistant isolates expressed a β-lactamase encoding gene. Additionally, two isolates with VIM-2 
carbapenemases showed a MEM intermediate resistance phenotype. In general, the presence of β-
lactamases was wide-spread and correlated in all cases with elevated MIC values against 
carbapenems and/or cephalosporins in dependence on the particular enzyme type. 
Despite the occurrence of acquired β-lactamases, we also analyzed the presence of different types of 
integrase genes. To date, three classes of antibiotic-resistance mediating integrons have been 
described, based on the amino acid sequence of their IntI integrase gene (intI1-3) (29). No type 2 and 
3 integrase genes were found, while type 1 integrase genes were detected in 49 clinical isolates. 
Integrase detection was defined positive, when either 90 % gene coverage or a combination of at 
least 70 % coverage together with de novo assembly and blast detection was observed. Interestingly, 
in all but two isolates with acquired β-lactamases integrase genes were expressed. 
 
3.2.4 A systematic approach for comprehensive gene sequence and expression data 
analysis 
With the scope of data whole transcriptome sequencing offers, the aim of this thesis was, besides 
the analysis of acquired genetic elements, not only to study individual core gene expression or 
previously discovered mutational hot spots, but to have a comprehensive, unbiased view at intrinsic 
gene regulation and sequence alterations as a whole and thereby investigate the global changes 
leading to a particular resistance phenotype. However, comprehensive and systematic analysis of 
such enormous amounts of data is challenging. 
Overall, RNA-sequencing identified 1411 genes up- and 496 genes down-regulated at a median of at 
least two-fold over all clinical isolates compared to the PA14 wt. 2,349,331 SNPs were detected of 
which 19,358 led to amino acid exchanges (5575 genes) and 938 to intragenic stops (330 genes) 
(Figure 3.13).  
Thus, we had to come up with an approach to facilitate the search for relevant genetic alterations 
and distinguish them from resistance phenotype irrelevant modifications. 
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Figure 3.13 Global distribution of gene expression 
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3.2.4.1 Data storage and management within a web-based database facilitated 
genotype-phenotype correlations 
Systematic and comprehensive analysis of RNA-seq data is challenging and makes data mining a 
topical issue. To cope with this challenge, we developed an online accessible database, the Bactome 
(https://bactome.helmholtz-hzi.de), which was programmed by Klaus Hornischer (Helmholtz Centre 
for Infection Research). Bactome comprises the gene expression levels, sequence composition, 
genomic location and annotation of the genes of all taxonomically different 135 clinical isolates, as 
well as further information on the origin, phenotype and resistance profile of each strain (Figure 
3.14). 
 
 
 
Figure 3.14 Display of additional strain specific information in Bactome. 
Exemplified for the isolate PSAE 1661, Bactome comprises, next RNA-seq data, detailed information on the 
colony morphology, sample origin, including infection site, and the antibiotic resistance profile for each of the 
clinical isolates to facilitate phenotype-specific grouping as for example according to a particular antibiotic 
resistance phenotype. 
 
Furthermore, using the information provided by the RNA-seq data in combination with R scripts, the 
database may perform a number of custom adjustable, statistical analyses in order to search for 
parallel evolved adaptive genetic variations that are distinct from unlinked neutrally evolving ones. 
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As a basis for the statistical comparison, the clinical isolates were compared in groups according to 
common phenotypic features, with one group exhibiting (positive) and the other opposing (negative) 
the particular phenotype, as for example resistance or susceptibility toward a particular antibiotic. 
The database then offers four options for comparative analysis: “SNPs position-wise”, “SNPs gene-
wise”, “Stop codons”, and “Gene expression” (Figure 3.15). 
 
 
 
Figure 3.15 Custom adjustable group comparisons in Bactome facilitate the detection of genetic enrichments 
for pre-selected phenotypes. 
A: As a basis for the statistical comparison, the clinical isolates need to be grouped according to whether they 
are positive or negative for a particular phenotypic feature. B: Next, Bactome offers 4 comparison modes to 
search for the accumulation of corresponding genetic markers. The groups can be analyzed for SNP clustering, 
either at distinct positions or within genes, unnaturally frequent intragenic stop codon formation or significant 
differential gene expression.  Each comparison mode thereby comprises individual setup options, which include 
the additional incorporation of insertions and deletions, the choice between synonymous and non-synonymous 
SNPs, the analysis of upstream and downstream regions of genes, and the joining of non-synonymous SNP 
positions despite differing effects. Furthermore, stringency may be adjusted by varying minimal read coverage 
and SNP quality threshold (see text for further details). 
 
The “SNPs position-wise” mode compares each nucleotide position of every strain in both groups to 
the PA14 reference and generates a matrix for all non-synonymous SNPs. For the “SNPs gene-wise” 
mode, the same is done, but merging all SNPs within one gene sequence, and with the option to 
include synonymous SNP to identify genes with high mutation rates despite possibly conserved 
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amino acid sequence. Besides, the gene-wise analysis can be extended to upstream and downstream 
sequences of each gene by defining the desired margins. Both comparisons contain the option of 
including insertion and deletions in the analysis, additionally to SNP mutations. Furthermore, a SNP 
quality threshold can be defined, as well as a minimal read coverage threshold to adjust stringency. A 
third option, the “Join Position SNPs” can be used in the position-wise mode, which, instead of 
handling them separately, joins non-synonymous SNPs occurring at the same nucleotide position but 
leading to different amino acid exchanges. This enables to detect mutational hot spots within a gene, 
without the necessity to have the same mutational mechanism involved. 
In the “Stop codons” selection, intragenic stop codons are detected for every gene in every strain. 
For this purpose, a matrix is generated from comparing protein sequences corresponding to each 
gene for truncation. The respective protein sequences are created by introducing the previously 
detected SNPs (relative to the PA14 reference sequence) into the gene sequence of the PA14 
reference strain and converting the nucleotide to the amino acid code.  
Once the matrices have been generated, the accumulation of SNPs and intragenic stops in particular 
genes within one of the two defined groups of clinical isolates is calculated by Fisher’s exact test. 
To identify significant differential gene expression between the two groups, Student’s T-test is 
performed on the normalized reads for every gene (nrpk), independent of the PA14 wt gene 
expression. Additionally, median expressions for every gene is calculated for both groups, together 
with the standard deviations and median differences between the groups, and any genes with a 
median of zero are excluded from the output list of significantly differentially regulated genes. 
In addition to complete data output files, graphically displayed information is available for the top 30 
hits obtained from each comparison.  The kind of display of the information varies depending on the 
selected comparison mode (Figure 3.16). For SNPs and stops, bar charts indicate the distribution of 
the mutations within the groups and specify the amounts of detected mutations and wild type 
positions together with the number of strains for which the information could not be determined 
(e.g. due to insufficient read coverage at the selected position). Furthermore, a click on the gene 
name opens an integrative browser in which the median gene expression over all isolates for the 
selected gene is shown. Zooming in, one receives further information about the appearance and 
frequency of mutations within this gene, regarding all clinical isolates. The gene expression mode on 
the contrary displays the median gene expression calculated for the first (red) and second (blue) 
group by the transcript abundance for each nucleotide position within the selected gene.  
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Figure 3.16 Graphical display of group comparison results in Bactome. 
For the top 30 hits obtained from every group comparison, an additional graphical illustration of the results is 
available via Bactome. A: SNP and stop comparisons generate bar charts to depict the distribution of mutations 
with the amounts of strains in each group for which the mutation could be identified (+), not identified (-) or 
not determined due to low read coverage (nd). Clicking on the gene name opens an integrative browser which 
displays the median expression of the gene over all clinical isolates (B), or zoomed in, the occurrence and 
frequency of mutations over all clinical isolates (C). In gene expression comparison mode, this is replaced by a 
graph depicting the median gene expression for the first (red) and second (blue) group of the selected isolates. 
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In all cases, the adjusted p-values (padj; Benjamini-Hochberg (bh) corrected) are given to indicate 
significance of the findings. However, nonsense mutations that lead to premature translational stops 
are rare events across the genome. A summary of all intragenic stop sites of the sequenced clinical 
isolates is depicted in Figure 3.17. The majority of 5562 analyzed genes did not contain intragenic 
stops in any of the 135 clinical isolates and less than ten genes were stop-mutated in more than two 
isolates. Hence, it was not surprising that we did not identify any statistically significant accumulation 
of stops using adjusted p-values.  
 
 
 
Figure 3.17 Transcriptome wide distribution of intragenic stop codons among clinical isolates. 
Nonsense mutations are rare events. While the majority of 5562 analyzed genes did not contain any intragenic 
stops, less than 10 genes were mutated in three or more clinical isolates, and only one gene (fdnG) was 
mutated in all 135 isolates. In total, 330 nonsense mutations were identified over all isolates, corresponding to 
0.04 % of the transcribed genes. 
 
Despite the limitations of conventional statistics, we were nevertheless interested in investigating 
the possible role of nonsense mutations in the display of particular phenotypes. Thus, we decided to 
include the option of choosing the uncorrected p-values for the stop comparison mode to receive as 
well genes which would not be considered “significant” anymore after bh-correction. However, these 
uncorrected p-values should be interpreted as “significance score” in this case. To minimize false 
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positive results, additional permutation was performed for each dataset. This was also applied on the 
SNP and gene expression comparisons to gain more insight into the specificity and reliability of the 
chosen padj cut-offs. For the purpose of permutation, the expression values of each gene and SNP 
information of each position in the genome, respectively, were randomly rearranged within each 
strain. The resulting new matrices were then used as input for the respective statistical group 
comparisons. The minimal p-value obtained from ten permutations was considered as significance 
cut-off for the detected genes of the dataset, if it was lower than the usually used cut-off of 0.05. 
For each group comparison, the option to choose between using the original matrices or permutated 
ones for the statistical calculation was implemented as selectable feature in Bactome. 
3.2.5 Identifying intrinsic β-lactam resistance markers via unbiased phenotype-
genotype correlation studies 
With the possibilities of Bactome data management and the embedded tools for statistical analysis, 
we could now start a comprehensive search for core genetic variations that are connected to 
antibiotic resistance phenotypes. For this purpose, the 135 clinical isolates were grouped into “non-
susceptible” and “susceptible” (according to CLSI guidelines [15]) towards the β-lactam antibiotics 
ceftazidime (CAZ) and meropenem (MEM), respectively. In order to focus on intrinsic resistance 
mechanisms, those isolates that expressed acquired resistance-conferring genes were excluded from 
the list of “non-susceptible” isolates, which resulted in 57 CAZ and 73 MEM non-susceptible isolates 
that were investigated for parallel evolved genetic variation regarding I) the enrichment of SNPs at a 
distinct position,  II) the enrichment of SNPs within a particular gene, III) the enrichment of  
intragenic stop codons and IV) differentials in gene expression levels. 
3.2.5.1 Global gene expression analysis emphasizes the importance of ampC 
expression in CAZ resistance and suggests the selection of cross-resistances 
Whereas no significantly SNP enriched positions or genes could be detected, the group comparison 
of non-susceptible (n=57) versus susceptible (n=59) CAZ isolates revealed a list of four genes with 
accumulations of nonsense mutations and two significantly differentially regulated genes, both of 
which were up-regulated in the CAZ non-susceptible group (Table 3.3).  
As the most significantly regulated gene, the chromosomally encoded β-lactamase ampC was 
identified with a p-value of 1.12E-07 (in contrast, the lowest p-value obtained after permutation was 
as high as 1.19E-01). This finding was not unexpected, since overexpression of ampC is known to be 
the most important intrinsic CAZ resistance mechanism. However, it emphasizes that determination 
of ampC expression could be used as a very suitable marker for molecular resistance detection in this 
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case. The second lowest p-value was obtained by PA14_10780, a gene directly downstream of ampC, 
producing an unknown, hypothetical protein. Most likely PA14_10780 itself does not actively 
contribute to CAZ resistance, but is merely up-regulated due to the preceding ampC overexpression. 
 
Table 3.3 Group comparison for CAZ susceptible and non-susceptible isolates. 
While the expression of two genes was significantly differentially regulated in the non-susceptible group of 
isolates (expression comparison mode) and four genes exhibited an accumulation of nonsense mutations (stop 
comparison mode), respectively, no significant enrichments were seen for position-wise and gene-wise SNP 
comparison mode with parameters minimal SNP score threshold 50 and minimal read coverage 1.  
              
Antibiotic 
Isolates [n] Expression comparison 
a
 Stop comparison 
b
 
Susceptible Non-susceptible Gene Enrichment (padj) Gene Enrichment (pval) 
CAZ 59 57 (19)* ampC 4.85 (1.12E-07) PA14_21520 12 (5.57E-03) 
   
PA14_10780 2.32 (2.94E-03) oprD 2.3 (7.17E-03) 
     
mexB 11 (1.22E-02) 
     
PA14_03180 11 (1.29E-02) 
 
* Isolates with acquired resistance enzymes which were excluded from the statistical group comparison 
Enrichment = fold enrichment in the non-susceptible group 
a
 Expression was analyzed as logarithmic, normalized reads per kilobase (lnrpk) values for every gene, giving the median, 
corresponding standard deviation (SD) and median difference between the two groups for each gene together with the 
adjusted p-value (padj) obtained from T-test. Genes were filtered for padj < 0.05 and median differences > 1, and genes 
with any median = 0 or SD > median were excluded. 
b
 Nucleotide positions of all transcripts were analyzed for nonsense mutations and significance was determined by Fisher 
test, including all SNPs with a SAMtools quality score of at least 50. Shown are all hits with an uncorrected p-value of < 0.05. 
 
In addition to two hypothetical genes, the porin gene oprD, and mexB, coding for a component of the 
MexAB-OprM efflux pump, were much more frequently stop mutated in the CAZ non-susceptible 
group. For all genes, p-values ranged between 1.29E-02 and 5.57E-03, while the lowest p-value 
calculated from ten permutated datasets was 1.15E-01, which confirmed a low potential of false 
positive hits within our list. However, the results were surprising, as MexAB-OprM has been 
described to enhance β-lactam efflux and thus promote non-susceptibility. One reason could be that 
efflux pumps play a role in initial, first step antibiotic tolerance rather than mediating high level 
antibiotic resistance. Thus, as soon as additional, more effective resistance mechanisms are 
employed, efflux overexpression might no longer provide advantages for the bacteria. 
The second surprising finding within the list was the porin gene oprD, whose absence is primarily 
associated with carbapenem resistance, as CAZ cell entry via oprD is only marginal (see section 3.2.7). 
This result emphasizes the tight interconnections of cross resistance evolution in clinical isolates. 
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Interestingly, when we compared CAZ susceptible with only resistant variants (excluding 
intermediate resistant isolates), we additionally found a significant differential expression of mexE, a 
component of the MexEF-OprN multidrug efflux pump (Table 3.4). Curiously, overexpression of the 
MexEF-OprN pump has not been associated with CAZ resistance so far, but with an increased MIC of 
the fluoroquinolones CIP and levofloxacin (LVX) and a slightly increased MIC of MEM (via a MexT 
dependent repression of oprD) [66,226,227]. However, the transcriptional regulator AmpR has been 
described to be involved in the regulation of both, ampC and mexEF-oprN, as well as further genes 
involved in efflux, virulence and secretion [105,228,229]. Thus, we had a separate look at ampR 
expression and could indeed find the gene to be transcribed less in the resistant as opposed to the 
susceptible group of isolates, albeit only 1.48-fold (p-value 0.004). Since AmpR does not only regulate 
the expression of ampC but also of the efflux pump mexEF-oprN, this finding stresses once more the 
easy development of cross-resistances among clinical isolates that might be selected through 
antibiotic treatment pressure, highlighting the need for more targeted diagnostics and drug use. 
 
Table 3.4 Group comparison for CAZ susceptible and resistant isolates for significant gene regulation. 
Expression data are shown as logarithmic, normalized reads per kilobase (lnrpk) values for every gene, giving 
the median, corresponding standard deviation (SD) and median difference between the two groups for each 
gene, together with the adjusted p-value (padj) obtained from T-test. Genes were filtered for padj < 0.05, 
median differences value < 1, and genes with any median = 0 were excluded. 
              
Gene Padj 
CAZ resistant CAZ susceptible 
Difference 
Median SD Median SD 
ampC 3.59E-08 7.69 2.51 2.60 2.35 5.09 
PA14_10780 2.52E-03 6.13 2.49 3.69 2.01 2.44 
PA14_61270 8.64E-03 4.92 0.98 3.60 1.51 1.32 
PA14_52490 1.12E-02 5.50 1.46 4.21 1.97 1.29 
PA14_56090 1.94E-02 6.48 0.96 5.43 1.08 1.05 
PA14_40660 3.42E-02 2.74 1.70 1.44 1.34 1.30 
PA14_28210 3.74E-02 5.20 1.03 3.76 1.46 1.45 
mexE 4.21E-02 2.85 1.89 1.39 1.72 1.45 
PA14_31730 4.33E-02 4.72 1.46 3.34 1.23 1.37 
pvdD 4.98E-02 0.42 0.95 2.04 1.14 -1.62 
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3.2.5.2 ampC expression as a molecular marker for CAZ resistance 
As ampC was the only global expression marker found in the CAZ non-susceptible group, we were 
further interested in evaluating the potential of this gene as a future molecular marker for CAZ 
resistance. As shown in Figure 3.18, there was a clear correlation (r=0.638) between increased ampC 
gene expression and elevated CAZ MIC values ranging from 0.5 to 64 µg/ml. Only in rare cases, when 
extraordinary high resistance levels of MIC values above 64 µg/ml had been observed, additional 
mechanisms seemed to play a role. Furthermore, the majority of CAZ resistant (35/36) and 
intermediate-resistant (8/13) isolates exhibited high (>3 log2FC) ampC expression values, while most 
(49/56) susceptible variants in turn showed only slight or no constitutive overexpression. Only seven 
isolates (5 %) exhibited strongly increased ampC expression (> 5 log2FC) compared to reference strain 
PA14, but nevertheless showed a CAZ susceptible phenotype. Interestingly, all of them harbored 
mutations within the ampC gene. Particularly significant hereby were deletions of one to 10 
nucleotides, additionally confirmed by Sanger sequencing, which led to frameshifts and thus most 
likely abolished functional protein production. 
 
 
 
Figure 3.18 Correlation of ampC expression and CAZ MIC among clinical isolates. 
Correlation was calculated from the ampC gene reads normalized by total reads per strain (nrpgs) in R from a 
total of 116 isolates (19 isolates which harbored acquired resistance conferring enzymes towards CAZ were 
excluded from the original panel). Box plots indicate 0.25 and 0.75 quartiles and the median (bold line). The 
sample minima and maxima are shown as whiskers with outliers depicted as open circles. Antibiotic 
susceptibility was classified in susceptible (S), intermediate (I), and resistant (R), according to CLSI guidelines. 
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In order to use ampC overexpression as a resistance marker, a defined threshold had to be 
determined to distinguish between CAZ susceptible and non-susceptible strains. For the calculation 
of this threshold, a receiver operating characteristic (ROC) curve was used (Figure 3.19). The 
correlation specifying area under the curve (AUC) was 0.889, when isolates with acquired CAZ 
resistance conferring enzymes and non-functional ampC had been excluded. Although it was not 
possible to define one particular gene expression threshold which strictly separated susceptible and 
non-susceptible strains, we could detect 63 % non-susceptibility (true positives) without including 
any false positives at an ampC expression threshold of 5.0 (log2FC). At an ampC expression threshold 
of 3.9 (log2FC), even identification of 75 % non-susceptibility was achieved while remaining with a 
tolerable amount of less than 5 % likewise detected susceptible strains (false positives).  
 
Figure 3.19 ROC correlation of ampC expression and CAZ resistance phenotype. 
Calculation of the receiver operating characteristic (ROC) curve for the correlation of ampC expression (log2FC) 
and CAZ susceptibility or non-susceptibility was performed from 107 isolates (isolates with acquired CAZ 
resistance conferring enzymes and strains with presumably non-functional AmpC due to severe mutational 
gene disruption were excluded). Correlation was determined by calculating the area under the curve (AUC): 
0.889. We could detect 63 % non-susceptibility (true positives) not including any false positives at an ampC 
expression threshold of 5.0 (log2FC). 75 % non-susceptibility was achieved at an ampC expression threshold of 
3.9 (log2FC), while remaining with less than 5 % likewise detected susceptible strains (false positives). On the 
other hand, an ampC expression threshold of 1.2 (log2FC) allowed detection of > 90 % true positives but also 
included a range of 42 % false positives. 
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3.2.5.3 Global screen for nonsense mutations highlights the link of MEM 
resistance to functional OprD 
When we compared groups of MEM susceptible and non-susceptible isolates with each other to find 
significant genetic alterations, we detected oprD, which was both down-regulated in the non-
susceptible group and frequently nonsense mutated with p-values of 4.19E-02 and 1.40E-01, 
respectively. Furthermore, the gene gbuA exhibited slightly increased expression in the non-
susceptible group (p-value 2.65E-02; Table 3.3). Though, it has to be noted that p-values from ten 
permutation of this dataset reached 4.00E-02 for significant differential gene expression and 
1.43E-01 for enrichment of nonsense mutations. Thus, all obtained values were just on the border of 
the defined significance thresholds. 
 
Table 3.5 Group comparison for MEM susceptible and non-susceptible isolates. 
The statistical comparison between groups of MEM susceptible and non-susceptible isolates identified only one 
gene enriched for nonsense mutations in the non-susceptible group and two significant differentially expressed 
genes. SNP comparison mode (both, gene-wise and position-wise) did not show any significant hits with 
parameters minimal SNP score threshold 50 and minimal read coverage 1.  
              
Antibiotic 
Isolates [n] Expression comparison 
a
 Stop comparison 
b
 
Susceptible Non-susceptible  Gene Enrichment (padj)  Gene Enrichment (pval) 
MEM 46 73 (16)* gbuA 1.22 (2.65E-02) oprD 1.45 (1.40E-01) 
      oprD - 1.79 (4.19E-02)     
       * Isolates with acquired resistance enzymes which were excluded from the statistical group comparison 
Enrichment = fold enrichment in the non-susceptible group 
a
 Expression was analyzed as logarithmic, normalized reads per kilobase (lnrpk) values for every gene, giving the median, 
corresponding standard deviation (SD) and median difference between the two groups for each gene together with the 
adjusted p-value (padj) obtained from T-test. Genes were filtered for padj < 0.05, median differences > 1 and genes with 
any median = 0 or SD > median were excluded. 
b
 Nucleotide positions of all transcripts were analyzed for nonsense mutations and significance was determined by Fisher 
test, including all SNPs with a SAMtools quality score of at least 50.  
 
However, a false positive detection is at least in the case of oprD rather unlikely as the P. aeruginosa 
outer membrane protein OprD is a 443 amino acid long porin, specific for the uptake of basic amino 
acids, small peptides and analogues such as the carbapenem antibiotics imipenem and meropenem 
[80]. Consequently, a decreased expression of functional OprD is expected to confer carbapenem 
resistance [81,90,96]. The significance of gbuA, coding for a guanidinobutyrase which is involved in 
the conversion of alanine to succinate, still requires further investigation. However, as OprD and 
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GbuA are both regulated in connection to arginine availability [86,99,230], a coincidental correlation 
is possible. 
Figure 3.20 A depicts the distribution of premature translation termination mutations in oprD. These 
mutations occurred generally throughout the sequence, as opposed to single amino acid exchanges, 
which were mostly restricted to either the periplasmic hinge or the surface associated loops (Figure 
3.20 B, C).  
 
 
 
Figure 3.20 OprD sequence modifications by non-synonymous SNPs. 
A: Nonsense mutation sites indicating premature translational stops. B: Total amounts of SNPs leading to single 
amino acid exchanges. The x-axis highlights the positions of the modified amino acids relative to protein length. 
Mutations in MEM resistant (n = 46) isolates are depicted above the x-axis (black), amino acid exchanges in 
MEM susceptible (n = 32) strains below the x-axis (grey). The positions of the eight external loops are labeled 
L1 to L8 (according to Huang et al. [92]). C: SNPs (excluding stop sites) mapped to the tridimensional structure 
of PAO1 OprD based on the model by Biswas et al. [93]. SNPs exclusively found in the MEM susceptible isolates 
are labeled in green, those found in the MEM resistant in red and those found in both in blue. 
 
Furthermore, there was no systematic accumulation of SNPs depending on the resistance phenotype. 
MEM resistant and susceptible isolates exhibited almost identical mutation patterns due to natural 
sequence variations among susceptible P. aeruginosa variants (e.g. PAO1, LESB58). Altogether, 25 
different positions with frequent single amino acid exchanges were identified. While the number of 
SNPs was equally distributed among the different MEM resistance phenotypes, the amount of strains 
with stop codons in oprD significantly decreased from resistant (11) and intermediate (23) to 
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susceptible (4) variants, with no more than one stop site per strain. Interestingly though, there was 
an unexpected accumulation of the Q327* mutation in 14 intermediate resistant strains from the 
Hannover Medical School. 
Combining sequence and expression information, there was a clear correlation (τ=0.434) between 
the presence of nonsense mutations in oprD and/or a strong transcriptional repression (< -3 log2FC) 
and elevated MEM MIC values. Eight out of 31 (26 %) MEM resistant and 17 out of 42 (40 %) 
intermediate resistant isolates harbored nonsense mutations within oprD, while 18 (58 %) MEM 
resistant and 16 (38 %) intermediate resistant isolates showed strong gene repression. Both 
mechanisms overlapped in seven (22 %) and three (7 %) cases for resistant and intermediate 
resistant isolates, respectively. 
To evaluate how gene inactivation and repression correlated to protein expression, we performed 
immunoblot analysis with an OprD specific antibody and compared the actual protein levels of a total 
of 63 isolates of different MEM resistance phenotypes with the expression and sequence information 
obtained from RNA-sequencing. Remarkably, all tested nonsense mutations led to an abolishment of 
efficient translation (Figure 3.21).  
 
Figure 3.21 Correlation of oprD expression and OprD protein abundance with resistance against 
meropenem. 
OprD protein levels were detected by Western blot analysis with a polyclonal anti-OprD antibody in 63 clinical 
isolates exhibiting various MIC values (in µg/ml) (MEM-resistant = red, intermediate = yellow, susceptible = 
green), oprD expression (shown as log2 fold change) and amino acid stop mutations (e.g. Q165*) are depicted 
underneath. Additionally acquired β-lactamases leading to MEM resistance are highlighted in red font of the 
isolate name. Arrows indicate susceptible strains with a complete lack of OprD protein. M = PageRuler 
prestained protein ladder. 
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Furthermore, Western blot analysis revealed no or only very faint protein bands in any of the tested 
intermediate (n=3) or resistant (n=32) strains. 
Whenever there was a faint band remaining, the respective isolate possessed additional, acquired 
resistance enzymes (PSAE 1152, vim-1; PSAE 2136, vim-2). The tested susceptible strains (n=28) on 
the other hand contained clearly visible amounts of OprD. However, there was an exception of a few 
isolates that were MEM susceptible despite the finding that no OprD protein was detectable.  
Interestingly, there was only partial correlation between the oprD mRNA levels and protein 
production. In several cases, the amount of OprD protein was higher than in the PA14 reference 
strain, despite transcriptional down-regulation. On the other hand, numerous isolates with a 
complete lack of functional protein did not show significant transcriptional repression or sequence 
modification. One reason could be that OprD is subject to frequent, possibly MexT mediated, 
posttranscriptional regulation, as has been described before in PAO1 [106]. 
Moreover, we were particularly surprised to find four clearly susceptible (MIC 0.5-4 µg/ml) isolates 
with apparent premature translational stops (Y91*, W138*, W417*). We additionally visualized outer 
membrane proteins of these four isolates on Coomassie stained SDS gels, which is a less specific, but 
more sensitive approach (Figure 3.22).  
 
 
 
Figure 3.22 Outer membrane analysis of MEM susceptible isolates with oprD nonsense mutation. 
Outer membranes of five susceptible clinical isolates with premature translational stops Y91* (MHH13428), 
W138* (MHH14088) and W417* (B271, RKI_53_11), the PA14 wt and PA14ΔoprD mutant were extracted, 
solubilized in SDS sample buffer and loaded to SDS-polyacrylamide gels (10 % or 15 %, respectively). 
MHH13428 and MHH14088 clearly did not produce functional OprD protein (standard (M) = PageRuler 
prestained protein ladder; OprD at 49 kDa). Protein bands cut for mass spectrometric identification are framed 
in red. 
 
While the two isolates with W417* mutations exhibited faint protein bands at 49 kDa, which may be 
OprD, MHH13428 and MHH14088 clearly did not contain any matching protein band. This very 
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interesting observation has been made before by a Spanish multicenter study analyzing carbapenem 
intermediate and susceptible patients’ isolates of P. aeruginosa from bacteremia [97]. To receive 
further information on how MEM might enter the bacterial cell on alternative ways, if it does not use 
OprD, the composition of selected protein bands cut from the coomassie stained SDS gel was 
analyzed by mass spectrometry. As there was no commonly differentially expressed protein band 
among the OprD deficient, MEM susceptible isolates, five unusually overexpressed sections 
compared to the PA14 wt were chosen (marked in red). 
 
Table 3.6 Mass spectrometric identification of differentially expressed proteins in OprD negative, MEM 
susceptible clinical isolates. 
Shown are the best identification hits for every protein band after comparison to PA14 and PAO1 specific 
SwissProt database entries. 
          
Sample Accesion no. Proteinfunction Name Locus tag 
1 116050339 Ferripyoverdine receptor FpvA PA14_33680 
2 
116052985; 
15600030 
Putative outer membrane protein (possibly 
Fe transport) 
- 
PA14_63960; 
PA4837   
3 
116050756; 
15597956 
Outer membrane porin, OprD family 
OprQ / 
OprE3 
PA14_28400;  
PA2760 
4 
116050756; 
15597956 
Outer membrane porin, OprD family 
OprQ / 
OprE3 
PA14_28400;  
PA2760 
5 15598049 Outer membrane lipoprotein OprI precursor OprI PA2853  
 
As shown in Table 3.6, mass spectrometric analyses identified the extracted bands as containing the 
ferripyoverdine receptor FpvA (1), a putative outer membrane protein which is possibly involved in 
iron transport (2), and the lipoprotein OprI (5). More interestingly however, the porin OprQ was 
detected in both isolates, which belongs to the OprD outer membrane porin family. However, the 
oprQ gene did not show increased expression in these isolates compared to the PA14 wt, posing the 
possibility that the OprQ protein band may have only been concealed by OprD in the OprD positive 
isolates. Thus, while OprQ might hint at alternative carbapenem entry, though this remains to be 
validated experimentally, clearly larger numbers of clinical isolates will be necessary to completely 
understand the regulatory and compensatory mechanism that may counter-balance the lack of OprD 
and contribute to the regained antibiotic susceptibility. 
3.2.6 Penicillin binding proteins show high sequence variability, but their role in β-
lactam resistance remains unclear 
Although modifications in penicillin binding proteins (PBPs) are well known β-lactam resistance 
mechanisms in Gram-positive bacteria [52], their role in the resistance of Gram-negatives is still 
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largely unclear. However, is has been demonstrated that inactivation or lack of particular PBPs can 
indirectly affect β-lactam resistance via up-regulation of intrinsic β-lactamases [155,231,232]. 
We therefore wanted to investigate the role of PBPs in ampC expression regulation and searched for 
mutational patterns connected to β-lactam resistance. 
 
 
 
Figure 3.23 PBP sequence modification by SNPs leading to single amino acid exchanges. 
The x-axis (relative to protein length) highlights the positions of the modified amino acids (Aa). Sequence 
variations between the reference strain PA14 and the common laboratory strain PAO1 (equally susceptible to 
β-lactam treatment) are depicted in grey. 
 
29 strains exhibited major sequence disruptions (insertions and/or deletions) in any of the 
investigated PBPs. Interestingly, out of those, 20 isolates of wide geographical distribution contained 
the same three nucleotide deletion in the gene ponA, coding for a PBP1a with a missing proline at 
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amino acid position 616. The remaining nine strains revealed frameshifts in pbpA (PBP2), dacB 
(PBP4), dacC (PBP6), mrcB (PBP1a), ftsI (PBP3) and pbpG, respectively. However, possibly due to 
compensatory mechanisms, there was no correlation between loss of function of a particular PBP 
and increased ampC expression among our subset of clinical isolates (data not shown).  
Despite only very few severe sequence modifications, we found a large variety of non-synonymous 
SNPs in any of the strains and PBPs, leading to a range of 2 % (PBP6) to 9 % (PBPG) of altered amino 
acids in total for the respective protein. SNPs were mostly equally distributed within the genes with a 
few exceptional accumulations at specific positions in PBP1A, PBP1B, PBP4 and PBPG (Figure 3.23). 
However, these positions with high mutation rates (> 20 isolates) indicated natural sequence 
variations among β-lactam susceptible P. aeruginosa variants. Additionally, PBP sequences of 
resistant and susceptible isolates were mutated equally frequently. 
Thus, PBPs seem to play either no or only a very minor role in the emergence of antibiotic resistance 
in Gram-negatives. 
3.2.7 The majority of β-lactam non-susceptible clinical isolates harbor dominant 
genetic resistance determinants 
β-lactam resistance in P. aeruginosa is mediated mostly by three different mechanisms: reduced 
influx due to porin loss (OprD), degradation by intrinsic β-lactamases (AmpC), and expression of 
different types of acquired β-lactamases. The extent of contribution of efflux pump up-regulation is 
still controversy discussed and varies greatly depending on the substrate. As shown by knock-out 
mutants of the corresponding efflux repressors in Table 3.7, only overexpression of mexAB-oprM 
clearly influenced CAZ and MEM susceptibility in the PA14 strain background.  
 
Table 3.7 β-lactam resistance profile of efflux and porin mutants. 
            
Strain 
MIC [µg/ml]* 
Efflux system
a
 CAZ MEM 
PA14 wt 1 (S) 0.19 (S)   
PA14ΔnfxB 1 (S) 0.19 (S) mexCD-oprJ 
PA14ΔmexR 4 (S) 1 (S) mexAB-oprM 
PA14ΔmexS 1 (S) 0.38 (S) mexEF-oprN 
PA14ΔmexZ 1 (S) 0.19 (S) mexXY 
PA14ΔoprD 1.5 (S) 4 (S) 
 PA14ΔoprDΔmexR 4 (S) >32 (R)   
 
* Classification of resistance and susceptibility according to CLSI guidelines is indicated in brackets. 
a
 Efflux systems which were overexpressed due to the knock-out of the corresponding repressor. 
MIC values were determined by E-test. 
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Nevertheless, MIC values for this mutant still ranged within low susceptibility classification. 
Surprisingly, a mexR-oprD double knock-out led to high MEM resistance (MIC > 32 µg/ml), although 
both mechanisms alone only moderately decreased MEM susceptibility (MIC values of 4 µg/ml 
lacking OprD and 1 µg/ml overexpressing mexAB-oprM, respectively). However, a combination of 
lack of OprD and enhanced expression of MexAB-OprM was found in less than 50 % of the MEM non-
susceptible isolates, despite its resulting high MIC increase. One explanation is probably the 
simultaneously decreasing fitness of these double mutants in infection models compared to the wild 
type strains [233]. 
Of note, there was no direct correlation between mexAB-oprM expression and CAZ or MEM MIC 
values (data not shown). 
As shown in Figure 3.24, we found a partial overlap of intrinsic and acquired resistance mechanisms 
(9 % and 12 % for CAZ and MEM resistance mechanisms, respectively) within our panel of clinical 
isolates. Though this indicated that either one does not diminish acquisition of the other, most 
isolates exhibited intrinsic resistance mechanism. 
 
 
 
Figure 3.24 Overlapping acquired and intrinsic mechanisms conferring ceftazidime and meropenem 
resistance. 
Lack of OprD was defined as strains with either nonsense mutations in oprD, expression repression ≤ - 2.5 
log2FC, no visible protein band in Western blot analysis or combinations thereof. MexAB-oprM overexpression 
was defined as ≥ 2 log2FC. Venn diagrams were created with VENNY [224]. 
 
As mexAB-oprM efflux pump overexpression alone did not strongly affect β-lactam resistance, we 
concentrated on individual mechanisms with a more pronounced effect for a direct correlation 
approach of genetic markers with resistance phenotypes. 
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Overall, we were able to predict the resistance phenotypes of 82 % of CAZ and 87 % of MEM non-
susceptible clinical isolates by dominant genetic markers detected via RNA-sequencing (Figure 3.25). 
In 18 % and 25 % of the MEM and CAZ resistant isolates, respectively, the acquisition of resistance 
mediating enzymes was observed. Of the remaining CAZ non-susceptible strains, more than 75 % 
showed constitutive ampC overexpression (log2FC ≥ 3.9). The overexpression cut-off was defined by 
calculation of the receiver operating characteristic (ROC) curve for the correlation of ampC 
expression and CAZ susceptibility with a false discovery rate of 5 %. 
Among the remaining 73 MEM non-susceptible isolates, which did not express additional acquired 
enzymes leading to carbapenem resistance, further 61 showed significant decrease in OprD based on 
strong gene repression as well as lack of protein due to nonsense mutations. 
 
 
 
Figure 3.25 Contribution of diverse intrinsic and acquired resistance mechanisms to the β-lactam resistance 
phenotype in clinical isolates. 
Lack of OprD was defined by nonsense mutations in oprD, expression repression ≤ -2.5 log2FC, lack of visible 
protein band in Western blot analysis or combinations thereof.  
 
However, of the residual 14 CAZ non-susceptible strains, six exhibited an ampC expression level 
below the defined threshold of 3.9 log2FC, but still greater than 2 log2FC and further three isolates 
were only intermediate-resistant, just on the boarder to susceptibility. Of the residual 12 MEM non-
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susceptible strains, all except three showed oprD down-regulation (at least -0.8 log2FC) in 
combination with mexAB-oprM overexpression. Thus, apart from strict thresholds, it is likely that for 
only five CAZ and three MEM non-susceptible variants de facto no genetic resistance determining 
marker could be identified (4.8 %).  
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3.3 Impact of sub-inhibitory antibiotic concentrations on bacterial cells 
In addition to primary antibiotic targets, also a variety of secondary mechanisms has already been 
described as important contributors to antibiotic tolerance [156-161]. These mechanisms can be 
either unique for a particular class of antibiotics or part of a common response towards structurally 
diverse compounds [157,159]. As drug concentrations during treatment can vary across a patient’s 
body, and microorganisms frequently encounter low level antibiotics gradients in their 
environments, in particular the response of bacteria upon low level antibiotic exposure and the 
identification of thereby induced mechanisms aiding in the evolution of resistances were of interest 
for this study. For this purpose, five structurally different compounds including the quinolone 
ciprofloxacin (CIP), the aminoglycoside tobramycin (TOB), and the β-lactams meropenem (MEM, 
carbapenem), ceftazidime (CAZ, cephalosporin) and piperacillin (PIP, penicillin) were chosen as 
representative bactericidal antibiotics and administered in low level concentrations to investigate 
bacterial responses. 
3.3.1 Sub-inhibitory antibiotic treatment enhanced ROS production 
For the observation of low level effects, we choose to use the highest sub inhibitory concentrations 
for which no severe cell damage was observed compared to an untreated control. In liquid culture 
containing nutrient rich medium (LB), the PA14 wt strain did not show a growth deficiency when 
challenged with antibiotic concentrations of one tenth of the MIC values (determined by broth 
dilution), when it was plated for live cell counts during up to three hours post treatment (Figure 
3.26). 
 
 
Figure 3.26 Growth of sub-inhibitory antibiotic treated PA14 wt in LB. 
PA14 wt was grown in LB broth until an OD600 of 0.5 before cultures were challenged with different antibiotics 
(MEM, CIP, PIP, CAZ, and TOB) in concentrations of 1/10 of MIC values. Bacteria were plated at indicated time 
points on LB-agar plates to calculate the amount of colony forming units (CFU) per ml. 
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While the low concentrations of antibiotics did not seem to impact directly on cell proliferation rates, 
we still observed an increase in reactive oxygen species (ROS) production within the cells as 
determined by staining with a hydroxyl radical sensitive dye and flow cytometric analysis (Figure 
3.27). The amount of fluorescent cells ranged between one and five percent, with the exception of 
CIP treated samples at the three hour time point, where the fluorescent cells comprised 17 % of the 
total population. For PIP, CAZ and TOB exposed cells, reactive oxygen stress was highest two hours 
after drug addition, while in the case of MEM and CIP highest values were reached after three hours. 
 
 
Figure 3.27 Enhanced production of reactive oxygen species by sub-inhibitory antibiotic treatment. 
PA14 wt cells were grown in LB broth and treated with sub-inhibitory concentrations of different antibiotics. 
Production of reactive oxygen species (ROS) was assayed at time points one, two and three hours post 
antibiotic treatment by staining with the hydroxyl radical sensitive fluorescent dye H2DCFDA and subsequent 
flow cytometric analysis. Representative results from one experiment out of at least two are shown. 
 
It is known that lethal concentrations of bactericidal antibiotics, particularly quinolones, may induce 
oxidative stress responses [164]. However, it was surprising to observe the same effect at very low, 
sub-inhibitory antibiotic concentrations. Thus, we were interested in exploring the underlying 
transcriptional modifications, and investigate whether they differ from or are similar to those 
previously described for lethal concentrations in other organisms [164]. Furthermore, it was 
interesting to see whether we would find a differential expression of any genes previously predicted 
to contribute to resistance from P. aeruginosa transposon mutant screens [234]. 
3.3.2 Transcriptional responses upon sub-inhibitory antibiotic stress 
In order to investigate gene regulation as a function of sub-inhibitory antibiotic stress, transcriptional 
profiling was used. For this purpose, PA14 wt cells were cultivated in LB broth until early logarithmic 
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growths phase (OD600 of 0.5) and challenged with the respective low level concentrations of 
antibiotics. The samples were harvested for cDNA-library preparation at time points one, two and 
three hours post antibiotic treatment, and sequencing was performed in single-end mode. For 
reliable data analysis, the experiment was performed in duplicates. 
When analyzing the RNA-seq data, we first noticed that there was no distinct clustering of the 
corresponding biological duplicates in principal component analysis (Figure 3.28). Clustering rather 
occurred in groups, depending on the sample harvesting time point and individual experiment 
replica. This indicated only very slight transcriptional effects due to sub-MIC antibiotic treatment 
compared to growth phase dependent gene expression regulation, and resembled the results of a 
previous report, where no differential gene expression could be detected at all in sub-MIC antibiotic 
treated E. coli [164]. 
 
Figure 3.28 Principal component analysis based on gene expression of sub-inhibitory antibiotic treated PA14 
wt samples 
Clustering was performed according to similarities in gene expression based on rpg values. Harvesting time 
points of the samples are indicated. 
 
For this reason, data analysis to identify differentially regulated genes was performed in two steps. 
First, differential expression was analyzed separately for each of the two individual experiments. All 
genes which were regulated overlapping for each condition in both approaches with a bh-corrected 
p-value of less than 0.05 were selected to comprise the antibiotic dependent transcriptional 
response. For the calculation of exact expression fold changes of these genes, however, the 
biological replicas were treated as duplicates in a second DESeq analysis. From this analysis, the fold 
changes of all previously identified genes were taken without considering the corresponding p-values 
from duplicate analysis. 
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In total, 105 genes were differentially regulated in both replicates. While only five differentially 
expressed genes could be detected for sub-MIC PIP treated cells, regulation was more pronounced 
for MEM (19 genes), CAZ (12 genes), TOB (21 genes), and CIP (71 genes). A detailed list of all 
differentially regulated genes is presented in Table 3.8.  
 
Table 3.8 Gene expression changes upon sub-inhibitory antibiotic treatment. 
            
 
            
Antibiotic Locus tag Gene 
Diff. Expression [log2FC] 
 
Antibiotic Locus tag Gene 
Diff. Expression [log2FC] 
1 h 2 h 3 h 
 
1 h 2 h 3 h 
MEM PA14_06080 creD 2,611 6,659 5,840 
 
CIP PA14_07980 
 
1,693 3,321 3,547 
 
PA14_06090 
 
2,170 6,345 3,923 
 
 
PA14_07990 
 
1,610 3,262 3,725 
 
PA14_06750 nirS -0,066 1,408 2,342 
 
 
PA14_08000 
 
1,506 2,933 3,798 
 
PA14_06810 norC 0,888 0,254 2,819 
 
 
PA14_08010 
 
1,846 4,185 4,087 
 
PA14_06830 norB 1,359 0,964 3,242 
 
 
PA14_08020 
 
1,565 3,790 4,139 
 
PA14_06840 
 
1,551 1,052 3,222 
 
 
PA14_08030 
 
1,654 3,511 4,394 
 
PA14_08200 
 
0,933 -1,553 -0,804 
 
 
PA14_08040 
 
2,261 3,864 4,397 
 
PA14_13770 narK2 -0,468 0,565 1,608 
 
 
PA14_08050 
 
1,733 3,408 4,176 
 
PA14_13780 narG 0,453 0,341 0,541 
 
 
PA14_08060 
 
1,322 3,427 4,046 
 
PA14_14540 
 
0,381 -2,616 -2,996 
 
 
PA14_08070 
 
1,649 3,204 4,012 
 
PA14_20200 nosZ 0,781 1,499 2,464 
 
 
PA14_08090 
 
1,599 3,279 4,126 
 
PA14_20230 nosR 0,637 1,469 3,521 
 
 
PA14_08100 
 
0,978 2,731 4,022 
 
PA14_29640 fhp 0,536 1,410 0,763 
 
 
PA14_08110 
 
2,183 3,211 3,958 
 
PA14_29660 
 
0,636 1,383 0,421 
 
 
PA14_08120 
 
1,233 3,051 4,392 
 
PA14_37210 
 
-1,623 -3,215 -3,233 
 
 
PA14_08130 
 
1,679 3,324 3,996 
 
PA14_42450 popB 0,638 1,406 3,015 
 
 
PA14_08140 
 
2,147 3,895 4,193 
 
PA14_46740 
 
-0,752 0,433 1,262 
 
 
PA14_08150 
 
1,667 3,291 4,176 
 
PA14_50460 flgD 0,208 -0,456 -2,675 
 
 
PA14_08160 
 
1,699 4,366 4,263 
 
PA14_50480 flgB -0,081 -0,448 -3,539 
 
 
PA14_08180 
 
2,434 3,416 4,736 
CAZ PA14_06750 nirS -0,535 0,844 2,056 
 
 
PA14_08190 
 
1,973 4,274 4,822 
 
PA14_06810 norC 0,200 0,529 2,243 
 
 
PA14_08200 
 
2,510 3,336 4,685 
 
PA14_06830 norB 0,402 0,918 3,069 
 
 
PA14_08210 
 
1,614 3,641 4,152 
 
PA14_06875 rsmY 2,864 1,409 1,434 
 
 
PA14_08220 
 
1,736 4,263 4,460 
 
PA14_13280 moeA1 1,104 2,277 0,281 
 
 
PA14_08230 
 
2,160 3,614 4,057 
 
PA14_13750 narK1 -0,090 1,517 0,889 
 
 
PA14_08240 
 
1,509 3,468 4,305 
 
PA14_13770 narK2 -0,611 -0,418 1,669 
 
 
PA14_08250 
 
2,241 3,489 3,908 
 
PA14_20200 nosZ 0,177 0,879 2,232 
 
 
PA14_08260 
 
1,714 3,707 4,035 
 
PA14_20230 nosR 0,226 1,347 3,034 
 
 
PA14_08270 
 
1,804 3,757 4,476 
 
PA14_25620 
 
0,166 -0,214 0,181 
 
 
PA14_08280 
 
1,739 3,920 4,711 
 
PA14_29640 fhp 0,082 1,298 0,684 
 
 
PA14_08300 
 
1,564 3,600 4,462 
 
PA14_51850 
 
0,093 0,541 0,040 
 
 
PA14_08310 
 
1,240 3,022 3,757 
TOB PA14_06750 nirS 1,122 0,430 2,583 
 
 
PA14_08320 
 
0,734 2,871 3,630 
 
PA14_06810 norC 1,704 0,063 2,956 
 
 
PA14_08330 
 
0,867 2,425 3,186 
 
PA14_06830 norB 2,200 0,487 3,727 
 
 
PA14_13940 
 
-0,036 1,456 2,435 
 
PA14_06840 
 
2,629 0,325 2,600 
 
 
PA14_14540 
 
1,245 2,989 3,900 
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PA14_06875 rsmY 2,223 1,136 0,767 
 
 
PA14_14550 
 
1,521 3,070 3,883 
 
PA14_07560 rpsU -2,566 -0,952 -1,687 
 
 
PA14_14590 queA -0,926 1,683 2,316 
 
PA14_13770 narK2 0,946 -1,236 1,314 
 
 
PA14_17530 recA 1,802 2,593 2,902 
 
PA14_13780 narG 1,580 0,220 -0,144 
 
 
PA14_19530 
 
-1,613 0,873 4,604 
 
PA14_20190 nosD 3,021 0,518 2,658 
 
 
PA14_19940 
 
0,897 4,762 2,606 
 
PA14_20200 nosZ 2,344 0,569 2,946 
 
 
PA14_23680 ibpA 0,865 1,137 2,450 
 
PA14_20230 nosR 1,474 0,431 3,819 
 
 
PA14_25150 
 
1,688 2,322 3,270 
 
PA14_25670 acpP 0,704 0,266 -0,904 
 
 
PA14_25160 lexA 2,007 2,956 3,555 
 
PA14_29640 fhp 0,792 0,991 0,857 
 
 
PA14_49510 pyoS3I 0,192 1,782 2,578 
 
PA14_29660 
 
0,708 0,971 0,286 
 
 
PA14_49520 pyoS3A 0,684 2,359 3,297 
 
PA14_39070 
 
1,258 0,060 -2,250 
 
 
PA14_52330 
 
2,294 2,799 2,812 
 
PA14_46740 
 
-0,156 0,589 0,054 
 
 
PA14_52480 
 
0,517 2,701 3,247 
 
PA14_49410 
 
0,916 1,019 -0,677 
 
 
PA14_52490 
 
0,632 2,561 3,337 
 
PA14_50740 
 
0,753 -0,063 -0,193 
 
 
PA14_52500 
 
1,155 4,183 4,193 
 
PA14_61000 
 
2,251 0,765 2,788 
 
 
PA14_52510 
 
-0,616 2,826 3,989 
 
PA14_61380 
 
0,649 0,315 -1,359 
 
 
PA14_52520 
 
1,278 2,451 2,949 
 
PA14_70640 rubA1 1,404 0,051 -1,934 
 
 
PA14_53680 
 
1,042 999,000 3,439 
PIP PA14_06680 nirH 0,477 3,658 0,569 
 
 
PA14_53810 
 
0,136 2,042 3,581 
 
PA14_06875 rsmY 1,197 2,305 1,063 
 
 
PA14_53820 
 
0,738 3,096 3,752 
 
PA14_08200 
 
1,197 -1,289 -0,479 
 
 
PA14_55610 
 
2,604 3,716 2,885 
 
PA14_29800 
 
-0,127 -1,315 -2,614 
 
 
PA14_57010 groEL -0,114 1,109 2,236 
 
PA14_52320 
 
-1,848 1,533 -3,114 
 
 
PA14_57020 groES -0,089 0,637 2,191 
CIP PA14_00810   2,148 2,056 3,812 
 
 
PA14_59220 
 
1,709 3,962 4,607 
 
PA14_01010 
 
-0,120 0,695 2,537 
 
 
PA14_60630 
 
0,236 0,785 3,633 
 
PA14_01030 
 
0,378 0,587 2,387 
 
 
PA14_62970 dnaK 0,138 1,265 2,812 
 
PA14_04180 
 
0,044 0,312 3,390 
 
 
PA14_62990 grpE -0,033 0,948 2,268 
 
PA14_06830 norB 2,440 1,089 3,413 
 
 
PA14_63010 recN 2,284 3,123 3,508 
 
PA14_07950 prtN 1,549 3,194 3,752 
 
 
PA14_66790 hslU 0,346 1,328 2,292 
 
PA14_07970 
 
1,685 3,314 3,360 
 
 
PA14_69130 glpT -1,639 -1,186 -0,638 
 
 
Figure 3.29 depicts overlapping gene regulation for the different antibiotics. Interestingly, the 
majority of genes were regulated compound specifically upon CIP treatment, while TOB, CAZ, PIP, 
and MEM treated bacteria exhibited largely overlapping differential gene expression. 
Besides large clusters of hypothetical genes, low levels of CIP mostly induced the expression of 
specific DNA repair mechanisms and SOS response (prtN, recA, recN, dnaK, lexA, pyoS3, 
PA14_00810), in combination with heat shock proteins and chaperons (ibpA, hslU, grpE, groEL, 
groES). This matched results of general quinolone stress responses in diverse bacteria with the 
particular induction of the SOS response and DNA repair mechanisms [234,235]. 
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Figure 3.29 Antibiotic dependent transcriptional overlaps. 
A total of 105 genes were differentially regulated in both duplicates upon sub-MIC antibiotic exposure (not 
considering the individual time points). PIP treated cells displayed 3 uniquely expressed genes and two 
overlapping ones (PA14_08200, MEM; rsmY, CAZ, TOB,). 
 
Despite the large amount of CIP specific expression alteration, only few genes were regulated 
similarly distinct for the remaining antibiotics, as 30S ribosomal subunit coding rpsU (TOB) or 
membrane alteration protein coding creD (MEM). creD overexpression has been described to be 
highly inducible by classical ampC inducers and to be involved in β-lactam resistance, most likely 
through enhanced intrinsic β-lactamase activity [236]. creD overexpression may therefore rather 
indicate facilitated cross-resistance development, as MEM itself is a strong AmpC inducer, but cannot 
be hydrolyzed by this enzyme, in contrast to cephalosporins and other β-lactam antibiotics [141]. 
Although rpsU has not been connected with aminoglycoside resistance yet, respective transposon 
mutants could previously be associated with reduced susceptibility towards lipopeptide and 
glycopeptide antibiotics [237]. Elucidating its role in tobramycin stress adaptation, however, requires 
further investigation. 
Overlapping gene regulation could be found for the regulatory RNA rsmY which was down-regulated 
in several different antibiotic treated samples (CAZ, TOB, and PIP). rsmY is known to regulate the 
GacA/GacS two-component system, which has previously been demonstrated to be involved in the a 
variety of  different antibiotic resistances, including β-lactam and aminoglycoside non-susceptibility 
[238]. 
Remarkably, all tested antibiotics, independent of their functional classes, also induced expression of 
nitrate metabolism operons, including nir, nor, nar, and nos genes, with a particular increase in 
oxidoreductases. This indicates the induction of denitrification pathways, as shown in Figure 3.30. 
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Figure 3.30 Denitrification in Pseudomonas aeruginosa. 
Denitrification pathway of P. aeruginosa PAO1, including involved genes and chemical substrates according to 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) [239]. 
 
P. aeruginosa usually prefers oxygen as terminal electron acceptor under aerobic conditions. 
However, a decrease in oxygen consumption had been detected previously in kanamycin treated 
E. coli [165], which made us curious about the metabolic reason for a possible induction of 
denitrification associated genes. 
Interestingly, Kohanski and colleagues had previously described a common mechanism of antibiotic 
induced cell death by bactericidal agents, which included an interference with energy metabolism 
and the tricarboxylic acid (TCA) cycle [164]. Though, in their hypothesis, enhanced respiration was 
the underlying reason. Thus, we wondered what precise effects sub-inhibitory concentrations of 
antibiotic might have on energy metabolism pathways. 
3.3.3 Metabolic changes induced by sub-inhibitory antibiotic stress 
To investigate metabolic changes induced by sub-inhibitory antibiotic stress, we monitored the 
biosynthesis of a number of different amino acids, which originate from different metabolic 
pathways. This was done by feeding the bacterial cells in minimal medium with isotope labeled 
carbon sources, while challenging them with the respective antibiotics, followed by gas 
chromatography coupled mass spectrometry (GC-MS) analysis of the samples. 
Pseudomonas can utilize acetate in the form of acetyl-CoA directly as substrate in the TCA cycle, or 
alternatively assimilate glucose, which is first converted to pyruvate in the Entner-Doudoroff (ED) 
pathway, before it enters the TCA cycle [240]. Finally, both substances are used as carbon sources for 
the biosynthesis of amino acids. Thus, to get insight into the occurring metabolic changes and their 
locations, the conversion of both substrates, glucose and acetate, was comparatively monitored. 
As depicted in Figure 3.31, neither the use of isotope labelled glucose nor acetate led to growth 
deficiencies in minimal medium when the samples were treated with the respective low level 
antibiotic concentrations. The corresponding 
13
C incorporation in newly synthesized amino acids is 
featured in Figure 3.32. 
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Figure 3.31 Growth of sub-inhibitory antibiotic treated PA14 wt in minimal medium. 
Cells were grown in BM2 minimal medium to an OD600 of 0.8 and treated with either isotope labeled glucose 
(A) or acetate (B), followed by addition of indicated antibiotics. Bacteria were plated 1, 2, and 3 hours post 
antibiotic treatment on LB-agar plates to calculate the amount of colony forming units (CFU) per ml. 
 
Interestingly, all administered antibiotics slightly increased the integration of glucose derived 
13
C into 
the twelve surveyed amino acids over time, suggesting a general enhancement of metabolic 
processes. However, much more striking was a significant, strong increase in the detection of isotope 
labeled serine after three hours of growth in 
13
C glucose, which was equally pronounced for all 
antibiotics. Serine is produced from 3-phosphoglycerate, which makes it the first amino acid directly 
generated from glucose (PseudoCyc, [241]). Our findings therefore suggest significantly increased 
activity of the glycolytic pathway. 
In contrast to the relatively long retardation time for glucose incorporation, samples supplied with 
isotope labeled acetate exhibited distinct metabolic patterns considerably faster (after one hour). 
One likely reason is that acetate derived carbon enters metabolic pathways faster as it can be used 
directly for the TCA cycle, which also makes it a preferred carbon source for P. aeruginosa.  
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Figure 3.32 Alterations in amino acid synthesis of sub-inhibitory antibiotic treated bacterial cells. 
Amino acid synthesis was monitored with GC-MS using isotope labeled glucose (A, C, E), or acetate (B, D, F). 
Sample were grown in BM2 minimal medium to an OD600 of 0.8, until cultures were supplemented with the 
labeled carbon sources and challenged with sub-inhibitory concentrations of antibiotics (MEM (0.1 µg/ml), CIP 
(0.0125 µg/ml), PIP (1.6 µg/ml), CAZ (0.8 µg/ml), TOB (0.1 µg/ml)). Samples were harvested at time point 1 h 
(A, B), 2 h (C, D), and 3 h (E, F) post antibiotic treatment. 
13
C incorporation is shown relative to untreated PA14 wt control samples. 
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Most interestingly, however, we noticed a significantly enhanced biosynthesis of particular, acetate 
derived amino acids for all antibiotic treatments. These amino acids were either directly derived from 
TCA cycle dependent metabolic pathways, as threonine, proline, aspartate, glutamate and lysine or 
were indirectly TCA cycle dependent as leucine and isoleucine, which require glutamate and acetyl-
CoA. 
These findings suggest that even sub-inhibitory concentrations of antibiotics already induce common 
stress responses which are I) largely independent of their specific cellular targets and II) apparently 
involve an overstimulation of the TCA cycle, as also suggested previously for lethal antibiotic 
concentrations. The strong increase in glucose derived serine could further implicate that also NAD
+
 
and NADP
+
 dependent pathways independent of the TCA cycle, as such involved in the conversion of 
glucose, might be subject to hyperactivation. However, validating this hypothesis requires further 
investigation. 
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4 Discussion 
4.1 The increasing threat of bacterial antibiotic resistance 
The frequency of antibiotic resistance in bacterial pathogens is steadily increasing around the world, 
resulting in a growing threat to public health [242]. On the one hand, adequate treatment is 
diminishing due to the low discovery rate of novel compounds [188]. On the other hand, the lack of 
optimal and prompt diagnostics leads to widespread and empirical use of antibiotics, which further 
promotes the expansion of resistance and the occurrence of multi- or even pandrug-resistant 
phenotypes [243]. 
4.1.1 Antibiotic treatment leads to resistance selection 
One main problem is the selection of resistant variants with genetic mutations that provide fitness 
advantages upon antibiotic exposure and help these mutants to easily outgrow the respective 
susceptible “wild type”-part of the population. A Europe-wide multicenter study has demonstrated 
that countries with a higher consumption of antimicrobials in hospitals also show higher frequencies 
of developing methicillin resistant Staphylococcus aureus (MRSA) [244]. Direct consumption-
resistance correlations could also be seen for carbapenemase or extended spectrum β-lactamase 
(ESBL) producing Gram-negatives [245,246], and single and multi-resistant P. aeruginosa [247-249] in 
individual institutions. Additionally, there are significant connections between drug-use and initial 
colonization with resistant organisms [250,251]. 
Although the presence of antibiotic agents is a factor to promote resistance, their subsequent 
absence does not automatically lead to susceptibility reversion. For instance, non-reverting 
resistances to the often used trimethoprim/sulphonamide combination therapy have been described 
in E. coli, despite significantly decreased use of these antibiotics in the respective communities 
[252,253]. This occurs, when the resistance does not harbor a significant fitness cost [254]. 
4.1.2 Antibiotic concentration reservoirs promote adaptation 
A second significant problem, in addition to resistance selection, is over time adaptation of the 
bacteria when they are confronted with antibiotic concentration reservoirs. The amounts of 
antimicrobial compounds which bacteria encounter can vary greatly, depending on their respective 
environments. Both in individual humans (within a patient’s body) and at the level of the whole 
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human population (within the environment of communities), we frequently find varying, gradual 
antibiotic pressure. 
In aquatic and soil habitats, some antibiotics as a number of β-lactams and aminoglycosides which 
are derived from natural sources (e.g. other bacteria or fungi) may increase in quantities dependent 
on their producers. However, the greatest portion of antimicrobial substances is released into the 
environment due to man-made industrial pollution from hospitals or pharmaceutical industries [255]. 
Despite growing knowledge and concerns on the subject of resistance evolution, antibiotic 
prescription generally showed an increasing trend in the European Union comparing the years 1999-
2008 [256]. In 2008 the inpatient Defined Daily Doses (DDD) of antibiotics for systemic bacterial 
infection treatment was between one and 3.5, the outpatient antibiotics consumption even ranged 
between 10 and 45 DDD per 1000 inhabitants in the participating countries [256], with the majority 
prescribed for the treatment of respiratory tract infections [257]. 
Due to pharmacokinetic aspects, these antibiotics create high density temporal and spatial gradients 
within the human body as they vary in their diffusion rates into various tissues, local inactivation, 
responses to the host’s microbiota or pathogenic flora, and metabolic inactivation [258]. 
Furthermore, the different administered compounds show a wide range in the degree to which they 
are degraded in humans. Some are metabolized by 90 %, while others are metabolized by only 10 % 
or even less [259]. Based on nationwide consumption rates it was found that 70 % of the total 
amounts of antibiotics used in Germany are excreted unchanged as active compounds [255]. Thus, it 
is not surprising that several broad spectrum antibiotics, in particular ciprofloxacin, have been found 
in high concentrations reaching up to mg per ml ranges in connection with sewage outlets from 
hospitals or pharmaceutical industries [260]. In another study, β-lactams were detected in the ng per 
ml range in hospital effluent and in the influent of a municipal sewage treatment plant [261]. 
Degradation and dissipation of these products in the environment differ greatly, often leading to 
mixed antibiotic gradients over time [262].  
Thus, we are presently left with an increasingly alarming future perspective when it comes to 
combating bacterial infections. One way to cope with this problem is to improve diagnostics to 
enable more targeted and prompt treatment. This would positively affect the course of the disease 
of the individual patient, and at the same time help to advance hygiene measures to minimize the 
emergence and spread of resistant bacteria. 
4.2 Limitations of culture-based diagnostics 
Presently, antibiotic resistance is determined based on minimal inhibitory concentrations (MICs), 
which are the lowest concentrations of an antimicrobial that will inhibit the visible growth of a 
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microorganism after overnight incubation [263]. These MIC values in combination with the 
pharmacodynamic parameters of the drug (e.g. cytotoxicity) are the foundation for the definition of 
clinical breakpoints, which guide clinicians in their treatment by dividing isolates into “susceptible” or 
“resistant” [264]. However, methods depending on culture-based techniques which include in vitro 
growth inhibition tests have several disadvantages and limitations. 
 
Cultivation is time-consuming 
The currently performed growth dependent MIC determination requires a considerable amount of 
time. Patient swabs need to be plated and incubated for more than 12 hours to gain pure, single 
bacterial colonies. Next, a second round of incubation is necessary to test for antibiotic growth 
inhibition, which takes another 16 to 20 hours for P. aeruginosa, but may even exceed 24 hours for 
other bacterial species [265]. For slow-growing bacteria, as e.g. Mycobacterium tuberculosis, the 
whole process may even take months [187]. This considerable time delay until a suitable antibiotic 
therapy can be determined may be critical for the outcome of an infection. Furthermore, 
approximately 10 % of all infectious bacterial pathogens are believed to be non-culturable, limiting 
their phenotypic evaluation altogether [187]. 
 
MIC determination and breakpoint definition require high standardization 
MIC threshold detection and breakpoint determination results are sensitive and vary not only 
depending on the initial inoculum and growths conditions (medium, incubation time and 
temperature), which have been standardized by the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI), but also 
differ depending on the used detection devices. Recently, a Spanish study comparatively evaluated 
accurate susceptibility testing and interpretation by sending 13 pre-characterized P. aeruginosa 
strains to 54 participating centers. Very major errors (false negative characterization) occurred in up 
to 22 % of the cases for β-lactam antibiotics [266]. Additionally, breakpoint definition and testing 
parameter guidelines from the two main institutions, EUCAST and CLSI, differ for many antibiotics 
and thus lack direct comparability [265,267]. This may render a particular strain resistant in one 
laboratory, while the same one is still considered susceptible in another [268], and thereby 
substantially affect adequate treatment and prompt infection eradication. 
 
Single colony MIC values are not optimal for population resistance determination 
Furthermore, it is known that even within a susceptible wild-type population, a small fraction of cells 
(< 10
-9
) is not affected when challenged with an antimicrobial agent, allowing their selection during 
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clinical treatment [254]. However, MIC measurements of single colonies do not consider this, often 
pharmacodynamics-dependent, resistance selection window between the MIC of the susceptible 
population and the MIC of the resistant variants. To improve risk management for the evolution of 
resistant populations, it has therefore been suggested to introduce a mutant prevention 
concentration instead (MPC), based on the upper boundary of the selection window [269]. Data 
provided by several studies already emphasized the sometimes remarkable discrepancies between 
MIC and MPC values [270-272]. However, this approach requires significantly larger inoculums and 
labor intense concentration gradient plating, questioning its feasibility in daily clinical routine. 
 
Proto-resistance mutations are not taken into account 
Last but not least, growth dependent susceptibility testing is only able to detect the present 
phenotypic state of a bacterium. However, besides target alterations that lead directly to antibiotic 
resistance, also mutations which merely promote resistance evolution occur. These so called proto-
resistance mutations alone do not significantly affect antibiotic susceptibility, but facilitate resistance 
evolution and quick MIC increases upon antibiotic pressure [273]. One such example is the gyrA 
mutation T83I. While this mutation does not obligatory confer ciprofloxacin (CIP) resistance in 
P. aeruginosa clinical isolates (MIC values ranging from 2 to 8 µg/ml), double mutants harboring the 
additional S87L variation in parC always exhibit high level CIP resistance (MIC = 32 µg/ml) [69]. Thus, 
optimal antibiotic therapy should ideally refrain from using CIP for the treatment of such strains to 
minimize the risks for rapid high level resistance evolution and spread. 
One way to overcome the problems and limitations connected to cultivation-based antibiotic 
resistance profiling (phenotype observation) could be the use of molecular methods for the direct 
screening of genetic determinants (genotype observation) instead.  
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4.3 Transcriptome sequencing of drug resistant clinical isolates 
Within our pilot study, we fully sequenced the transcriptomes of 149 clinical P. aeruginosa isolates to 
search for genetic markers which are suitable for fast and reliable resistance phenotype 
determination to advance clinical microbiology. Our focus was hereby set on RNA instead of DNA 
sequencing, as this strategy allows for the combined data acquisition of gene sequence information 
and - at the same time - gene expression patterns. 
4.3.1 Inexpensive whole transcriptome sequencing provided reasonable single 
nucleotide coverage throughout the whole P. aeruginosa genome 
The first goal for our broad transcriptome study was to find a way of sequencing a maximum number 
of clinical isolates with minimal costs. The Illumina GenomeAnalyzer-IIx (GAIIx) provided up to two 
times 40 million reads in paired-end mode (75-150 bp length). This was a sufficient capacity for the 
simultaneous sequencing of several cDNA libraries of different strains and thereby allowed to lower 
sequencing costs by multiplexing. At the time of the start of this project, no commercially available, 
strand-specific method for transcriptome sequencing existed, which was suitable for multiplexing of 
several samples on one Illumina sequencing lane. Perkins and colleagues had published a strand-
specific method for analyzing Salmonella typhi, but using random primers for cDNA synthesis [274], 
which may introduce a sequence bias to transcriptional profiles. Therefore, a custom protocol was 
developed for high-throughput application and especially optimized for the sequencing of 
P. aeruginosa, including the use of adapter-specific primers for reverse transcription [275]. One 
particular challenge during protocol optimization was the effective enrichment of mRNA, which 
comprises only about 1-5 % of the total bacterial RNA, as opposed to the > 90 % portion of rRNA 
[212]. Consequently, the more rRNA is removed, the more samples can be multiplexed for 
sequencing. For this purpose, different hybridization-based and enzymatic rRNA removal approaches 
were compared for their effectiveness. In P. aeruginosa, enzymatic degradation of the rRNA using 
terminator-5’-phosphate-dependent exonuclease (TEX) proved to be ineffective due to incomplete 
rRNA removal (only 5-10 %) and simultaneous mRNA damage (Figure 3.3). As this enzyme is specific 
for RNAs containing a 5’-monophosphate (rRNA), with no exonuclease activity on RNAs with 5’-
triphosphates (mRNA), also partially degraded mRNAs seem to be subject to digestion. This 
influenced in our experiments expression patterns and abolished start site detection. Similar effects 
had been observed in meta-transcriptomic studies with other organisms [214], rendering this 
enzyme rather inapplicable for these kinds of transcriptomic studies. 
Better results could be obtained with the hybridization-dependent commercially available 
MICROBExpress Kit in combination with Pseudomonas sp. specific capture-oligomers for the 
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depletion of 16S and 23S rRNA. According to the manufacturer, an rRNA reduction of more than 95 % 
could be achieved for E. coli. We were able to remove rRNA by up to 40 % in the P. aeruginosa PA14 
strain (Figure 3.3 A). Furthermore, this method did not significantly affect native mRNA expression 
profiles (Figure 3.3 B), which had also been confirmed by other studies [183,213,214]. Thus, it did not 
interfere with transcriptional start site detection. MICROBExpress proved to be the most effective of 
all tested hybridization approaches (Table 3.1) and the depletion range matched a previous report in 
E. coli, where 38 % rRNA decrease was observed [194]. For maximal reduction, it was combined with 
additional rRNA removal by duplex-specific nucleases in the clinical strains. This method had 
previously been shown to efficiently reduce rRNA in E. coli without interfering with native 
transcription patterns [194,276]. A combination of MICROBExpress (before library preparation) and 
DSN (after library preparation) finally yielded in up to 75 % mRNA per sample. However, rRNA 
removal efficiency strongly varied (between less than 10 % and more than 70 % mRNA content) 
depending on the individual sample and partly on the sequencing pools as a whole (Figure 3.7). This 
could be due to the method of hybridization-based rRNA removal, which is only able to deplete 
completely intact rRNA. With the different physiology of clinical isolates, however, partial RNA 
fragmentation/degradation might be a problem for some (particularly mucoid) samples, despite the 
use of protective agents. Additionally, the initial rRNA/mRNA ratios of isolates with very diverse 
metabolic activity and growth phenotype may vary and thus partially account for the observed 
differences. 
A maximum of twelve individual strains were pooled for clinical isolate sequencing. This resulted in 
1.8 to 13.8 million reads per sample, of which on average five million reads aligned to the PA14 
genome (Figure 3.6A). Thereby, we obtained up to 90 % total genome coverage (Figure 3.6B), with up 
to 80 % of nucleotide positions covered with three or more reads. According to previous studies, this 
amount was sufficient for high quality expression analysis of bacterial transcriptomes [277] and, due 
to the high percentage of total genome coverage, additionally allowed for the successful detection 
and investigation of mutations within the expressed regions. The high amount of total genome 
coverage is partly due to the nature of bacterial chromosomes, which display a dense alignment of 
expression sites in their operon structure. However, P. aeruginosa additionally shows the particular 
feature of a broad, constitutive subliminal gene expression throughout the chromosome, which has 
also been observed by others before [278]. This special characteristic renders the organism 
particularly suitable for transcriptome-based sequence determination. Moreover, advances in 
sequencing depth (Illumina HiSeq 2500) presently provide five to seven fold increased read amounts 
[279]. This enables even higher multiplexing of samples, which further significantly reduces 
sequencing costs and at the same time allows for consistent > 93 % total genome coverage in 
P. aeruginosa (our unpublished data). This indicates presumably the upper boarder of 
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accomplishable total genome coverage, as we observed saturation at around 90 % coverage despite 
more than twice increased read quantities for some samples (Figure 3.5). Furthermore, it was 
previously shown that only approximately 90 % of the P. aeruginosa genome belongs to strongly 
conserved, ‘core’ genetic elements [219,220]. Thus, the remaining 10 % may be flexible between 
different clinical isolates and possibly contribute to varying overall sequence coverage when mapped 
to the PA14 reference strain. 
Thus, RNA-sequencing could for the purposes of this and related studies virtually replace 
conventional DNA-sequencing with the additional advantage of delivering expression information. 
4.3.2 In depth taxonomical profiling could distinguish between actual clonal 
outbreaks and sequence type related strains 
With the data obtained from RNA-sequencing, we could identify 214 genes, which were highly 
expressed in all clinical isolates. Sequence comparisons of these commonly expressed genes allowed 
performing in depth taxonomical profiling of the clinical strains (Figure 3.8) with much higher 
resolution than conventional strategies such as variable number of tandem repeats (VNTR) or 
multilocus sequence typing (MLST) [221,222]. We could clearly identify a particular clonal outbreak 
at the Hannover Medical School, as the corresponding isolates exhibited very similar sequence and 
expression profiles. Furthermore, we observed that two phylogenetic clusters which we identified as 
most likely representing high-risk MLST sequence types ST235 (clustering around PSAE0613) and 
ST175 (clustering around MHH7368), still displayed considerable sequence variability, as well as gene 
expression differences (compare Figure 3.9). These findings suggests that the presently used 
methods to determine clonal relationships based on only few open reading frame sequences (MLST) 
may not be sufficient for proper phylogenetic analysis and could lead to misinterpretations. 
These limitations of currently used MLST schemes have as well already been acknowledged in other 
areas, as for instance on differentiating Bacillus on the species level [280], and new differentiation 
strategies based on greater numbers of open reading frame sequences have been proposed [281].  
With sequencing costs decreasing, the acquisition of sufficient large numbers of gene sequences is 
best done by whole genome sequencing (WGS) or whole transcriptome sequencing (WTS) [187]. 
4.3.3 The acquired β-lactam resistome 
β-lactam resistance in P. aeruginosa can be divided into two parts: intrinsic mutational changes and 
the horizontal acquisition of new genes. The detection of each mechanism requires a different 
analytical approach. Acquired resistance mediating enzymes were identified by a combination of de 
novo assembly and gene coverage investigation. Their acquisition was observed in 18 % and 25 % of 
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the non-clonal MEM and CAZ resistant isolates, respectively. Generally, the presence and nature of 
acquired β-lactamases varied greatly, which matches the known diversity between different 
populations, with country specific epidemiological patterns [114]. A nationwide investigation in 
France regarding the occurrences of extended-spectrum β-lactamases (ESBLs) and metallo-β-
lactamases (MBLs) identified 9.5 % of CAZ resistant P. aeruginosa to harbor one of these enzymes 
[282]. In a German study, 19.9 % of all carbapenem resistant P. aeruginosa isolates harbored 
carbapenemases, most frequently VIM-2 [283]. A surveillance study including 14 European and 
Mediterranean countries on carbapenem non-susceptible P. aeruginosa identified 25.6 % being 
positive for MBLs [284]. 
We discovered nine different β-lactamases (OXA-2 and 4, VIM-1 and 2, GIM-2, IMP-1 and 7, PER-1, 
and CTX-M-3) in overall 19 isolates (14 %) of which six contained two respective enzymes (4.4 %) 
(Figure 3.12). In any of these cases, one enzyme was a MBL or ESBL, while the second enzyme 
belonged to the class D oxacillinases. Furthermore, the presence of an acquired β-lactamase always 
led to resistance towards the corresponding antibiotic. 
The detection of carbapenemase producing organisms is an important matter for the choice of 
appropriate therapeutic schemes and the implementation of infection control measures. However, 
presently, phenotypic identification poses a number of difficulties as it cannot simply be based on the 
resistance profile, and specific testing has not been well standardized yet and often lacks accuracy 
[129]. For example does the detection of acquired MBLs in P. aeruginosa often rely on disk diffusion 
assays, which lack, depending on the test used, either reliable sensitivity (31 % to 88 %) or specificity 
(28 % to 81 %) [285], demonstrating the need for molecular detection systems in this field to improve 
surveillance and avoid resistance spread. One already widely used method for some β-lactamases is 
the detection by multiplex-PCR [286]. However, this method cannot distinguish between the mere 
presence and actual expression of the corresponding genes. 
We could show that RNA-sequencing provides clearly improved conditions for the detection of 
acquired β-lactamases, with a high sensitivity (96 %) and a low false discovery rate of only 0.67 % for 
carbapenemases (Figure 3.10). 
4.3.4 Unbiased global correlation studies as an approach to detect novel phenotype 
specific genetic markers 
The greatest benefit of global approaches as WGS or WTS is based on their comprehensive data. 
Thus, instead of individually screening for known resistance markers, we aimed to use this data to 
investigate the enrichment of particular genetic changes in CAZ and MEM non-susceptible isolates. 
This was done by database supported statistical analyses, which compared the sequence information 
and transcript abundance of all genes in all isolates with each other. This approach substantially 
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facilitates the detection of frequent, resistance-phenotype specific modification and allows as well 
the identification of previously unknown factors. 
 
Identification of enriched genetic determinants in CAZ non-susceptible isolates 
With the above mentioned approach, we identified the intrinsic β-lactamase ampC and a directly 
adjacent gene as significantly more expressed in the CAZ non-susceptible group of isolates 
(Table 3.3). AmpC overexpression is known to reflect an important intrinsic β-lactam resistance 
mechanism in P. aeruginosa [287]. Interestingly, we also found oprD and mexB to contain more 
frequently nonsense mutations in the CAZ non-susceptible group. The MexAB-OprM pump usually 
promotes β-lactam non-susceptibility through enhanced drug efflux [58]. However, it has also been 
shown that this pump is dispensable or maybe even disadvantageous in adaptation to the CF lung 
environment [288]. Therefore, the successive mutational inactivation of the pump to compensate 
preceding overexpression may comprise a fitness advantage in the host, once alternative and more 
efficient β-lactam resistance mechanisms have developed. Of note, all of the CAZ resistant isolates 
with mexB mutations, except one, showed constitutive ampC overexpression. Furthermore, the 
absence of functional OprD is not primarily associated with ceftazidime resistance, as CAZ cell entry 
is equally distributed between a number of porins, including OprC, OprD, and OprE [289]. Therefore 
the frequent nonsense mutations in this gene in the CAZ non-susceptible group emphasize the tight 
interconnections of cross resistance evolution in clinical isolates. This could also be seen when 
comparing CAZ resistant and susceptible isolates and thereby detecting the enhanced expression of 
mexE (Table 3.4) in the resistant group of isolates. While overexpression of the MexEF-OprN efflux 
pump is not directly associated with CAZ resistance [66,226], its regulation is influenced by the 
transcriptional regulator AmpR, which is also the main regulator controlling ampC transcription 
[290,291]. 
 
MEM non-susceptible isolates showed specific genetic enrichments 
When screening for genetic enrichments in the MEM non-susceptible group, we identified oprD as 
the only gene which frequently showed nonsense mutations and expression repression in these 
isolates (Table 3.5). It is already known that a lack of OprD significantly contributes to carbapenem 
resistance in P. aeruginosa [81,90,96], as this outer membrane protein is a porin, which can be used 
for cell entry by carbapenem antibiotics as imipenem and meropenem [80]. 
Analyzing the oprD sequences of all isolates in more detail, we observed a number of mutations 
leading to premature translation termination, which were located throughout the open reading 
frame (Figure 3.20). Single amino acid exchanges on the other hand occurred preferentially in the 
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surface-associated loop regions. Mutations in these regions mostly do not interfere with the barrel 
structure of the porin, but still allow high variability to influence host pathogen interactions and aid 
in immune evasion [98]. It is described that some mutations in the loop regions may also alter 
carbapenem binding properties and thereby influence drug uptake, as particularly loop two, for 
instance, is required for imipenem interaction [88,94]. However, we could not detect any particular 
enrichment of such mutations, as MEM resistant and susceptible isolates exhibited almost identical 
SNP patterns (Figure 3.20 B). 
Although we were able to trace back most carbapenem resistance phenotypes to either 
carbapenemase expression or diminished functional OprD, we were surprised to also find a few 
meropenem susceptible strains, which exhibited a complete lack of OprD protein (due to premature 
stop codons within the oprD sequence) (Figure 3.21 and 3.22). This finding has also been observed 
previously in P. aeruginosa clinical isolates, however, no clear explanation could be found yet [97]. So 
far it is only known that porins OprC, OprE and OprF are most likely not involved in MEM transport 
[289]. We therefore performed mass spectrometric analysis on proteins enriched in the outer 
membranes of these isolates to search for compensatory effects, and identified the porin OprQ as a 
candidate in two analyzed strains (Figure 3.22 and Table 3.6). OprQ might hint at an alternative way 
of meropenem entry in clinical isolates, although a P. aeruginosa PAO1 oprQ interposon mutant 
strain did not show changes in carbapenem susceptibility [292]. This emphasizes the need for further 
studies to completely understand the complex regulatory and compensatory mechanism (as 
counterbalancing the lack of OprD) of antibiotic resistance. 
4.3.5 Evaluating RNA-sequencing for direct resistance prediction 
Our RNA-sequencing data allowed not only for global phenotype-genotype comparisons, but was 
also sufficient to screen each strain individually for all known genetic β-lactam resistance markers 
and perform direct correlations to the respective strain’s antibiotic susceptibility profile. Thereby we 
were able to identify the causative genetic variations responsible for non-susceptibility in 82 % and 
87 % of the clinical isolates for CAZ and MEM, respectively, when strict expression cut-offs were used 
(Figure 3.25). Even up to 95.2 % was achieved with less stringent restriction.  
Recently, there have been several whole-genome sequencing approaches which identified bacterial 
adaptive genetic evolution, including antibiotic resistance determinants, which were consistent with 
the predicted antibiotic resistance phenotype [293-295]. Furthermore, Gordon and colleagues 
evaluated the accuracy of WGS prediction compared to exhibited resistance phenotypes in 
Staphylococcus aureus in detail and calculated overall error rates of 0.5-0.7 % for selected antibiotics 
[296]. In addition to the detection of target mutations, RNA-sequencing is actually able to provide 
gene expression data. This enabled us to focus not only on antibiotic resistance due to target site 
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mutations (as known for quinolones), but also mechanisms applied for the defense against other 
clinically important antibiotics, which are more dependent on enzymatic substrate degradation (e.g. 
β-lactams or aminoglycosides). However, opposed to target site mutations, gene expression covers a 
dynamic range which complicates threshold prediction for one phenotype or the other (as shown in 
this study for ampC). Thus, while target alterations and the expression of acquired resistance genes 
can directly distinguish between susceptibility and non-susceptibility, constitutive overexpression or 
repression of intrinsically present genes obtained from WTS data may at the moment rather be used 
as additional information for the identification of antibiotic resistances, but not yet predict 
susceptibility with sufficient accuracy.  
4.3.6 High-throughput target screening as a future clinical outlook 
Despite the enormous progress in sequencing during the last years, clinical adoption of whole 
genome or transcriptome sequencing in resistance prediction is challenging, even if all genetic 
determinants are known. Although it is unlikely that WGS or WTS will be able to replace phenotypic 
resistance determination in the near future, the great potential of these applications is obvious. With 
the RNA-sequencing approaches, sequence information and transcript abundance of any expressed 
genome position are recorded and can be applied repeatedly for new phenotype-related analysis to 
address various questions. This may be used to determine individual genetic markers, which can be 
screened directly in the hospitals using alternative technologies. 
One system demonstrating high potential for such applications is the Sequenom MassARRAY®. This 
device uses matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF-
MS) for high-throughput analysis of nucleotide sequence variations [297]. The principal method to 
detect them is thereby based on multiplexed single nucleotide primer extension to simultaneously 
discover up to 50 sequence polymorphisms [298]. This new approach has recently already been used 
in several human studies for large scale detection of specific DNA mutations [299-302] and MLST 
determination in the Gram-negative bacterium Neisseria gonorrhoeae with greater than 98 % 
accuracy [303]. 
However, antibiotic resistance results from complex interactions and can be based not only on 
specific single target alterations, but also on enzyme up-regulation due to an unpredictable high 
amount of different spontaneous mutations, as in the case of ampC. Thus, a combination of 
sequence and expression information will be necessary for resistance prediction. If the Sequenom 
method is used on cDNA instead of DNA, this could provide the required additional information and 
allow not only the detection of SNPs, but also gene expression by the evaluation of the relative 
abundance of a primer extension reaction based on the native sequence of a selected gene. Thus, 
this method could be used to monitor ampC overexpression as a molecular marker for the prediction 
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of CAZ resistance. MEM resistance, however, correlated to the abundance of OprD protein levels. 
The random appearance of loss of function mutations throughout the whole oprD sequence and lack 
of direct mRNA to protein level correlations limit the value of resistance phenotype prediction based 
on oprD transcription. 
Therefore a better approach for molecular diagnostics might be the screening for specific protein 
abundances, as opposed to mRNA levels, in combination with DNA-based target mutation detection. 
Furthermore, mass spectrometry has already been used successfully in the detection and 
identification of β-lactamases based on the hydrolysis patterns of their different target compounds 
[304-307]. As several hundreds of different horizontally transferable β-lactamases are known, their 
detection could be greatly facilitated by screening directly for their hydrolytic activity.  
Although there is still work to be done, a mass spectrometric approach may in the future be suitable 
for a combined analysis of molecular markers including DNA target mutations, protein abundances, 
and small molecule degradation. It would undoubtedly be of great benefit to have early resistance 
marker detection available for all clinically important antibiotics to maximize successful therapy 
outcome and minimize resistance selection and spread. 
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4.4 The impact of low-level antibiotic concentration reservoirs  
It is indisputable that high antibiotic concentrations, as they are desired during therapeutic infection 
treatment, can select for resistant bacterial mutants and furthermore that widespread and empirical 
use of antibiotics promotes the expansion of resistance and the occurrence of multi- or even 
pandrug-resistant phenotypes [243]. However, pharmacodynamic models generally assume that the 
selection window for these mutants occurs between the minimal inhibitory concentration of the 
susceptible wild type (MICsusc) and that of the corresponding resistant bacteria (MICres) [308,309]. 
Concentrations below MICsusc will not inhibit growth and were therefore long assumed not to be 
selective. Recently, however, several studies elucidated that the process of selection required only 
minimal fitness advantages with minute differences in growth already being sufficient [156,310]. 
Resistant E. coli mutants were even able to outgrow susceptible ones at concentrations of one fifth 
of the MIC for ciprofloxacin and one twentieth of the MIC for tetracycline [311]. In another study, 
Gullberg and colleagues proved that concentrations significantly below MIC values were sufficient to 
select for ciprofloxacin resistant E. coli and streptomycin resistant Salmonella typhimurium [312]. 
Nevertheless, much of our current knowledge on the evolution of antibiotic resistances is based on 
mutant selection in lethal drug concentrations. The importance of low-level, sub-inhibitory drug 
amounts and respective bacterial adaptation mechanisms is still largely unclear.  
4.4.1 Common transcriptional changes cope with oxidative stress  
To investigate the particular aspect of low-level antibiotic influence, we challenged P. aeruginosa 
PA14 cells with sub-inhibitory concentrations of five different bactericidal antibiotics, the quinolone 
ciprofloxacin (CIP), the aminoglycoside tobramycin (TOB), and the β-lactams meropenem (MEM, 
carbapenem), ceftazidime (CAZ, cephalosporin) and piperacillin (PIP, penicillin). In our experiments, 
antibiotic concentrations as low as one tenth of the MIC values clearly affected the cells in several 
ways, despite no apparent growth deficiency compared to the untreated wild-type control. 
We detected low level increases in oxidative stress by monitoring oxygen radical formation in all 
samples within the first hours after antibiotic exposure, with the by far strongest effect caused by CIP 
treatment after three hours (Figure 3.27). Certain reactive oxygen species (ROS), as hydroxyl radicals, 
have been described to be able to directly damage DNA and lead to the accumulation of mutations 
[313], and a recent study in E. coli clearly correlated an enhanced formation of ROS with an increased 
mutation rate [42]. This finding was suggested to originate mainly from induction of the SOS 
response (e.g. via RecA) by quinolones and β-lactams, or additional SOS independent DNA repair 
mechanisms in the case of ciprofloxacin [164,235]. Transcriptome analysis revealed that 
P. aeruginosa cells indeed activated SOS response mechanisms when treated with CIP, even at 
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concentrations of one tenth of the MIC values. As activation of the SOS genes occurs after DNA 
damage by the accumulation of single stranded DNA blocking the DNA polymerase at replication 
forks, it was not surprising to find this defense mechanism at low antibiotic concentrations only in 
the CIP treated samples, since the effect of β-lactam dependent, indirect DNA damage is generally 
less pronounced [164].  
Remarkably, antibiotic specific gene regulation was only partly target-specific (membrane alteration 
genes for β-lactams, a possible ribosomal subunit response for aminoglycosides, DNA repair 
mechanisms for fluoroquinolones) with large overlaps between individual compound classes. RsmY 
regulation, for example, was affected in β-lactams and aminoglycosides. This small, regulatory RNA is 
under control of the GacS/GacA two-component system, which regulates a broad range of stress 
responsive genes, but is also involved in the expression of acute and chronic virulence determinants 
[314-316]. Furthermore, genes involved in denitrification (nir, nor, nar, and nos) were commonly 
regulated in all samples independent of the administered antibiotic. Complete denitrification consists 
of four sequential steps to reduce nitrate (NO3
-
) to nitrogen gas (N2) via nitrite (NO2
-
), nitric oxide 
(NO) and nitrous oxide (N2O). Each step is catalyzed by individual metalloenzymes: nitrate reductase 
(NAR), nitrite reductase (NIR), nitric oxide reductase (NOR) and nitrous oxide reductase (N2OR) [317]. 
In P. aeruginosa, this metabolic pathway is regulated by the transcriptional regulator Anr (for 
anaerobic regulation of arginine catabolism and nitrate reduction), an analogue of the E. coli Fnr, 
which belongs to the Fnr-Crp regulator family [318,319]. These regulators sense the level of 
intracellular oxygen and induce required gene regulation to adapt to varying oxygen levels [320]. As 
our experiment was performed under aerobic conditions, it is possible that the increased generation 
of oxygen radicals led to a shortage and fluctuations in the levels of intracellular oxygen gas (O2) and 
thus induced Anr dependent transcriptional regulation. 
4.4.2 Sub-inhibitory antibiotic exposure affects the respiratory chain and leads to 
fundamental metabolic changes 
As Anr is a critical component aiding in the adaptation of the energy metabolism, we sought to 
investigate the overall metabolic impact of low-level antibiotic exposure by analyzing amino acid 
biosynthesis pathways. In P. aeruginosa, these biosynthesis pathways initially use either glucose or 
acetate as substrates for the generation of their products. Thus, the conversion of both substrates 
was comparatively monitored with the help of isotope 
13
C carbon. 
Interestingly, all administered antibiotics led to a metabolic activation with a slightly enhanced amino 
acid biosynthesis, though kinetics differed for glucose and acetate integration, respectively. This can 
most likely be explained by the underlying chemical processes, which allow the use of acetate 
directly as substrate for the tricarboxylic acid cycle (TCA), while glucose has to undergo pre-
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processing, e.g. in the Entner-Doudoroff pathway (ED), before its products can be used further 
(PseudoCyc, [241]). 
The most interesting finding, however, was that independent of the respective antibiotic targets all 
antibiotics featured the induction of similar metabolic patterns. The biosynthesis of amino acids 
generated from acetate which were either directly derived from the TCA cycle or indirectly TCA cycle-
dependent was markedly enhanced due to antibiotic treatment. Furthermore, there was a strong 
increase in serine, the first amino acid generated from glucose, precisely 3-phosphoglycerate, after 
its conversion with the help of NAD
+
 and NADP
+
 reduction. 
In 2007, Kohanski and colleagues had proposed a “common mechanism of bacterial killing” for all 
bactericidal antibiotics. Briefly, this mechanism was supposed to include augmented activity of the 
electron transport chain and a thereby stimulated generation of superoxides. These superoxides are 
capable of damaging iron-sulfur clusters within proteins and enable hydrogen peroxide to interact 
with the resulting free ferrous iron. Via the Fenton reaction, oxidation of this iron leads to the 
production of hydroxyl radicals. When the hydroxyl radical pool reaches critical concentrations, DNA, 
lipid and protein damage occur and ultimately lead to cell death [164]. A sequential study observed 
that, indeed, the cytotoxicity of quinolones and β-lactams seems to arise predominantly from lethal 
double stand DNA breaks due to guanine oxidation caused by a hydroxyl radical depended process 
[169]. 
Particularly the occurrence of the Fenton reaction upon lethal antibiotic treatment and the 
production of hydroxyl radicals which may damage cell components have been confirmed by several 
other studies in which mostly radical scavengers as thiourea or iron chelators as  2,2’-dipyridyl were 
used to promote bacterial survival of different Gram-positive and -negative species upon antibiotic 
encounter [321-326]. However, it is still discussed controversy whether ROS generation is indeed the 
major cause for antibiotic provoked cell death and where the required stimulation of the electron 
transport chain originates from. 
Kohanski and colleagues had monitored the NAD
+
/NADH ratio upon antibiotic killing in E. coli and 
their hypothesis included that the hyperstimulation of the electron transport chain is due to 
enhanced TCA cycle activity [164]. In this study, we could confirm this proposed mechanism and 
further show that the elevated NADH and NADPH levels arise from enhanced metabolic activity not 
only of the TCA cycle, but possibly also related glucose processing pathways. Additionally, low level 
sub-MIC concentrations of bactericidal antibiotics were sufficient to induce these metabolic changes.  
This argues not only in favor of the hypothesis presented by Kohanski, but also against the recently 
published models presented by Keren and Liu about the impact of bactericidal antibiotics. Both 
suggested that bactericidal killing does not depend on reactive oxygen species [165,166]. Liu 
investigated oxygen consumption post kanamycin and norfloxacin treatment with a Clark-type 
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electrode and argued based on the decline over time that an enhanced respiratory chain activity 
could not be the source of electrons required for ROS generation. We, however, could clearly 
demonstrate that antibiotics promote TCA cycle activity by measuring the biosynthesis of respiratory 
chain derived metabolites, whose production was significantly increased, compared to similar 
metabolites generated by other pathways. Furthermore, the biosynthesis was equally increased 
upon contact with all tested classes of antibiotics, even at the administered low-level concentrations. 
A next step will be to unravel how this common metabolic feedback is achieved by different classes 
of chemical compounds, and to further investigate combined stress response activation signals. 
4.4.3 A need for avoiding trace-antibiotic reservoirs and targeting bacterial stress 
responses 
Strikingly, such common stress response inductions even when facing low level antibiotic 
concentrations open new possibilities for bacteria. Antibiotic resistance may not only arise by the 
selection of previously mutated strains but also by an enhanced mutation potential upon drug 
encounter, which facilitates resistance evolution [42,169,327]. There is also evidence that some 
bacteria as E. coli promote oxidative stress protective mechanisms to enhance antibiotic tolerance in 
neighboring cells by the secretion of indole when facing increasing antibiotic gradients [328]. 
Altogether, this implies a particular threat for the development of further adaptations and cross 
resistances. Previous studies could show that sub-MIC treatment of E. coli cells with the β-lactam 
ampicillin, promoted resistance not only to ampicillin, but also different structurally unrelated 
antibiotics as norfloxacin, kanamycin or chloramphenicol [42]. Furthermore, within these studies a 
range of resistances was observed, often exceeding the values of the initially used sub-MIC 
concentrations. Thus, low-level antibiotics may likely promote the evolution of clinically significant 
resistance and cross-resistance levels. Making the matters worse, we are so far not able to predict 
the minimal antibiotic thresholds required for such occurrences as e.g. in one case 1/230 of the wild-
type MIC was sufficient to select for a ciprofloxacin resistant mutant in E. coli harboring the also 
clinically relevant gyrA S82L exchange [329].  
While these findings on the one hand illustrate the considerable threat emanating from the release 
of antibiotics into our environment, they may also open up new possibilities for effective 
antibacterial therapy by potentiating bactericidal activity with the use of additional drug targets. 
Their modes of action could include inhibiting dsDNA repair mechanisms (e.g. Rec) or enzymes 
involved in the process of controlling hydroxyl radical generation as catalases-peroxidases which are 
responsible for hydrogen peroxide detoxification (before it may enter the Fenton reaction) [330]. 
This approach could also be of particular interest for the treatment of P. aeruginosa, as it was 
recently proposed, that the bacterium’s enhanced antibiotic tolerance within biofilms might result to 
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a large extent from active starvation control (stringent response) and a connected reduction of 
oxidative stress, rather than passive growth arrest [331,332]. 
REFERENCES 110 
 
5 References 
 
1. Anzai Y, Kim H, Park JY, Wakabayashi H, Oyaizu H (2000) Phylogenetic affiliation of the 
pseudomonads based on 16S rRNA sequence. Int J Syst Evol Microbiol 50 Pt 4: 1563-1589. 
2. Palleroni NJ (2003) Prokaryote taxonomy of the 20th century and the impact of studies on the 
genus Pseudomonas: a personal view. Microbiology 149: 1-7. 
3. Yamamoto S, Kasai H, Arnold DL, Jackson RW, Vivian A, et al. (2000) Phylogeny of the genus 
Pseudomonas: intrageneric structure reconstructed from the nucleotide sequences of gyrB 
and rpoD genes. Microbiology 146 ( Pt 10): 2385-2394. 
4. Cultures DLID-GCoMaC. 
5. Goldberg JB (2000) Pseudomonas: global bacteria. Trends Microbiol 8: 55-57. 
6. Williams HD, Zlosnik JE, Ryall B (2007) Oxygen, cyanide and energy generation in the cystic fibrosis 
pathogen Pseudomonas aeruginosa. Adv Microb Physiol 52: 1-71. 
7. Van Alst NE, Picardo KF, Iglewski BH, Haidaris CG (2007) Nitrate sensing and metabolism modulate 
motility, biofilm formation, and virulence in Pseudomonas aeruginosa. Infect Immun 75: 
3780-3790. 
8. Vander Wauven C PA, Kley-Raymann M, Haas D. (1984) Pseudomonas aeruginosa mutants affected 
in anaerobic growth on arginine: evidence for a four-gene cluster encoding the arginine 
deiminase pathway. J Bacteriol 160: 928-934. 
9. Eschbach M, Schreiber K, Trunk K, Buer J, Jahn D, et al. (2004) Long-term anaerobic survival of the 
opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J Bacteriol 186: 
4596-4604. 
10. Haas D, Matsumoto H, Moretti P, Stalon V, Mercenier A (1984) Arginine degradation in 
Pseudomonas aeruginosa mutants blocked in two arginine catabolic pathways. Mol Gen 
Genet 193: 437-444. 
11. Palleroni NJ (1993) Pseudomonas classification. A new case history in the taxonomy of gram-
negative bacteria. Antonie Van Leeuwenhoek 64: 231-251. 
12. Lessie TG, Phibbs PV, Jr. (1984) Alternative pathways of carbohydrate utilization in 
pseudomonads. Annu Rev Microbiol 38: 359-388. 
13. Entner N, Doudoroff M (1952) Glucose and gluconic acid oxidation of Pseudomonas 
saccharophila. J Biol Chem 196: 853-862. 
14. Green SK, Schroth MN, Cho JJ, Kominos SK, Vitanza-jack VB (1974) Agricultural plants and soil as a 
reservoir for Pseudomonas aeruginosa. Appl Microbiol 28: 987-991. 
15. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, et al. (1995) Common virulence factors 
for bacterial pathogenicity in plants and animals. Science 268: 1899-1902. 
16. Petersen AD, Walker RD, Bowman MM, Schott HC, 2nd, Rosser EJ, Jr. (2002) Frequency of 
isolation and antimicrobial susceptibility patterns of Staphylococcus intermedius and 
Pseudomonas aeruginosa isolates from canine skin and ear samples over a 6-year period 
(1992-1997). J Am Anim Hosp Assoc 38: 407-413. 
17. Morrison AJ, Jr., Wenzel RP (1984) Epidemiology of infections due to Pseudomonas aeruginosa. 
Rev Infect Dis 6 Suppl 3: S627-642. 
18. Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical 
impact and complex regulation of chromosomally encoded resistance mechanisms. Clin 
Microbiol Rev 22: 582-610. 
19. NNIS (1998) National Nosocomial Infections Surveillance System report, data summary from 
October 1986-April 1998, issued June 1998. Am J Infect Control 26: 522-533. 
20. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance S (2005) Overview of 
nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41: 848-854. 
21. U.S. Department of Health and human Services - Centers for Disease Control and Prevention 
(2013) Antibiotic Resistance Threats in the United States. 
REFERENCES 111 
 
22. Lyczak JB, Cannon CL, Pier GB (2002) Lung infections associated with cystic fibrosis. Clin Microbiol 
Rev 15: 194-222. 
23. Ratjen F, Doring G (2003) Cystic fibrosis. Lancet 361: 681-689. 
24. Tümmler B, Kiewitz C (1999) Cystic fibrosis: an inherited susceptibility to bacterial respiratory 
infections. Mol Med Today 5: 351-358. 
25. Visca P, Colotti G, Serino L, Verzili D, Orsi N, et al. (1992) Metal regulation of siderophore 
synthesis in Pseudomonas aeruginosa and functional effects of siderophore-metal 
complexes. Appl Environ Microbiol 58: 2886-2893. 
26. Hauser AR (2009) The type III secretion system of Pseudomonas aeruginosa: infection by 
injection. Nat Rev Microbiol 7: 654-665. 
27. Reszka KJ, Bilski PJ, Britigan BE (2010) Quenching of singlet oxygen by pyocyanin and related 
phenazines. Photochem Photobiol 86: 742-746. 
28. Abdel-Mawgoud AM, Lepine F, Deziel E (2010) Rhamnolipids: diversity of structures, microbial 
origins and roles. Appl Microbiol Biotechnol 86: 1323-1336. 
29. Burrows LL (2005) Weapons of mass retraction. Mol Microbiol 57: 878-888. 
30. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, et al. (2012) Multidrug-resistant, 
extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal 
for interim standard definitions for acquired resistance. Clin Microbiol Infect 18: 268-281. 
31. Robert Koch Institut (2012) Hygienemaßnahmen bei Infektionen oder Besiedlung mit 
multiresistenten gramnegativen Stäbchen. In: Bundesgesundheitsblatt 55; Abteilung: 
Kommission für Krankenhaushygiene und Infektionsprävention, editor: Springer-Verlag. pp. 
1311–1354. 
32. Gasink LB, Fishman NO, Weiner MG, Nachamkin I, Bilker WB, et al. (2006) Fluoroquinolone-
resistant Pseudomonas aeruginosa: assessment of risk factors and clinical impact. Am J Med 
119: 526 e519-525. 
33. Aloush V, Navon-Venezia S, Seigman-Igra Y, Cabili S, Carmeli Y (2006) Multidrug-resistant 
Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 50: 
43-48. 
34. Carmeli Y, Troillet N, Karchmer AW, Samore MH (1999) Health and economic outcomes of 
antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 159: 1127-1132. 
35. Tansarli GS, Karageorgopoulos DE, Kapaskelis A, Falagas ME (2013) Impact of antimicrobial 
multidrug resistance on inpatient care cost: an evaluation of the evidence. Expert Rev Anti 
Infect Ther 11: 321-331. 
36. Forrest RD (1982) Early history of wound treatment. J R Soc Med 75: 198-205. 
37. Foster W, Raoult A (1974) Early descriptions of antibiosis. J R Coll Gen Pract 24: 889-894. 
38. Waksman SA (1947) What is an antibiotic or an antibiotic substance? Mycologia 39: 565-569. 
39. Coates A, Hu Y, Bax R, Page C (2002) The future challenges facing the development of new 
antimicrobial drugs. Nat Rev Drug Discov 1: 895-910. 
40. Schwentker FF, Gelman S, Long PH (1984) Landmark article April 24, 1937. The treatment of 
meningococcic meningitis with sulfanilamide. Preliminary report. By Francis F. Schwentker, 
Sidney Gelman, and Perrin H. Long. JAMA 251: 788-790. 
41. Coates AR, Halls G, Hu Y (2011) Novel classes of antibiotics or more of the same? Br J Pharmacol 
163: 184-194. 
42. Kohanski MA, Dwyer DJ, Collins JJ (2010) How antibiotics kill bacteria: from targets to networks. 
Nat Rev Microbiol 8: 423-435. 
43. Walsh C (2003) Antibiotics: Actions, Origins, Resistance: ASM Press. 
44. Moore NM, Flaws ML (2011) Treatment strategies and recommendations for Pseudomonas 
aeruginosa infections. Clin Lab Sci 24: 52-56. 
45. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM (1999) Aminoglycosides: activity and resistance. 
Antimicrob Agents Chemother 43: 727-737. 
46. Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, et al. (2009) Quinolones: action and resistance 
updated. Curr Top Med Chem 9: 981-998. 
47. Poole K (2004) Resistance to beta-lactam antibiotics. Cell Mol Life Sci 61: 2200-2223. 
REFERENCES 112 
 
48. Worthington RJ, Melander C (2013) Overcoming resistance to beta-lactam antibiotics. J Org Chem 
78: 4207-4213. 
49. Bartlett JG (2003) Pocket Book of Infectious Disease Therapy. Baltimore: Lippincott Williams & 
Wilkins. 
50. Holtje JV (1998) Growth of the stress-bearing and shape-maintaining murein sacculus of 
Escherichia coli. Microbiol Mol Biol Rev 62: 181-203. 
51. Madigan MT, Martinko JM, Stahl DA, Clark DP (2011) Brock Biology of Microorganisms: Pearson. 
52. Zapun A, Contreras-Martel C, Vernet T (2008) Penicillin-binding proteins and beta-lactam 
resistance. FEMS Microbiol Rev 32: 361-385. 
53. Tipper DJ, Strominger JL (1965) Mechanism of action of penicillins: a proposal based on their 
structural similarity to acyl-D-alanyl-D-alanine. Proc Natl Acad Sci U S A 54: 1133-1141. 
54. Fish DN, Piscitelli SC, Danziger LH (1995) Development of resistance during antimicrobial therapy: 
a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 15: 
279-291. 
55. Dimatatac EL, Alejandria MM, Montalban C, Pineda C, Ang C, et al. (2003) Clinical outcomes and 
costs of care of antibiotic resistant Pseudomonas aeruginosa infections. Philipp J Microbiol 
Infect Dis 32: 159-167. 
56. Morita Y, Tomida J, Kawamura Y (2014) Responses of Pseudomonas aeruginosa to antimicrobials. 
Front Microbiol 4: 422. 
57. Yoshimura F, Nikaido H (1982) Permeability of Pseudomonas aeruginosa outer membrane to 
hydrophilic solutes. J Bacteriol 152: 636-642. 
58. Schweizer HP (2003) Efflux as a mechanism of resistance to antimicrobials in Pseudomonas 
aeruginosa and related bacteria: unanswered questions. Genet Mol Res 2: 48-62. 
59. Nikaido H (1994) Prevention of drug access to bacterial targets: permeability barriers and active 
efflux. Science 264: 382-388. 
60. Poole K (2001) Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa 
and related organisms. J Mol Microbiol Biotechnol 3: 255-264. 
61. Piddock LJ (2006) Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 4: 
629-636. 
62. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56: 20-51. 
63. Kohler T, van Delden C, Curty LK, Hamzehpour MM, Pechere JC (2001) Overexpression of the 
MexEF-OprN multidrug efflux system affects cell-to-cell signaling in Pseudomonas 
aeruginosa. J Bacteriol 183: 5213-5222. 
64. Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, et al. (1999) Use of a genetic approach to 
evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. 
Antimicrob Agents Chemother 43: 1340-1346. 
65. Jahandideh S (2013) Diversity in structural consequences of MexZ mutations in Pseudomonas 
aeruginosa. Chem Biol Drug Des 81: 600-606. 
66. Sobel ML, Hocquet D, Cao L, Plesiat P, Poole K (2005) Mutations in PA3574 (nalD) lead to 
increased MexAB-OprM expression and multidrug resistance in laboratory and clinical 
isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 49: 1782-1786. 
67. Sobel ML, Neshat S, Poole K (2005) Mutations in PA2491 (mexS) promote MexT-dependent 
mexEF-oprN expression and multidrug resistance in a clinical strain of Pseudomonas 
aeruginosa. J Bacteriol 187: 1246-1253. 
68. Elena SF, Lenski RE (2003) Evolution experiments with microorganisms: the dynamics and genetic 
bases of adaptation. Nat Rev Genet 4: 457-469. 
69. Bruchmann S, Dötsch A, Nouri B, Chaberny IF, Häussler S (2013) Quantitative contributions of 
target alteration and decreased drug accumulation to Pseudomonas aeruginosa 
fluoroquinolone resistance. Antimicrob Agents Chemother 57: 1361-1368. 
70. Masuda N, Gotoh N, Ohya S, Nishino T (1996) Quantitative correlation between susceptibility and 
OprJ production in NfxB mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 
40: 909-913. 
REFERENCES 113 
 
71. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, et al. (2000) Substrate specificities of 
MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. 
Antimicrob Agents Chemother 44: 3322-3327. 
72. Baum EZ, Crespo-Carbone SM, Morrow BJ, Davies TA, Foleno BD, et al. (2009) Effect of MexXY 
overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa. Antimicrob Agents 
Chemother 53: 2785-2790. 
73. Srikumar R, Kon T, Gotoh N, Poole K (1998) Expression of Pseudomonas aeruginosa multidrug 
efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia 
coli strain. Antimicrob Agents Chemother 42: 65-71. 
74. Li XZ, Nikaido H, Poole K (1995) Role of mexA-mexB-oprM in antibiotic efflux in Pseudomonas 
aeruginosa. Antimicrob Agents Chemother 39: 1948-1953. 
75. Hancock RE, Brinkman FS (2002) Function of pseudomonas porins in uptake and efflux. Annu Rev 
Microbiol 56: 17-38. 
76. Yoshimura F, Nikaido H (1985) Diffusion of beta-lactam antibiotics through the porin channels of 
Escherichia coli K-12. Antimicrob Agents Chemother 27: 84-92. 
77. Nikaido H (1989) Outer membrane barrier as a mechanism of antimicrobial resistance. 
Antimicrob Agents Chemother 33: 1831-1836. 
78. Hancock RE (1987) Role of porins in outer membrane permeability. J Bacteriol 169: 929-933. 
79. Stover CK, Pham XQ, Erwin AL, Mizoguchi SD, Warrener P, et al. (2000) Complete genome 
sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406: 959-
964. 
80. Trias J, Nikaido H (1990) Outer membrane protein D2 catalyzes facilitated diffusion of 
carbapenems and penems through the outer membrane of Pseudomonas aeruginosa. 
Antimicrob Agents Chemother 34: 52-57. 
81. Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC (1999) Carbapenem activities against 
Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob 
Agents Chemother 43: 424-427. 
82. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y (2006) Potency of carbapenems for the 
prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency 
of a new carbapenem doripenem. J Antibiot (Tokyo) 59: 220-228. 
83. Naenna P, Noisumdaeng P, Pongpech P, Tribuddharat C (2010) Detection of outer membrane 
porin protein, an imipenem influx channel, in Pseudomonas aeruginosa clinical isolates. 
Southeast Asian J Trop Med Public Health 41: 614-624. 
84. Trias J, Nikaido H (1990) Protein D2 channel of the Pseudomonas aeruginosa outer membrane 
has a binding site for basic amino acids and peptides. J Biol Chem 265: 15680-15684. 
85. Muramatsu H, Horii T, Morita M, Hashimoto H, Kanno T, et al. (2003) Effect of basic amino acids 
on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates. Int J Med 
Microbiol 293: 191-197. 
86. Tamber S, Hancock RE (2006) Involvement of two related porins, OprD and OpdP, in the uptake of 
arginine by Pseudomonas aeruginosa. FEMS Microbiol Lett 260: 23-29. 
87. Tamber S, Ochs MM, Hancock RE (2006) Role of the novel OprD family of porins in nutrient 
uptake in Pseudomonas aeruginosa. J Bacteriol 188: 45-54. 
88. Li H, Luo YF, Williams BJ, Blackwell TS, Xie CM (2012) Structure and function of OprD protein in 
Pseudomonas aeruginosa: from antibiotic resistance to novel therapies. Int J Med Microbiol 
302: 63-68. 
89. Lynch MJ, Drusano GL, Mobley HL (1987) Emergence of resistance to imipenem in Pseudomonas 
aeruginosa. Antimicrob Agents Chemother 31: 1892-1896. 
90. Wolter DJ, Hanson ND, Lister PD (2004) Insertional inactivation of oprD in clinical isolates of 
Pseudomonas aeruginosa leading to carbapenem resistance. FEMS Microbiol Lett 236: 137-
143. 
91. Ochs MM, Bains M, Hancock RE (2000) Role of putative loops 2 and 3 in imipenem passage 
through the specific porin OprD of Pseudomonas aeruginosa. Antimicrob Agents Chemother 
44: 1983-1985. 
REFERENCES 114 
 
92. Huang H, Jeanteur D, Pattus F, Hancock RE (1995) Membrane topology and site-specific 
mutagenesis of Pseudomonas aeruginosa porin OprD. Mol Microbiol 16: 931-941. 
93. Biswas S, Mohammad MM, Patel DR, Movileanu L, van den Berg B (2007) Structural insight into 
OprD substrate specificity. Nat Struct Mol Biol 14: 1108-1109. 
94. Huang H, Hancock RE (1996) The role of specific surface loop regions in determining the function 
of the imipenem-specific pore protein OprD of Pseudomonas aeruginosa. J Bacteriol 178: 
3085-3090. 
95. Epp SF, Kohler T, Plesiat P, Michea-Hamzehpour M, Frey J, et al. (2001) C-terminal region of 
Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to 
meropenem. Antimicrob Agents Chemother 45: 1780-1787. 
96. Pirnay JP, De Vos D, Mossialos D, Vanderkelen A, Cornelis P, et al. (2002) Analysis of the 
Pseudomonas aeruginosa oprD gene from clinical and environmental isolates. Environ 
Microbiol 4: 872-882. 
97. Ocampo-Sosa AA, Cabot G, Rodriguez C, Roman E, Tubau F, et al. (2012) Alterations of OprD in 
carbapenem-intermediate and -susceptible strains of Pseudomonas aeruginosa isolated from 
patients with bacteremia in a Spanish multicenter study. Antimicrob Agents Chemother 56: 
1703-1713. 
98. Galdiero S, Falanga A, Cantisani M, Tarallo R, Della Pepa ME, et al. (2012) Microbe-host 
interactions: structure and role of Gram-negative bacterial porins. Curr Protein Pept Sci 13: 
843-854. 
99. Ochs MM, Lu CD, Hancock RE, Abdelal AT (1999) Amino acid-mediated induction of the basic 
amino acid-specific outer membrane porin OprD from Pseudomonas aeruginosa. J Bacteriol 
181: 5426-5432. 
100. Perron K, Caille O, Rossier C, Van Delden C, Dumas JL, et al. (2004) CzcR-CzcS, a two-component 
system involved in heavy metal and carbapenem resistance in Pseudomonas aeruginosa. J 
Biol Chem 279: 8761-8768. 
101. Conejo MC, Garcia I, Martinez-Martinez L, Picabea L, Pascual A (2003) Zinc eluted from 
siliconized latex urinary catheters decreases OprD expression, causing carbapenem 
resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 47: 2313-2315. 
102. Caille O, Rossier C, Perron K (2007) A copper-activated two-component system interacts with 
zinc and imipenem resistance in Pseudomonas aeruginosa. J Bacteriol 189: 4561-4568. 
103. Muller C, Plesiat P, Jeannot K (2011) A two-component regulatory system interconnects 
resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother 55: 1211-1221. 
104. Köhler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, et al. (1997) Characterization of 
MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas 
aeruginosa. Mol Microbiol 23: 345-354. 
105. Ochs MM, McCusker MP, Bains M, Hancock RE (1999) Negative regulation of the Pseudomonas 
aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. 
Antimicrob Agents Chemother 43: 1085-1090. 
106. Köhler T, Epp SF, Curty LK, Pechere JC (1999) Characterization of MexT, the regulator of the 
MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 181: 
6300-6305. 
107. Nikolaidis I, Favini-Stabile S, Dessen A (2013) Resistance to antibiotics targeted to the bacterial 
cell wall. Protein Sci. 
108. Majiduddin FK, Materon IC, Palzkill TG (2002) Molecular analysis of beta-lactamase structure 
and function. Int J Med Microbiol 292: 127-137. 
109. Bush K, Jacoby GA (2010) Updated functional classification of beta-lactamases. Antimicrob 
Agents Chemother 54: 969-976. 
110. Jacoby G, Bush K. 
111. Perez-Llarena FJ, Kerff F, Zamorano L, Fernandez MC, Nunez ML, et al. (2013) Characterization of 
the new AmpC beta-lactamase FOX-8 reveals a single mutation, Phe313Leu, located in the R2 
loop that affects ceftazidime hydrolysis. Antimicrob Agents Chemother 57: 5158-5161. 
REFERENCES 115 
 
112. Bebrone C, Bogaerts P, Delbruck H, Bennink S, Kupper MB, et al. (2013) GES-18, a new 
carbapenem-hydrolyzing GES-Type beta-lactamase from Pseudomonas aeruginosa that 
contains Ile80 and Ser170 residues. Antimicrob Agents Chemother 57: 396-401. 
113. Pollini S, Maradei S, Pecile P, Olivo G, Luzzaro F, et al. (2013) FIM-1, a new acquired metallo-
beta-lactamase from a Pseudomonas aeruginosa clinical isolate from Italy. Antimicrob Agents 
Chemother 57: 410-416. 
114. Cornaglia G, Giamarellou H, Rossolini GM (2011) Metallo-beta-lactamases: a last frontier for 
beta-lactams? Lancet Infect Dis 11: 381-393. 
115. Ambler RP (1980) The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 289: 321-
331. 
116. Naas T, Nordmann P (1999) OXA-type beta-lactamases. Curr Pharm Des 5: 865-879. 
117. Walsh TR, Toleman MA, Poirel L, Nordmann P (2005) Metallo-beta-lactamases: the quiet before 
the storm? Clin Microbiol Rev 18: 306-325. 
118. Queenan AM, Bush K (2007) Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 
20: 440-458, table of contents. 
119. Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, et al. (2002) Nosocomial spread of the 
integron-located veb-1-like cassette encoding an extended-pectrum beta-lactamase in 
Pseudomonas aeruginosa in Thailand. Clin Infect Dis 34: 603-611. 
120. Morfin-Otero R, Rodriguez-Noriega E, Deshpande LM, Sader HS, Castanheira M (2009) 
Dissemination of a bla(VIM-2)-carrying integron among Enterobacteriaceae species in 
Mexico: report from the SENTRY Antimicrobial Surveillance Program. Microb Drug Resist 15: 
33-35. 
121. Mendes RE, Bell JM, Turnidge JD, Castanheira M, Jones RN (2009) Emergence and widespread 
dissemination of OXA-23, -24/40 and -58 carbapenemases among Acinetobacter spp. in Asia-
Pacific nations: report from the SENTRY Surveillance Program. J Antimicrob Chemother 63: 
55-59. 
122. Medeiros AA (1997) Evolution and dissemination of beta-lactamases accelerated by generations 
of beta-lactam antibiotics. Clin Infect Dis 24 Suppl 1: S19-45. 
123. Poirel L, Nordmann P (2002) Acquired carbapenem-hydrolyzing beta-lactamases and their 
genetic support. Curr Pharm Biotechnol 3: 117-127. 
124. Hall RM, Collis CM (1998) Antibiotic resistance in gram-negative bacteria: the role of gene 
cassettes and integrons. Drug Resist Updat 1: 109-119. 
125. Partridge SR, Tsafnat G, Coiera E, Iredell JR (2009) Gene cassettes and cassette arrays in mobile 
resistance integrons. FEMS Microbiol Rev 33: 757-784. 
126. Cambray G, Guerout AM, Mazel D (2010) Integrons. Annu Rev Genet 44: 141-166. 
127. Stokes HW, Hall RM (1989) A novel family of potentially mobile DNA elements encoding site-
specific gene-integration functions: integrons. Mol Microbiol 3: 1669-1683. 
128. Collis CM, Hall RM (1992) Site-specific deletion and rearrangement of integron insert genes 
catalyzed by the integron DNA integrase. J Bacteriol 174: 1574-1585. 
129. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, et al. (2010) Acquired carbapenemases 
in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 
16: 112-122. 
130. Akinci E, Vahaboglu H (2010) Minor extended-spectrum beta-lactamases. Expert Rev Anti Infect 
Ther 8: 1251-1258. 
131. Poirel L, Weldhagen GF, De Champs C, Nordmann P (2002) A nosocomial outbreak of 
Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 
in South Africa. J Antimicrob Chemother 49: 561-565. 
132. Claeys G, Verschraegen G, de Baere T, Vaneechoutte M (2000) PER-1 beta-lactamase-producing 
Pseudomonas aeruginosa in an intensive care unit. J Antimicrob Chemother 45: 924-925. 
133. Polotto M, Casella T, de Lucca Oliveira MG, Rubio FG, Nogueira ML, et al. (2012) Detection of P. 
aeruginosa harboring bla CTX-M-2, bla GES-1 and bla GES-5, bla IMP-1 and bla SPM-1 causing 
infections in Brazilian tertiary-care hospital. BMC Infect Dis 12: 176. 
REFERENCES 116 
 
134. Danel F, Hall LM, Duke B, Gur D, Livermore DM (1999) OXA-17, a further extended-spectrum 
variant of OXA-10 beta-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob 
Agents Chemother 43: 1362-1366. 
135. Naas T, Poirel L, Karim A, Nordmann P (1999) Molecular characterization of In50, a class 1 
integron encoding the gene for the extended-spectrum beta-lactamase VEB-1 in 
Pseudomonas aeruginosa. FEMS Microbiol Lett 176: 411-419. 
136. Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin 
Microbiol Rev 18: 657-686. 
137. Girlich D, Naas T, Nordmann P (2004) Biochemical characterization of the naturally occurring 
oxacillinase OXA-50 of Pseudomonas aeruginosa. Antimicrob Agents Chemother 48: 2043-
2048. 
138. Sanders CC, Sanders WE, Jr. (1986) Type I beta-lactamases of gram-negative bacteria: 
interactions with beta-lactam antibiotics. J Infect Dis 154: 792-800. 
139. Rodriguez-Martinez JM, Poirel L, Nordmann P (2009) Extended-spectrum cephalosporinases in 
Pseudomonas aeruginosa. Antimicrob Agents Chemother 53: 1766-1771. 
140. Poole K (2011) Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2: 65. 
141. Livermore DM (1995) beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8: 
557-584. 
142. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, et al. (2004) Pseudomonas aeruginosa 
biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase 
and alginate production. Antimicrob Agents Chemother 48: 1175-1187. 
143. Tam VH, Chang KT, Schilling AN, LaRocco MT, Genty LO, et al. (2009) Impact of AmpC 
overexpression on outcomes of patients with Pseudomonas aeruginosa bacteremia. Diagn 
Microbiol Infect Dis 63: 279-285. 
144. Xavier DE, Picao RC, Girardello R, Fehlberg LC, Gales AC (2010) Efflux pumps expression and its 
association with porin down-regulation and beta-lactamase production among Pseudomonas 
aeruginosa causing bloodstream infections in Brazil. BMC Microbiol 10: 217. 
145. Drissi M, Ahmed ZB, Dehecq B, Bakour R, Plesiat P, et al. (2008) Antibiotic susceptibility and 
mechanisms of beta-lactam resistance among clinical strains of Pseudomonas aeruginosa: 
first report in Algeria. Med Mal Infect 38: 187-191. 
146. Cheng Q, Park JT (2002) Substrate specificity of the AmpG permease required for recycling of 
cell wall anhydro-muropeptides. J Bacteriol 184: 6434-6436. 
147. Holtje JV, Kopp U, Ursinus A, Wiedemann B (1994) The negative regulator of beta-lactamase 
induction AmpD is a N-acetyl-anhydromuramyl-L-alanine amidase. FEMS Microbiol Lett 122: 
159-164. 
148. Langaee TY, Dargis M, Huletsky A (1998) An ampD gene in Pseudomonas aeruginosa encodes a 
negative regulator of AmpC beta-lactamase expression. Antimicrob Agents Chemother 42: 
3296-3300. 
149. Jacobs C, Frere JM, Normark S (1997) Cytosolic intermediates for cell wall biosynthesis and 
degradation control inducible beta-lactam resistance in gram-negative bacteria. Cell 88: 823-
832. 
150. Dietz H, Pfeifle D, Wiedemann B (1996) Location of N-acetylmuramyl-L-alanyl-D-
glutamylmesodiaminopimelic acid, presumed signal molecule for beta-lactamase induction, 
in the bacterial cell. Antimicrob Agents Chemother 40: 2173-2177. 
151. Bagge N, Ciofu O, Hentzer M, Campbell JI, Givskov M, et al. (2002) Constitutive high expression 
of chromosomal beta-lactamase in Pseudomonas aeruginosa caused by a new insertion 
sequence (IS1669) located in ampD. Antimicrob Agents Chemother 46: 3406-3411. 
152. Schmidtke AJ, Hanson ND (2008) Role of ampD homologs in overproduction of AmpC in clinical 
isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother 52: 3922-3927. 
153. Juan C, Moya B, Perez JL, Oliver A (2006) Stepwise upregulation of the Pseudomonas aeruginosa 
chromosomal cephalosporinase conferring high-level beta-lactam resistance involves three 
AmpD homologues. Antimicrob Agents Chemother 50: 1780-1787. 
REFERENCES 117 
 
154. Juan C, Macia MD, Gutierrez O, Vidal C, Perez JL, et al. (2005) Molecular mechanisms of beta-
lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical 
strains. Antimicrob Agents Chemother 49: 4733-4738. 
155. Moya B, Dötsch A, Juan C, Blazquez J, Zamorano L, et al. (2009) Beta-lactam resistance response 
triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 5: 
e1000353. 
156. Fajardo A, Martinez-Martin N, Mercadillo M, Galan JC, Ghysels B, et al. (2008) The neglected 
intrinsic resistome of bacterial pathogens. PLoS One 3: e1619. 
157. Breidenstein EB, Khaira BK, Wiegand I, Overhage J, Hancock RE (2008) Complex ciprofloxacin 
resistome revealed by screening a Pseudomonas aeruginosa mutant library for altered 
susceptibility. Antimicrob Agents Chemother 52: 4486-4491. 
158. Schurek KN, Marr AK, Taylor PK, Wiegand I, Semenec L, et al. (2008) Novel genetic determinants 
of low-level aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents 
Chemother 52: 4213-4219. 
159. Alvarez-Ortega C, Wiegand I, Olivares J, Hancock RE, Martinez JL (2010) Genetic determinants 
involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics. 
Antimicrob Agents Chemother 54: 4159-4167. 
160. Fernandez L, Alvarez-Ortega C, Wiegand I, Olivares J, Kocincova D, et al. (2013) Characterization 
of the polymyxin B resistome of Pseudomonas aeruginosa. Antimicrob Agents Chemother 57: 
110-119. 
161. Valentini M, Lapouge K (2013) Catabolite repression in Pseudomonas aeruginosa PAO1 
regulates the uptake of C4 -dicarboxylates depending on succinate concentration. Environ 
Microbiol 15: 1707-1716. 
162. Linares JF, Moreno R, Fajardo A, Martinez-Solano L, Escalante R, et al. (2010) The global 
regulator Crc modulates metabolism, susceptibility to antibiotics and virulence in 
Pseudomonas aeruginosa. Environ Microbiol 12: 3196-3212. 
163. Zhang L, Chiang WC, Gao Q, Givskov M, Tolker-Nielsen T, et al. (2012) The catabolite repression 
control protein Crc plays a role in the development of antimicrobial-tolerant subpopulations 
in Pseudomonas aeruginosa biofilms. Microbiology 158: 3014-3019. 
164. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ (2007) A common mechanism of 
cellular death induced by bactericidal antibiotics. Cell 130: 797-810. 
165. Liu Y, Imlay JA (2013) Cell death from antibiotics without the involvement of reactive oxygen 
species. Science 339: 1210-1213. 
166. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K (2013) Killing by bactericidal antibiotics does not 
depend on reactive oxygen species. Science 339: 1213-1216. 
167. Wang X, Zhao X, Malik M, Drlica K (2010) Contribution of reactive oxygen species to pathways of 
quinolone-mediated bacterial cell death. J Antimicrob Chemother 65: 520-524. 
168. Grant SS, Kaufmann BB, Chand NS, Haseley N, Hung DT (2012) Eradication of bacterial persisters 
with antibiotic-generated hydroxyl radicals. Proc Natl Acad Sci U S A 109: 12147-12152. 
169. Foti JJ, Devadoss B, Winkler JA, Collins JJ, Walker GC (2012) Oxidation of the guanine nucleotide 
pool underlies cell death by bactericidal antibiotics. Science 336: 315-319. 
170. Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, et al. (1995) Whole-genome 
random sequencing and assembly of Haemophilus influenzae Rd. Science 269: 496-512. 
171. Metzker ML (2005) Emerging technologies in DNA sequencing. Genome Res 15: 1767-1776. 
172. Collins FS, Morgan M, Patrinos A (2003) The Human Genome Project: lessons from large-scale 
biology. Science 300: 286-290. 
173. Loman NJ, Constantinidou C, Chan JZ, Halachev M, Sergeant M, et al. (2012) High-throughput 
bacterial genome sequencing: an embarrassment of choice, a world of opportunity. Nat Rev 
Microbiol 10: 599-606. 
174. Kurzweil R (2001) The 21st Century: a Confluence of Accelerating Revolutions. KurzweilAI.net. 
175. NCBI-Genome-Reports ftp://ftp.ncbi.nlm.nih.gov/genomes/GENOME_REPORTS/prokaryotes.txt. 
Accessed 31st of January 2014. 
REFERENCES 118 
 
176. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, et al. (2008) Accurate whole 
human genome sequencing using reversible terminator chemistry. Nature 456: 53-59. 
177. Ronaghi M, Uhlen M, Nyren P (1998) A sequencing method based on real-time pyrophosphate. 
Science 281: 363, 365. 
178. Shendure J, Porreca GJ, Reppas NB, Lin X, McCutcheon JP, et al. (2005) Accurate multiplex 
polony sequencing of an evolved bacterial genome. Science 309: 1728-1732. 
179. Metzker ML (2010) Sequencing technologies - the next generation. Nat Rev Genet 11: 31-46. 
180. Sorek R, Cossart P (2010) Prokaryotic transcriptomics: a new view on regulation, physiology and 
pathogenicity. Nat Rev Genet 11: 9-16. 
181. Wang Z, Gerstein M, Snyder M (2009) RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev 
Genet 10: 57-63. 
182. Croucher NJ, Thomson NR (2010) Studying bacterial transcriptomes using RNA-seq. Curr Opin 
Microbiol 13: 619-624. 
183. Yoder-Himes DR, Chain PS, Zhu Y, Wurtzel O, Rubin EM, et al. (2009) Mapping the Burkholderia 
cenocepacia niche response via high-throughput sequencing. Proc Natl Acad Sci U S A 106: 
3976-3981. 
184. Cho BK, Zengler K, Qiu Y, Park YS, Knight EM, et al. (2009) The transcription unit architecture of 
the Escherichia coli genome. Nat Biotechnol 27: 1043-1049. 
185. Albrecht M, Sharma CM, Reinhardt R, Vogel J, Rudel T (2010) Deep sequencing-based discovery 
of the Chlamydia trachomatis transcriptome. Nucleic Acids Res 38: 868-877. 
186. Katsanis SH, Katsanis N (2013) Molecular genetic testing and the future of clinical genomics. Nat 
Rev Genet 14: 415-426. 
187. Didelot X, Bowden R, Wilson DJ, Peto TE, Crook DW (2012) Transforming clinical microbiology 
with bacterial genome sequencing. Nat Rev Genet 13: 601-612. 
188. Palmer AC, Kishony R (2013) Understanding, predicting and manipulating the genotypic 
evolution of antibiotic resistance. Nat Rev Genet 14: 243-248. 
189. Winsor GL, Lam DK, Fleming L, Lo R, Whiteside MD, et al. (2011) Pseudomonas Genome 
Database: improved comparative analysis and population genomics capability for 
Pseudomonas genomes. Nucleic Acids Res 39: D596-600. 
190. Woodcock DM, Crowther PJ, Doherty J, Jefferson S, DeCruz E, et al. (1989) Quantitative 
evaluation of Escherichia coli host strains for tolerance to cytosine methylation in plasmid 
and phage recombinants. Nucleic Acids Res 17: 3469-3478. 
191. Simon R PU, Pühler A (1983) A broad host range mobilization system for in vivo genetic 
engineering: Transposon mutagenesis in gram negative bacteria. Biotechnology. 
192. Liberati NT, Urbach JM, Miyata S, Lee DG, Drenkard E, et al. (2006) An ordered, nonredundant 
library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants. Proc Natl Acad 
Sci U S A 103: 2833-2838. 
193. Dötsch A, Eckweiler D, Schniederjans M, Zimmermann A, Jensen V, et al. (2012) The 
Pseudomonas aeruginosa transcriptome in planktonic cultures and static biofilms using RNA 
sequencing. PLoS One 7: e31092. 
194. Yi H, Cho YJ, Won S, Lee JE, Jin Yu H, et al. (2011) Duplex-specific nuclease efficiently removes 
rRNA for prokaryotic RNA-seq. Nucleic Acids Res 39: e140. 
195. Dabney J, Meyer M (2012) Length and GC-biases during sequencing library amplification: a 
comparison of various polymerase-buffer systems with ancient and modern DNA sequencing 
libraries. Biotechniques 52: 87-94. 
196. Lunter G, Goodson M (2011) Stampy: a statistical algorithm for sensitive and fast mapping of 
Illumina sequence reads. Genome Res 21: 936-939. 
197. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map 
format and SAMtools. Bioinformatics 25: 2078-2079. 
198. Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 
11: R106. 
199. Zerbino DR (2010) Using the Velvet de novo assembler for short-read sequencing technologies. 
Curr Protoc Bioinformatics Chapter 11: Unit 11 15. 
REFERENCES 119 
 
200. Corpet F (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16: 
10881-10890. 
201. Paradis E, Claude J, Strimmer K (2004) APE: Analyses of Phylogenetics and Evolution in R 
language. Bioinformatics 20: 289-290. 
202. Huson DH, Scornavacca C (2012) Dendroscope 3: an interactive tool for rooted phylogenetic 
trees and networks. Syst Biol 61: 1061-1067. 
203. Letunic I, Bork P (2011) Interactive Tree Of Life v2: online annotation and display of phylogenetic 
trees made easy. Nucleic Acids Res 39: W475-478. 
204. Pruitt KD, Tatusova T, Maglott DR (2005) NCBI Reference Sequence (RefSeq): a curated non-
redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 33: 
D501-504. 
205. NCBI Resource Coordinators (2013) Database resources of the National Center for 
Biotechnology Information. Nucleic Acids Res 41: D8-D20. 
206. UniProt Consortium (2011) Ongoing and future developments at the Universal Protein Resource. 
Nucleic Acids Res 39: D214-219. 
207. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, et al. (2012) The Pfam protein families 
database. Nucleic Acids Res 40: D290-301. 
208. Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, et al. (1999) Cloning and 
characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a 
Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 43: 1584-1590. 
209. Hoang TT, Karkhoff-Schweizer RR, Kutchma AJ, Schweizer HP (1998) A broad-host-range Flp-FRT 
recombination system for site-specific excision of chromosomally-located DNA sequences: 
application for isolation of unmarked Pseudomonas aeruginosa mutants. Gene 212: 77-86. 
210. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR (1989) Site-directed mutagenesis by overlap 
extension using the polymerase chain reaction. Gene 77: 51-59. 
211. Larsen JE, Lund O, Nielsen M (2006) Improved method for predicting linear B-cell epitopes. 
Immunome Res 2: 2. 
212. Brown TA (2002) Genomes: Garland Science, New York. 
213. Peano C, Pietrelli A, Consolandi C, Rossi E, Petiti L, et al. (2013) An efficient rRNA removal 
method for RNA sequencing in GC-rich bacteria. Microb Inform Exp 3: 1. 
214. He S, Wurtzel O, Singh K, Froula JL, Yilmaz S, et al. (2010) Validation of two ribosomal RNA 
removal methods for microbial metatranscriptomics. Nat Methods 7: 807-812. 
215. Rutherford K, Parkhill J, Crook J, Horsnell T, Rice P, et al. (2000) Artemis: sequence visualization 
and annotation. Bioinformatics 16: 944-945. 
216. Lee DG, Urbach JM, Wu G, Liberati NT, Feinbaum RL, et al. (2006) Genomic analysis reveals that 
Pseudomonas aeruginosa virulence is combinatorial. Genome Biol 7: R90. 
217. Mathee K, Narasimhan G, Valdes C, Qiu X, Matewish JM, et al. (2008) Dynamics of Pseudomonas 
aeruginosa genome evolution. Proc Natl Acad Sci U S A 105: 3100-3105. 
218. Winstanley C, Langille MG, Fothergill JL, Kukavica-Ibrulj I, Paradis-Bleau C, et al. (2009) Newly 
introduced genomic prophage islands are critical determinants of in vivo competitiveness in 
the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res 19: 12-23. 
219. Spencer DH, Kas A, Smith EE, Raymond CK, Sims EH, et al. (2003) Whole-genome sequence 
variation among multiple isolates of Pseudomonas aeruginosa. J Bacteriol 185: 1316-1325. 
220. Kung VL, Ozer EA, Hauser AR (2010) The accessory genome of Pseudomonas aeruginosa. 
Microbiol Mol Biol Rev 74: 621-641. 
221. Romling U, Wingender J, Muller H, Tümmler B (1994) A major Pseudomonas aeruginosa clone 
common to patients and aquatic habitats. Appl Environ Microbiol 60: 1734-1738. 
222. Sefraoui I, Berrazeg M, Drissi M, Rolain JM (2013) Molecular Epidemiology of Carbapenem-
Resistant Pseudomonas aeruginosa Clinical Strains Isolated from Western Algeria Between 
2009 and 2012. Microb Drug Resist. 
223. Wiehlmann L, Wagner G, Cramer N, Siebert B, Gudowius P, et al. (2007) Population structure of 
Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 104: 8101-8106. 
224. Oliveros JC (2007) VENNY. An interactive tool for comparing lists with Venn Diagrams. 
REFERENCES 120 
 
225. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, et al. (2009) Circos: an information 
aesthetic for comparative genomics. Genome Res 19: 1639-1645. 
226. Llanes C, Köhler T, Patry I, Dehecq B, van Delden C, et al. (2011) Role of the MexEF-OprN efflux 
system in low-level resistance of Pseudomonas aeruginosa to ciprofloxacin. Antimicrob 
Agents Chemother 55: 5676-5684. 
227. Zaoui C, Overhage J, Löns D, Zimmermann A, Müsken M, et al. (2012) An orphan sensor kinase 
controls quinolone signal production via MexT in Pseudomonas aeruginosa. Mol Microbiol 
83: 536-547. 
228. Westfall LW, Carty NL, Layland N, Kuan P, Colmer-Hamood JA, et al. (2006) mvaT mutation 
modifies the expression of the Pseudomonas aeruginosa multidrug efflux operon mexEF-
oprN. FEMS Microbiol Lett 255: 247-254. 
229. Balasubramanian D, Schneper L, Merighi M, Smith R, Narasimhan G, et al. (2012) The regulatory 
repertoire of Pseudomonas aeruginosa AmpC β-lactamase regulator AmpR includes virulence 
genes. PLoS One 7: e34067. 
230. Nakada Y, Itoh Y (2002) Characterization and regulation of the gbuA gene, encoding 
guanidinobutyrase in the arginine dehydrogenase pathway of Pseudomonas aeruginosa 
PAO1. J Bacteriol 184: 3377-3384. 
231. Avison MB, Horton RE, Walsh TR, Bennett PM (2001) Escherichia coli CreBC is a global regulator 
of gene expression that responds to growth in minimal media. J Biol Chem 276: 26955-
26961. 
232. Lin CW, Lin HC, Huang YW, Chung TC, Yang TC (2011) Inactivation of mrcA gene derepresses the 
basal-level expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. J 
Antimicrob Chemother 66: 2033-2037. 
233. Abdelraouf K, Kabbara S, Ledesma KR, Poole K, Tam VH (2011) Effect of multidrug resistance-
conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob 
Chemother 66: 1311-1317. 
234. Olivares J, Bernardini A, Garcia-Leon G, Corona F, M BS, et al. (2013) The intrinsic resistome of 
bacterial pathogens. Front Microbiol 4: 103. 
235. Lopez E, Elez M, Matic I, Blazquez J (2007) Antibiotic-mediated recombination: ciprofloxacin 
stimulates SOS-independent recombination of divergent sequences in Escherichia coli. Mol 
Microbiol 64: 83-93. 
236. Zamorano L, Reeve TM, Deng L, Juan C, Moya B, et al. (2010) NagZ inactivation prevents and 
reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas 
aeruginosa. Antimicrob Agents Chemother 54: 3557-3563. 
237. Blake KL, O'Neill AJ (2013) Transposon library screening for identification of genetic loci 
participating in intrinsic susceptibility and acquired resistance to antistaphylococcal agents. J 
Antimicrob Chemother 68: 12-16. 
238. Parkins MD, Ceri H, Storey DG (2001) Pseudomonas aeruginosa GacA, a factor in multihost 
virulence, is also essential for biofilm formation. Mol Microbiol 40: 1215-1226. 
239. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, et al. (2014) Data, information, 
knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 42: D199-205. 
240. Fuhrer T, Fischer E, Sauer U (2005) Experimental identification and quantification of glucose 
metabolism in seven bacterial species. J Bacteriol 187: 1581-1590. 
241. Romero P, Karp P (2003) PseudoCyc, a pathway-genome database for Pseudomonas aeruginosa. 
J Mol Microbiol Biotechnol 5: 230-239. 
242. World Health Organization (2012) The evolving threat of antimicrobial resistance: options for 
action. 
243. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) Accelerated evolution of 
resistance in multidrug environments. Proc Natl Acad Sci U S A 105: 13977-13981. 
244. MacKenzie FM, Bruce J, Struelens MJ, Goossens H, Mollison J, et al. (2007) Antimicrobial drug 
use and infection control practices associated with the prevalence of methicillin-resistant 
Staphylococcus aureus in European hospitals. Clin Microbiol Infect 13: 269-276. 
REFERENCES 121 
 
245. Furtado GH, Perdiz LB, Onita JH, Wey SB, Medeiros EA (2010) Correlation between rates of 
carbapenem consumption and the prevalence of carbapenem-resistant Pseudomonas 
aeruginosa in a tertiary care hospital in Brazil: a 4-year study. Infect Control Hosp Epidemiol 
31: 664-666. 
246. Meyer E, Schwab F, Schroeren-Boersch B, Gastmeier P (2010) Dramatic increase of third-
generation cephalosporin-resistant E. coli in German intensive care units: secular trends in 
antibiotic drug use and bacterial resistance, 2001 to 2008. Crit Care 14: R113. 
247. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB (2004) Predicting hospital rates of 
fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals 
and their surrounding communities. Clin Infect Dis 39: 497-503. 
248. Weng TC, Chen YH, Lee CC, Wang CY, Lai CC, et al. (2011) Correlation between fluoroquinolone 
consumption in hospitals and ciprofloxacin resistance amongst Pseudomonas aeruginosa 
isolates causing healthcare-associated infections, Taiwan, 2000-2009. Int J Antimicrob Agents 
37: 581-584. 
249. Hsueh PR, Chen WH, Luh KT (2005) Relationships between antimicrobial use and antimicrobial 
resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a 
university hospital in Taiwan. Int J Antimicrob Agents 26: 463-472. 
250. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO (2009) Risk factors and 
clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect 
Control Hosp Epidemiol 30: 1180-1185. 
251. Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, et al. (2010) Imipenem-resistant 
Pseudomonas aeruginosa gastrointestinal carriage among hospitalized patients: risk factors 
and resistance mechanisms. Diagn Microbiol Infect Dis 66: 1-6. 
252. Enne VI, Livermore DM, Stephens P, Hall LM (2001) Persistence of sulphonamide resistance in 
Escherichia coli in the UK despite national prescribing restriction. Lancet 357: 1325-1328. 
253. Sundqvist M, Geli P, Andersson DI, Sjolund-Karlsson M, Runehagen A, et al. (2010) Little 
evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim 
use. J Antimicrob Chemother 65: 350-360. 
254. Canton R, Morosini MI (2011) Emergence and spread of antibiotic resistance following exposure 
to antibiotics. FEMS Microbiol Rev 35: 977-991. 
255. Kummerer K (2009) Antibiotics in the aquatic environment--a review--part I. Chemosphere 75: 
417-434. 
256. European Surveillance of Antibiotic Consumption ESAC (2009) Final management report 2009-
2010. 
257. Goossens H, Ferech M, Vander Stichele R, Elseviers M, Group EP (2005) Outpatient antibiotic 
use in Europe and association with resistance: a cross-national database study. Lancet 365: 
579-587. 
258. Baquero F (2001) Low-level antibacterial resistance: a gateway to clinical resistance. Drug Resist 
Updat 4: 93-105. 
259. Kummerer K, Henninger A (2003) Promoting resistance by the emission of antibiotics from 
hospitals and households into effluent. Clin Microbiol Infect 9: 1203-1214. 
260. Larsson DG, de Pedro C, Paxeus N (2007) Effluent from drug manufactures contains extremely 
high levels of pharmaceuticals. J Hazard Mater 148: 751-755. 
261. Christiana T, Schneidera RJ, Färberb HA, Skutlarekb D, Meyerc MT, et al. (2003) Determination 
of Antibiotic Residues in Manure, Soil, and Surface Waters. Acta hydrochim hydrobiol 31: 36–
44. 
262. Subbiah M, Mitchell SM, Ullman JL, Call DR (2011) beta-lactams and florfenicol antibiotics 
remain bioactive in soils while ciprofloxacin, neomycin, and tetracycline are neutralized. Appl 
Environ Microbiol 77: 7255-7260. 
263. Andrews JM (2001) Determination of minimum inhibitory concentrations. J Antimicrob 
Chemother 48 Suppl 1: 5-16. 
264. Turnidge J, Paterson DL (2007) Setting and revising antibacterial susceptibility breakpoints. Clin 
Microbiol Rev 20: 391-408, table of contents. 
REFERENCES 122 
 
265. CLSI (2013) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Third 
Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute. 
266. Juan C, Conejo MC, Tormo N, Gimeno C, Pascual A, et al. (2013) Challenges for accurate 
susceptibility testing, detection and interpretation of beta-lactam resistance phenotypes in 
Pseudomonas aeruginosa: results from a Spanish multicentre study. J Antimicrob Chemother 
68: 619-630. 
267. European Committee on Antimicrobial Susceptibility Testing E (2014) Clinical breakpoints - 
bacteria. European Society of Clinical Microbiology and Infectous Diseases. 
268. Rodriguez-Martinez JM, Briales A, Velasco C, Diaz de Alba P, Martinez-Martinez L, et al. (2011) 
Discrepancies in fluoroquinolone clinical categories between the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) and CLSI for Escherichia coli harbouring qnr 
genes and mutations in gyrA and parC. J Antimicrob Chemother 66: 1405-1407. 
269. Zhao X, Drlica K (2008) A unified anti-mutant dosing strategy. J Antimicrob Chemother 62: 434-
436. 
270. Rodriguez-Martinez JM, Velasco C, Garcia I, Cano ME, Martinez-Martinez L, et al. (2007) Mutant 
prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the 
plasmid-carried quinolone resistance determinant qnrA1. Antimicrob Agents Chemother 51: 
2236-2239. 
271. Luo Y, Li J, Meng Y, Ma Y, Hu C, et al. (2011) Joint effects of topoisomerase alterations and 
plasmid-mediated quinolone-resistant determinants in Salmonella enterica Typhimurium. 
Microb Drug Resist 17: 1-5. 
272. Briales A, Rodriguez-Martinez JM, Velasco C, Diaz de Alba P, Dominguez-Herrera J, et al. (2011) 
In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic 
Escherichia coli isolates with mutations in gyrA and parC. Antimicrob Agents Chemother 55: 
1266-1269. 
273. Morar M, Wright GD (2010) The genomic enzymology of antibiotic resistance. Annu Rev Genet 
44: 25-51. 
274. Perkins TT, Kingsley RA, Fookes MC, Gardner PP, James KD, et al. (2009) A strand-specific RNA-
Seq analysis of the transcriptome of the typhoid bacillus Salmonella typhi. PLoS Genet 5: 
e1000569. 
275. Dötsch A, Becker T, Pommerenke C, Magnowska Z, Jansch L, et al. (2009) Genomewide 
identification of genetic determinants of antimicrobial drug resistance in Pseudomonas 
aeruginosa. Antimicrob Agents Chemother 53: 2522-2531. 
276. Giannoukos G, Ciulla DM, Huang K, Haas BJ, Izard J, et al. (2012) Efficient and robust RNA-seq 
process for cultured bacteria and complex community transcriptomes. Genome Biol 13: R23. 
277. Haas BJ, Chin M, Nusbaum C, Birren BW, Livny J (2012) How deep is deep enough for RNA-Seq 
profiling of bacterial transcriptomes? BMC Genomics 13: 734. 
278. Wang D, Seeve C, Pierson LS, 3rd, Pierson EA (2013) Transcriptome profiling reveals links 
between ParS/ParR, MexEF-OprN, and quorum sensing in the regulation of adaptation and 
virulence in Pseudomonas aeruginosa. BMC Genomics 14: 618. 
279. Minoche AE, Dohm JC, Himmelbauer H (2011) Evaluation of genomic high-throughput 
sequencing data generated on Illumina HiSeq and genome analyzer systems. Genome Biol 
12: R112. 
280. Priest FG, Barker M, Baillie LW, Holmes EC, Maiden MC (2004) Population structure and 
evolution of the Bacillus cereus group. J Bacteriol 186: 7959-7970. 
281. Jolley KA, Bliss CM, Bennett JS, Bratcher HB, Brehony C, et al. (2012) Ribosomal multilocus 
sequence typing: universal characterization of bacteria from domain to strain. Microbiology 
158: 1005-1015. 
282. Hocquet D, Plesiat P, Dehecq B, Mariotte P, Talon D, et al. (2010) Nationwide investigation of 
extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum 
oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France. 
Antimicrob Agents Chemother 54: 3512-3515. 
REFERENCES 123 
 
283. Kaase M (2012) [Carbapenemases in gram-negative bacteria. Current data and trends of 
resistance resulting from the work of national reference centres]. Bundesgesundheitsblatt 
Gesundheitsforschung Gesundheitsschutz 55: 1401-1404. 
284. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN (2014) Epidemiology and 
carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas 
aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J 
Antimicrob Chemother. 
285. Peter S, Lacher A, Marschal M, Holzl F, Buhl M, et al. (2014) Evaluation of phenotypic detection 
methods for metallo-beta-lactamases (MBLs) in clinical isolates of Pseudomonas aeruginosa. 
Eur J Clin Microbiol Infect Dis. 
286. Zander E, Fernandez-Gonzalez A, Schleicher X, Dammhayn C, Kamolvit W, et al. (2014) 
Worldwide dissemination of acquired carbapenem-hydrolysing class D beta-lactamases in 
Acinetobacter spp. other than Acinetobacter baumannii. Int J Antimicrob Agents 43: 375-377. 
287. Mark BL, Vocadlo DJ, Oliver A (2011) Providing beta-lactams a helping hand: targeting the AmpC 
beta-lactamase induction pathway. Future Microbiol 6: 1415-1427. 
288. Vettoretti L, Plesiat P, Muller C, El Garch F, Phan G, et al. (2009) Efflux unbalance in 
Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 
53: 1987-1997. 
289. Satake S, Yoshihara E, Nakae T (1990) Diffusion of beta-lactam antibiotics through liposome 
membranes reconstituted from purified porins of the outer membrane of Pseudomonas 
aeruginosa. Antimicrob Agents Chemother 34: 685-690. 
290. Balasubramanian D, Kumari H, Jaric M, Fernandez M, Turner KH, et al. (2014) Deep sequencing 
analyses expands the Pseudomonas aeruginosa AmpR regulon to include small RNA-
mediated regulation of iron acquisition, heat shock and oxidative stress response. Nucleic 
Acids Res 42: 979-998. 
291. Kumari H, Balasubramanian D, Zincke D, Mathee K (2014) Role of Pseudomonas aeruginosa 
AmpR on beta-lactam and non-beta-lactam transient cross-resistance upon pre-exposure to 
subinhibitory concentrations of antibiotics. J Med Microbiol 63: 544-555. 
292. Okamoto K, Gotoh N, Tsujimoto H, Yamada H, Yoshihara E, et al. (1999) Molecular cloning and 
characterization of the oprQ gene coding for outer membrane protein OprE3 of 
Pseudomonas aeruginosa. Microbiol Immunol 43: 297-301. 
293. Lieberman TD, Michel JB, Aingaran M, Potter-Bynoe G, Roux D, et al. (2011) Parallel bacterial 
evolution within multiple patients identifies candidate pathogenicity genes. Nat Genet 43: 
1275-1280. 
294. McAdam PR, Holmes A, Templeton KE, Fitzgerald JR (2011) Adaptive evolution of 
Staphylococcus aureus during chronic endobronchial infection of a cystic fibrosis patient. 
PLoS One 6: e24301. 
295. Mwangi MM, Wu SW, Zhou Y, Sieradzki K, de Lencastre H, et al. (2007) Tracking the in vivo 
evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. 
Proc Natl Acad Sci U S A 104: 9451-9456. 
296. Gordon NC, Price JR, Cole K, Everitt R, Morgan M, et al. (2014) Prediction of Staphylococcus 
aureus Antimicrobial Resistance by Whole-Genome Sequencing. J Clin Microbiol 52: 1182-
1191. 
297. Stanssens P, Zabeau M, Meersseman G, Remes G, Gansemans Y, et al. (2004) High-throughput 
MALDI-TOF discovery of genomic sequence polymorphisms. Genome Res 14: 126-133. 
298. Johansen P, Andersen JD, Borsting C, Morling N (2013) Evaluation of the iPLEX(R) Sample ID Plus 
Panel designed for the Sequenom MassARRAY(R) system. A SNP typing assay developed for 
human identification and sample tracking based on the SNPforID panel. Forensic Sci Int 
Genet 7: 482-487. 
299. Lee SH, Li CF, Lin HY, Lin CH, Liu HC, et al. (2014) High-throughput detection of common 
sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. Mol Genet 
Metab 111: 507-512. 
REFERENCES 124 
 
300. Wu Z, Zheng W, Xu J, Sun F, Chen H, et al. (2014) IL10 polymorphisms associated with Behcet's 
disease in Chinese Han. Hum Immunol 75: 271-276. 
301. Earp MA, Brooks-Wilson A, Cook L, Le N (2013) Inherited common variants in mitochondrial DNA 
and invasive serous epithelial ovarian cancer risk. BMC Res Notes 6: 425. 
302. Guan YP, Yang XX, Yao GY, Qiu F, Chen J, et al. (2014) Breast cancer association studies in a Han 
Chinese population using 10 European-ancestry-associated breast cancer susceptibility SNPs. 
Asian Pac J Cancer Prev 15: 85-91. 
303. Trembizki E, Smith H, Lahra MM, Chen M, Donovan B, et al. (2014) High-throughput informative 
single nucleotide polymorphism-based typing of Neisseria gonorrhoeae using the Sequenom 
MassARRAY iPLEX platform. J Antimicrob Chemother. 
304. Sparbier K, Schubert S, Weller U, Boogen C, Kostrzewa M (2012) Matrix-assisted laser desorption 
ionization-time of flight mass spectrometry-based functional assay for rapid detection of 
resistance against beta-lactam antibiotics. J Clin Microbiol 50: 927-937. 
305. Wang L, Han C, Sui W, Wang M, Lu X (2013) MALDI-TOF MS applied to indirect carbapenemase 
detection: a validated procedure to clearly distinguish between carbapenemase-positive and 
carbapenemase-negative bacterial strains. Anal Bioanal Chem 405: 5259-5266. 
306. Jung JS, Popp C, Sparbier K, Lange C, Kostrzewa M, et al. (2014) Evaluation of matrix-assisted 
laser desorption ionization-time of flight mass spectrometry for rapid detection of beta-
lactam resistance in Enterobacteriaceae derived from blood cultures. J Clin Microbiol 52: 
924-930. 
307. Hrabak J, Chudackova E, Walkova R (2013) Matrix-assisted laser desorption ionization-time of 
flight (maldi-tof) mass spectrometry for detection of antibiotic resistance mechanisms: from 
research to routine diagnosis. Clin Microbiol Rev 26: 103-114. 
308. Drlica K (2003) The mutant selection window and antimicrobial resistance. J Antimicrob 
Chemother 52: 11-17. 
309. Drlica K, Zhao X (2007) Mutant selection window hypothesis updated. Clin Infect Dis 44: 681-
688. 
310. Negri MC, Lipsitch M, Blazquez J, Levin BR, Baquero F (2000) Concentration-dependent selection 
of small phenotypic differences in TEM beta-lactamase-mediated antibiotic resistance. 
Antimicrob Agents Chemother 44: 2485-2491. 
311. Liu A, Fong A, Becket E, Yuan J, Tamae C, et al. (2011) Selective advantage of resistant strains at 
trace levels of antibiotics: a simple and ultrasensitive color test for detection of antibiotics 
and genotoxic agents. Antimicrob Agents Chemother 55: 1204-1210. 
312. Gullberg E, Cao S, Berg OG, Ilback C, Sandegren L, et al. (2011) Selection of resistant bacteria at 
very low antibiotic concentrations. PLoS Pathog 7: e1002158. 
313. Demple B, Harrison L (1994) Repair of oxidative damage to DNA: enzymology and biology. Annu 
Rev Biochem 63: 915-948. 
314. Lapouge K, Schubert M, Allain FH, Haas D (2008) Gac/Rsm signal transduction pathway of 
gamma-proteobacteria: from RNA recognition to regulation of social behaviour. Mol 
Microbiol 67: 241-253. 
315. Goodman AL, Kulasekara B, Rietsch A, Boyd D, Smith RS, et al. (2004) A signaling network 
reciprocally regulates genes associated with acute infection and chronic persistence in 
Pseudomonas aeruginosa. Dev Cell 7: 745-754. 
316. Brencic A, McFarland KA, McManus HR, Castang S, Mogno I, et al. (2009) The GacS/GacA signal 
transduction system of Pseudomonas aeruginosa acts exclusively through its control over the 
transcription of the RsmY and RsmZ regulatory small RNAs. Mol Microbiol 73: 434-445. 
317. Arai H, Kodama T, Igarashi Y (1997) Cascade regulation of the two CRP/FNR-related 
transcriptional regulators (ANR and DNR) and the denitrification enzymes in Pseudomonas 
aeruginosa. Mol Microbiol 25: 1141-1148. 
318. Zimmermann A, Reimmann C, Galimand M, Haas D (1991) Anaerobic growth and cyanide 
synthesis of Pseudomonas aeruginosa depend on anr, a regulatory gene homologous with fnr 
of Escherichia coli. Mol Microbiol 5: 1483-1490. 
REFERENCES 125 
 
319. Schobert M, Jahn D (2010) Anaerobic physiology of Pseudomonas aeruginosa in the cystic 
fibrosis lung. Int J Med Microbiol 300: 549-556. 
320. Unden G, Schirawski J (1997) The oxygen-responsive transcriptional regulator FNR of Escherichia 
coli: the search for signals and reactions. Mol Microbiol 25: 205-210. 
321. Imlay JA, Chin SM, Linn S (1988) Toxic DNA damage by hydrogen peroxide through the Fenton 
reaction in vivo and in vitro. Science 240: 640-642. 
322. Imlay JA, Linn S (1988) DNA damage and oxygen radical toxicity. Science 240: 1302-1309. 
323. Yeom J, Imlay JA, Park W (2010) Iron homeostasis affects antibiotic-mediated cell death in 
Pseudomonas species. J Biol Chem 285: 22689-22695. 
324. Liu Y, Liu X, Qu Y, Wang X, Li L, et al. (2012) Inhibitors of reactive oxygen species accumulation 
delay and/or reduce the lethality of several antistaphylococcal agents. Antimicrob Agents 
Chemother 56: 6048-6050. 
325. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, et al. (2012) Rapid killing of Acinetobacter 
baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob 
Agents Chemother 56: 5642-5649. 
326. Wang X, Zhao X (2009) Contribution of oxidative damage to antimicrobial lethality. Antimicrob 
Agents Chemother 53: 1395-1402. 
327. Livermore DM (2003) Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 36: 
S11-23. 
328. Lee HH, Molla MN, Cantor CR, Collins JJ (2010) Bacterial charity work leads to population-wide 
resistance. Nature 467: 82-85. 
329. Hughes D, Andersson DI (2012) Selection of resistance at lethal and non-lethal antibiotic 
concentrations. Curr Opin Microbiol 15: 555-560. 
330. Vlasits J, Jakopitsch C, Schwanninger M, Holubar P, Obinger C (2007) Hydrogen peroxide 
oxidation by catalase-peroxidase follows a non-scrambling mechanism. FEBS Lett 581: 320-
324. 
331. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, et al. (2011) Active starvation 
responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334: 
982-986. 
332. Jensen PO, Briales A, Brochmann RP, Wang H, Kragh KN, et al. (2013) Formation of hydroxyl 
radicals contributes to the bactericidal activity of ciprofloxacin against Pseudomonas 
aeruginosa biofilms. Pathog Dis. 
 
 
  
 
Danksagung 
 
Zuerst möchte ich mich bei Prof. Dr. Susanne Häußler für die Möglichkeit, dieses spannende Projekt 
in ihrer Abteilung bearbeiten zu dürfen sowie für die Übernahme des Korreferates und die intensive 
und stets enthusiastische Betreuung während meiner Doktorandenzeit bedanken. 
 
Weiterer Dank geht an Prof. Dr. Michael Steinert für die Übernahme des Hauptreferates und der 
Mentorenschaft sowie Prof. Dr. Dietmar Schomburg für die Übernahme des Prüfungsvorsitzes. 
 
Außerdem möchte ich mich bei der gesamten Arbeitsgruppe Molekulare Bakteriologie für die 
ausgesprochen gute Arbeitsatmosphäre und stete Hilfsbereitschaft bedanken. 
Vor allem Piotr Bielecki, Monika Schniederjans, Sebastian Bruchmann und Agata Bielecka für viele 
anregende Diskussionen sowie unseren Bioinformatikern Andreas Dötsch, Denitsa Eckweiler, Sarah 
Pohl, Klaus Hornischer und Uthayakumar Muthukumarasamy für ihre Unterstützung bei der 
Datenanalyse. 
 
Vielen Dank auch an Frank Klawonn für die hilfreichen Vorschläge zur statistischen Betrachtung 
meiner Daten sowie Wolf-Rainer Abraham und Esther Surges für die intensive Kooperation zur 
Untersuchung metabolischer Effekte durch geringe Antibiotikakonzentrationen. 
Ebenso danke ich Lothar Jänsch und Josef Wissing für ihre Zusammenarbeit zur Durchführung der 
massensprektrometrischen Analysen. 
 
Ein weiterer Dank geht an die HZI Graduiertenschule, welche die Weiterbildung während meiner 
Doktorandenzeit sowohl finanziell als auch durch viele interessante Tagungen, Kursangebote, 
Seminare und Vernetzungen sehr bereichert hat. 
 
Ein letzter, aber besonders wichtiger Dank gilt meiner Familie und meinem Mann Frederik für die 
uneingeschränkte Unterstützung während der letzten dreieinhalb Jahre sowie meiner TU-Connection 
Dagmar für den regen biologischen und nicht-biologischen Austausch. 
 
 
 
